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1  Introduction 
1.1  The cytokine IL-6 and its multiple functions 
The pleiotropic cytokine Interleukin 6 (IL-6), initially identified as a factor inducing the 
production of immunoglobulins in B lymphocytes [184], is produced by numerous immune 
and non-immune cells. They include T and B cells, macrophages, fibroblasts, endothelial 
cells, adipocytes and neuronal cells [274]. Expression of IL-6 occurs under physiological as 
well as under pathophysiological conditions, whereas its production is stronger upregulated 
during the latter [117, 325].  
IL-6 is considered an important player in host defense as a pyrogen (causing fever) [142, 202, 
236] and in regulating the acute phase response - amongst others - by inducing the release of 
C-reactive protein and serum amyloid A in hepatocytes [78]. Moreover, IL-6 has a pivotal 
role in growth and differentiation of haematopoietic precursor cells [106] and T lymphocytes 
[199]. For instance, the cytokine IL-6 induces together with TGFβ the differentiation of naive 
T cells into Th17 cells [17, 296]. Immune functions are also controlled through the autonomic 
nervous system by IL-6, which is provoked by neuronal activity [116]. Beyond 
immunological processes, IL-6 mediates many brain functions in the development and 
maintenance of the central nervous system (CNS) as well as in brain damage. In the CNS, IL-
6 and IL-6 receptors are expressed within various regions by astrocytes, microglia and 
neurons [75, 76, 160, 162, 237, 243, 247, 294, 295, 321]. Together with leptin and insulin-like 
growth factor (IGF) IL-6 has strong implication in the regulation of metabolic balance of 
sugar- and fat metabolism [163]. IL-6 has further been shown to control neurotransmitter 
expression [49, 54], enhance differentiation and survival of primary neurons and neuronal cell 
lines, and to exhibit neurotrophic activities by inducing together with its soluble IL-6 receptor 
several neurotrophins in astrocytes [110, 160, 161, 237]. The neuroprotective potential of IL-6 
has also been shown in vivo during cerebral ischemia in rats [147]. It is even capable of 
inducing the differentiation of progenitor cells into astrocytes [110, 187, 276]. Moreover, the 
modulation of endocrine processes within the CNS such as the activation of the hypothalamic-
pituitary-adrenal (HPA) axis is a crucial effect of IL-6 action [89, 248, 262, 309]. Likewise, 
IL-6 is involved in memory consolidation/learning, synaptic long-term potentiation and 
promotes plasticity [5, 7, 16, 166, 279]. Noteworthy, IL-6 is implicated in behavioural 
changes after infection, called sickness behaviour, including fever, anorexia (reduced food 
intake) and altered sleep-wake behaviour [20, 50]. During the strong brain-immune system 
interactions in sleep, cytokines exert a central role [133, 135, 156, 266]. The somnogenic 
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properties of IL-6 are described in section 1.7. Importantly, cytokines such as IL-6 mediate 
the bidirectional communication between the immune system and the nervous system, that 
maintains homeostasis throughout the body (protective) as well as the association with 
pathology (degenerative).  
Under various disease conditions, IL-6 levels become dysregulated or elevated and IL-6 is 
being produced at local tissue sites after acute infection or injury. But when chronically 
increased, IL-6 contributes to an overdriven immune response leading to tissue damage and 
thus to a prolonged or exaggerated course of illness, inflammation or autoimmunity. Altered 
IL-6/sIL-6R levels have been found in several human diseases such as multiple myeloma, 
Crohn’s disease, rheumatoid arthritis, sepsis, colon cancer, cardiovascular diseases, AIDS, 
osteoporosis, diabetes mellitus, asthma, stroke and other neuroinflammatory/-degenerative 
diseases (see 1.5) [114, 117, 325].  
 
 
1.2  Signal transduction of IL-6 
IL-6 belongs to the gp130-signalling family of long chain four α-helix bundle cytokines 
containing four α-helices (termed A, B, C and D) arranged in an up-up-down-down topology 
[28]. These cytokines use at least one glycoprotein 130 (gp130, IL-6 receptor β-chain, CD 
130) as a common signal-transducing subunit. Apart from IL-6, members of this family 
include interleukin 11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary 
neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC), viral 
IL-6, IL-27, neuropoietin (NP) and IL-31. In addition to gp130, each cytokine uses a specific 
set of receptors. For example, LIF and OSM induce the formation of gp130/LIF receptor 
heterodimer, whereas OSM can also signal via a receptor complex of gp130 and OSM 
receptor. The components of the receptor complex for IL-6 include a homodimer of gp130 
and the cytokine-binding glycoprotein IL-6 α-receptor (IL-6R) [93, 97] (Fig.1). The 
extracellular portions of both gp130 and IL-6R contain an immunglobulin G (Ig)-like domain 
at the N-terminus followed by one cytokine-binding module (CBM). The CBM comprises two 
fibronectin-type III (FN III) domains that carry a set of four conserved tyrosine residues and a 
tryptophan-serine-X-tryptophan-serine (WSXSW) motif. Gp130 possesses three additional 
FN III domains followed by a transmembrane and an intracellular cytoplasmic domain, which 
are involved in signal transduction. Adjacent to the CBM, the IL-6R contains a long flexible 
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stalk region, a transmembrane domain and a short cytoplasmatic domain that is not implicated 
in signalling events [27].  
 
 
 
 
 
 
 
 
Figure 1  Introducing the IL-6R complex components: schematic assembly of domain structures for IL-6R 
(blue) and gp130 (green). 
 
 
To initiate signal transduction, IL-6 first binds to the CBM domain of the IL-6R. Thereupon 
the complex of IL-6/IL-6R associates with two molecules of gp130 (Ig-like and CBM 
domains) and intracellular signalling events occur [93, 233, 274]. Interestingly, gp130 
proteins have been shown to be present on the plasma membrane as preformed but inactive 
dimers, which are only activated by ligand addition [281]. The tetrameric complex of (IL-6)-
(IL-6R)-(gp130)2 is sufficient [83, 215] to trigger auto-phosphorylation of gp130-associated 
Janus-tyrosine kinases (JAK), which in turn phosphorylate several tyrosine (Y) residues of the 
intracellular gp130 portion, which provide binding sites for molecules with a so-called SH2 
(src homology 2) domain. Such molecules are the STAT (signal transducer and activator of 
transcription) proteins, which are tyrosine phosphorylated/activated by JAKs and thereafter 
dimerise and translocate into the nucleus, where they bind as transcription factors to 
promoters of target genes [51, 93], e.g. C-reactive protein [313] or c-fos [96]. IL-6 mostly 
activates STAT3 and to a minor extent STAT1 from the seven known members of STATs 
[93, 326]. Additionally to the JAK/STAT pathway, the Ras-Raf-MAPK (mitogen activated 
protein kinase) pathway gets activated upon IL-6 stimulation. Therefore, the SHP-2 tyrosine 
phosphatases, which also contain SH2 domains, are recruited to the stimulated gp130 and 
undergo tyrosine phosphorylation by JAKs. Via their interaction with phosphorylated Grb2 
(growth factor receptor bound protein) the MAPK pathway is induced [93, 274]. An 
illustration of the transduction pathways is given in Fig. 2. 
The IL-6 transduction is tightly controlled and several mechanisms exist for downregulation 
of signalling [93, 315]. Upon cytokine stimulation, SOCS (suppressor of cytokine signalling) 
Ig-like domain
cytokine-binding module 
fibronectin-type III 
domains
transmembrane domain
cytoplasmic domain
flexible stalk region
plasma membrane
IL-6R gp130
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proteins are activated which inhibit the kinase activity of JAKs and thus the tyrosine 
phosphorylation of gp130 and STAT1/3, representing a negative feedback loop [263]. 
Further, dephosphorylation of receptors and JAKs is mediated by protein-tyrosine 
phosphatases [90, 141]. The activity of STATs can be inhibited by PIAS (protein inhibitors of 
activated STATs), e.g. PIAS3 blocks STAT3 DNA binding [45]. Another possibility of IL-6 
signal termination involves the degradation of the receptor-ligand complex by internalisation 
[59] or usage of the ubiquitin-proteasome pathway [278]. The latter is also used to degrade 
activated STATs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Major signal transduction pathways activated by IL-6: JAK/STAT pathway (right side) and 
MAPK pathway (left side). Cells expressing gp130 (green) and the membrane-bound IL-6R (blue) 
are responsive to IL-6 (red cylinder) (classic signalling). 
 
 
1.3  IL-6 classic signalling versus trans-signalling  
Activation of signal transduction by IL-6 (Fig. 2) via the receptor complex of membrane-
bound IL-6R and gp130 is called classic signalling. The signal transducer gp130 is 
ubiquitously expressed on all cells of the body, whereas the membrane-bound IL-6R has only 
been found on hepatocytes, monocytes/macrophages, some leukocytes as well as in certain 
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regions of the brain (see 1.1) [162, 197, 274, 321]. Cells lacking the membrane-bound IL-6R 
normally would not respond to IL-6 itself. But a naturally occurring soluble form of IL-6R 
(sIL-6R) can bind IL-6 with a similar affinity as the transmembrane IL-6R [232]. Therefore, 
IL-6 complexed with the sIL-6R can stimulate cells, which only express gp130, thus virtually 
all cells. Contrary to other soluble receptors (e.g. IL-1R, TNFαR) that are competitive 
inhibitors of their ligands [58, 307], the sIL-6R acts as an agonist. Hence, IL-6-mediated 
responses are enhanced by presence of the sIL-6R. This alternative transduction mode (Fig. 3) 
has been named IL-6 trans-signalling [180, 232]. Cells only responsive to IL-6 in presence of 
the sIL-6R are e.g. embryonic stem cells, early hematopoietic progenitor cells, endothelial 
cells, smooth muscle cells and neural cells. For the latter this finding was shown for neural 
stem cells [110], primary rat sympathetic neurons [160], primary dorsal root ganglia sensory 
neurons [282], primary rat hippocampal neurons [273], human fetal astrocytes [198], newborn 
rat astrocytes [161] and rat pheochromocytoma cells (PC12) [159]. Likewise, IL-6 trans-
signalling adopts an important role in neuronal differentiation and survival [162].  
The sIL-6R has been detected in various body fluids of healthy humans (25–35 ng/ml serum 
[100]; 0.8–1.8 ng/ml cerebrospinal fluid [74, 158]). It is generated by two different 
mechanisms, alternative mRNA splicing (10%) [151] and limited proteolytic cleavage of the 
ectodomain (shedding; 90%) by ADAM (a desintegrin and metalloprotease) 10 and ADAM 
17 [165, 180]. Stimuli leading to shedding of the IL-6R include bacterial metalloproteinases 
and pore-forming toxins [308], C-reactive protein [113], cholesterol depletion [165], phorbol 
esters [178] and apoptosis [41]. During differential splicing in humans a novel carboxy-
terminal protein sequence (GSRRRGSCGL) is created, which does not change the biological 
properties of the sIL-6R [103].  
In addition to the agonistic sIL-6R, a soluble form of gp130 (sgp130) with antagonistic 
properties exists at relatively high levels (100–400 ng/ml human serum) [169]. Sgp130 is 
generated by alternative mRNA splicing [55, 252, 277] as well as shedding [179]. The  
IL-6/sIL-6R complex can bind the soluble as well as the membrane-bound gp130, thus a 
molar excess of sgp130 is needed for antagonising IL-6/sIL-6R-triggered responses. Sgp130 
is therefore seen as a natural competitive inhibitor of IL-6 trans-signalling without affecting 
signalling via the membrane-bound IL-6R [115, 188, 234]. This is due to the fact that sgp130 
cannot bind neither to IL-6 nor to the complex of IL-6/membrane-bound IL-6R. To a much 
lesser extent sgp130 is also an inhibitor of LIF- and OSM-signalling [115, 245]. 
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Figure 3  IL-6 classic signalling versus trans-signalling. IL-6 classic signalling is mediated by membrane-
bound IL-6R and gp130 (left side). The soluble IL-6R (sIL-6R, blue) is generated via proteolytic 
cleavage (shedding) of proteases of the ADAM-family (yellow) or via alternative RNA splicing 
(not illustrated). The complex of sIL-6R/IL-6 can activate cells that only express gp130 but lack 
the membrane-bound IL-6R (trans-signalling, right side). 
 
 
1.4  Manipulation of IL-6 signalling: molecular tools 
Recombinant designer cytokines have been constructed that mimic components of IL-6 
signalling. A molecular agonist of IL-6 trans-signalling is named Hyper-IL-6, which is a 
fusion protein of human IL-6 and the human soluble IL-6R connected by a flexible peptide 
linker [70]. Hyper-IL-6 has a 100- to 1,000-fold higher effectivity on gp130-expressing cells 
than the combination of IL-6 and sIL-6R [70, 214]. As demonstrated by several studies, this 
designer cytokine is highly effective on neuronal cells such as primary rat astrocytes and 
neural cells and can stimulate cells that would not survive with IL-6 alone [159-162, 244, 
273]. 
Given the function of the natural soluble gp130 (see 1.3), the trans-signalling pathway can be 
specifically inhibited by a recombinant soluble fusion protein, which was constructed as a 
dimer of the extracellular part of human gp130 connected to a Fc-portion of a human IgG-
signal
gp130
IL-6R
ADAM 10/17
sIL-6R
IL-6
trans-signalling
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classic signalling
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1  Introduction   
  7 
antibody, designated as soluble gp130-Fc (sgp130-Fc, Fig. 4). The antagonistic activity of the 
dimer of sgp130-Fc was shown to be 10-fold higher than of the monomeric sgp130 [115]. 
This engineered inhibitor of IL-6/sIL-6R-mediated responses offers a tool for therapeutic 
application. The treatment with sgp130-Fc in murine models of rheumatoid arthritis [194], 
colitis [4], and colitis-associated colon carcinoma [14] suppressed or ameliorated the course 
of the disease. In sgp130-Fc systemic transgenic mice showing sufficient levels of protein in 
the serum to inhibit the hepatic acute phase response after Hyper-IL-6 challenge, 
inflammatory processes were blocked, supporting the ample role of IL-6/sIL-6R during 
inflammation in vivo [220].  
Eventually, the molecular tools Hyper-IL-6 and sgp130-Fc aid to specifically distinguish 
between IL-6 classic and trans-signalling at in vitro and in vivo applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Competitive inhibition of IL-6 trans-signalling by sgp130-Fc. The complex of IL-6/sIL-6R binds 
with the same affinity to membrane-bound gp130 and to sgp130-Fc, therefore a molar excess of 
sgp130-Fc inhibits trans-signalling responses (left side). Sgp130-Fc does not block classic-
signalling (right side), because IL-6 can associate with the membrane-bound IL-6R, but sgp130-Fc 
is not able to bind neither to this complex nor to IL-6 alone.  
no signal signal
sgp
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1.5  IL-6 signalling in CNS pathophysiology 
Elevated levels of IL-6 and sIL-6R in the CNS are implicated in a wide range of inflammatory 
and degenerative disorders of the brain. Activated microglia [254] and astrocytes [230, 295], 
that represent the primary immunocompetent cells of the brain, are the major sources of IL-6 
during CNS inflammation or injury. The initial beneficial effects of IL-6 turn then into the 
reverse, associated with exaggerated or chronic activation of microglia [211] and astrocytes 
[67], followed by overproduction of different cytokines and neurotoxins. In turn, further 
activation of glia cells and recruitment of inflammatory immune cells lead to persistence or 
progression of cell damage and disease (e.g. in multiple sclerosis, Parkinson’s and 
Alzheimer’s disease). Particularly, the sIL-6R-mediated IL-6 response and thus trans-
signalling is of substantial importance for pathogenesis.  
In multiple sclerosis (MS), which is a chronic inflammatory demyelinating CNS disease 
caused by autoreactive myelin-specific T-helper (Th) cells, including Th17 cells, that enter 
the CNS from the peripheral immune system through the blood-brain barrier (BBB) [98, 138, 
265], human serum levels of sIL-6R and sgp130 are increased and correlate with the disease 
severity [205]. In contrast, the amount of sgp130 in cerebrospinal fluid of MS patients was 
found decreased, which might lead to a reduced inhibition of the sIL-6R/IL-6 complex [206]. 
Mice deficient for IL-6 (IL-6 KO) remained resistant to myelin-oligodendrocyte glycoprotein 
(MOG) peptide induced experimental autoimmune encephalitis (EAE), which is an animal 
model for MS. This finding has been explained with the absence of expression of the adhesion 
molecules VCAM-1 and ICAM-1 on endothelial cells of the BBB, that normally guide the 
entry of primed T cells into the brain [65]. Likewise, blockade of IL-6 in wildtype mice by an 
anti-IL-6R monoclonal antibody inhibited the development of EAE and the induction of 
MOG petide-specific Th17 and Th1 cells [251]. This observation indicated a marked impact 
of IL-6 for the differentiation of Th17 cells (see 1.1) in EAE. Remarkably, a role of IL-6 
trans-signalling has been concluded for the early effector phase of rat EAE. The onset of EAE 
after suppression of IL-6 trans-signalling by sgp130-Fc was not prevented but less severe, 
mainly due to the observed reduction of adhesion molecule expression (VCAM-1) at the BBB 
[146]. 
Detection of elevated IL-6 in cerebrospinal fluid has been described for many other brain 
disorders, such as Parkinson’s and Alzheimer’s disease, stroke, traumatic brain damage, and 
encephalitis [116, 325]. A major role of glial cells, that produce and respond to cytokines, is 
discussed for the development of their neurological symptoms. 
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Transgenic mice strongly overexpressing IL-6 within the CNS by astrocytes developed 
neurological changes (e.g. tremor, ataxia), neuronal damage, astrogliosis, angiogenesis, 
induction of acute phase response, diffuse BBB leakage and show impairments in 
neuroendocrine, electrophysiological and learning functions [36, 37]. In contrast, transgenic 
mice that overexpressed IL-6 in neurons developed a gliosis similarly but no neuronal damage 
[69]. IL-6/sIL-6R double transgenic mice with systemic peripheral expression also showed 
strong neurological symtoms (e.g. tremor, paresis) and a massive reactive gliosis of 
astrocytes, which have not been observed in single transgenic mice [33].  
Moreover, both IL-6 and sIL-6R plasma levels are significantly elevated in psychiatric 
disorders such as in schizophrenia [152, 181], during post-traumatic stress disorder [154] and 
major depression [1, 86, 153, 176]. These and further results for chronic fatigue, alcoholism 
and eating disturbances point to a psychopathological role of IL-6, especially for trans-
signalling. Noteworthy, mental disorders are mostly paralleled by sleep disturbances.  
Furthermore, the brain controls the allocation of glucose to the brain itself and to the 
musculature and adipose tissue in the periphery, and reguates the metabolic setpoints, which 
are consolidated during sleep [213]. Alterations of these setpoints lead to pathological glucose 
regulation and thus disrupted energy supply causing diseases such as obesity, type 2 diabetes 
mellitus, hypertension, cardiovascular diseases, anorexia nervosa or major depression [213]. 
Interestingly, also these mentioned disorders are connected to dysregulated circulating IL-6 
and/or sIL-6R levels and altered sleep behaviour [117, 121].  
 
 
1.6  The sleeping brain 
1.6.1  What is sleep? 
Sleep is a fundamental physiologic brain process for health and well-being. It is behaviourally 
defined as a state of immobility and quiescence with reduced responsiveness, which is rapidly 
reversible. After prevention of sleep, the body is capable of recovering the lost amount in a 
rebound sleep (homeostatic) [255]. 
In almost all mammals and birds two forms/stages of sleep can be defined 
electrophysiologically via specific electroencephalogram (EEG) and electromyogram (EMG) 
patterns: non-rapid-eye-movement sleep (non-REM sleep; in humans slow wave sleep 
(SWS)) and rapid-eye-movement sleep (REM sleep). Non-REM sleep is further subdivided 
into light and deep sleep (delta sleep). Deep non-REM sleep is characterised by high 
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amplitude/voltage slow delta waves (0.5–4 Hz) and a relaxed muscle tone [72, 189]. Slow 
waves originate from synchronised periods of neuronal depolarisation (high firing) followed 
by periods of hyperpolarisation (down phase) within large areas of the cortex. In addition very 
slow cortical oscillations (<1Hz) are present [269]. The delta wave power (=slow wave 
activity) reflects the intensity of sleep, e.g. it increases during rebound deep sleep after a sleep 
loss [23]. REM sleep characteristics are the low voltage EEG (low EEG amplitude, as in 
wakefulness), high values of theta waves (4–9 Hz) from hippocampal origin, and muscle 
atonia [72, 189]. 
Sleep architecture is organised in cycles of alterations between non-REM sleep followed by 
REM sleep. Physiological noctural sleep in humans consists of 4 to 5 cycles of about 90–100 
min each. The length of sleep stages varies in the course of sleep, in which the first half of 
sleep is dominated by non-REM sleep and the second half by REM sleep. There are 
differences in sleep architecture between species. In rats, whose main activity period is during 
the dark, the sleep is polyphasic. They sleep about 70% during the light phase and 30% during 
the dark phase. The periodicity of the non-REM/REM cycle with 7–13 min is much shorter 
than in humans [156, 255].   
 
1.6.2  Regulation of sleep 
For a better understanding of sleep, it is useful to get a brief insight into the mechanisms 
underlying its regulation in the CNS. Homeostatic, circadian, neuronal and humoral 
(endocrine, metabolic, immunologic) processes are linked in a very complex network leading 
altogether to regulation of sleep-wake behaviour. Even though there are still many open 
questions, various hypotheses have been established on different levels of organisation of 
sleep, which are explained here briefly.  
The circadian control by the master clock located in the suprachiasmatic nucleus of the 
hypothalamus receives retinal input, and the time of day information (light/dark) is relayed to 
several brain regions. It coordinates the timing of the sleep-wake cycle by its circadian clock 
genes maintaining a 24-h rhythm [170, 256]. Borbely [22, 24] combined the interaction of 
circadian control with the homeostatic regulation of sleep in the “two process model”. In 
accordance, the homeostatic need to sleep accumulates during prolonged wakefulness and is 
discharged during sleep. It includes the process of synaptic homeostasis. The circadian 
component controls the thresholds at which sleep and wake occur [22, 24]. 
On an anatomical view, critical brain areas, neuronal circuits and neurotransmitters for sleep-
wake regulation have been delineated. Networks of cell groups of the posterior hypothalamus, 
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the basal forebrain and brainstem are crucial for wake maintenance, that activate the thalamus 
and cerebral cortex. Their neurons are monoaminergic (contain e.g. noradrenaline, dopamine, 
serotonin, histamine), cholinergic (e.g. actelycholine) and orexinergic (orexin=hypocretin). 
Cell groups for arousing are inhibited during sleep by basal forebrain, median and 
ventrolateral preoptic (VLPO) hypothalamic regions, which contain the inhibitory 
neurotransmitters gamma-aminobutyric acid (GABA) and galanin. These non-REM sleep 
active neurons are inhibited during wakefulness by the monoaminergic system. This direct 
mutual inhibition between the non-REM sleep-promoting neurons (e.g. VLPO) and the 
monoaminergic arousal groups forms the first switch of the “flip-flop switch model”. Only 
one side is active avoiding mixed states. This switch is stabilised by the wake active orexin 
neurons of the posterior lateral hypothalamus [52, 167, 240]. A second switch lies between 
non-REM and REM sleep, where “REM-on” neurons in pons and adjacent midbrain get 
activated, that also trigger REM muscle atonia [52, 150, 167].  
A more recent view on brain organisation of sleep revealed a mechanistic hypothesis. It 
describes sleep as a fundamental, local and use-dependent property of neuronal assemblies 
[135-137]. Neuronal assemblies are anatomically defined neuronal networks, e.g. cortical 
columns, where the high amplitude EEG delta waves of non-REM sleep is a local property. It 
has been found that cortical columns alterate between a sleep-like and a wake-like state by 
changing their input-output relationships. When an animal is awake, the wake-like state is 
present in most of the cortical columns. During sleep, most of the columns are synchronised 
in a functional sleep-like state. These states are also regulated homeostatically, thus the longer 
a column stays in a wake-like state, the higher the probability that it will change into the 
sleep-like state [223]. Importantly, these state oscillations are dependent on the past activity of 
the column state. For example, EEG delta power was enhanced during subsequent non-REM 
sleep after disproportionally local hand stimulation in wakefulness [123]. Column state 
alterations are not only dependent on the amount of afferent activity but also on the 
production of sleep regulatory substances (SRSs) [135-137]. SRSs that build the humoral part 
of sleep regulation include substances like adenosine, nitric oxide (NO), NF-κB, peptides 
such as growth hormone (GH), orexins, prostaglandins, serotonin, and other proteins such as 
cytokines. Cytokines present a humoral link in the interaction between immune and central 
nervous system and interact with other cytokines, neurotransmitters and hormones involved in 
sleep regulation [52, 82, 107, 133, 136, 156, 195, 203, 264]. Effects of cytokines are always 
dependent on the dose and circadian phase. During wakefulness in response to neuronal 
activity, SRS production by neurons and glia is enhanced locally. In a network of biochemical 
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cascades (“non-REM Sleep homeostat”), the downstream actions of SRSs on neurotransmitter 
and cytokine release, gene transcription and translation, including feedback loops, act on 
neuronal assemblies to alter the functional sleep/wake-like state (ATP-contributed) and 
communicate to the sub-cortical sleep regulatory circuits [120, 135-137]. 
Well-characterised SRSs are the cytokines TNFα and IL-1β, whose administration (central 
and systemic) enhance duration and intensity of non-REM sleep in laboratory animals and 
humans [135, 136, 203]. The interaction of IL-1β and serotonin appears to have a central role 
in the regulation of sleep [107]. There is also strong evidence that IL-6 affects sleep 
modulation (see section 1.7). Many other cytokines have somnogenic properties for non-REM 
sleep like IL-8, IL-18, Epo, NGF; are non-REM sleep inhibitors such as IL-4, IL-10, sTNF-R; 
or inhibit REM sleep like IL-1β, IL-2, IL-15, IL-18, TNFα [107, 120, 133-136, 156, 195, 
203]. 
Hormones of the hypothalamic-pituitary-adrenal (HPA) axis such as adrenocorticotropin 
(ACTH), corticotropin releasing hormone (CRH) as well as cortisol build a component of the 
interaction between sleep and stress system. The circadian secretory pattern of these HPA 
hormones in humans indicate lowest levels during early noctural sleep and a maximum at the 
morning (arousal). Furthermore, several research studies observed that CRH, ACTH and 
cortisol induced increased arousal [26, 156, 264, 299]. Cytokines including IL-1, IL-6 and 
TNFα have been shown to stimulate the HPA-axis (see 1.1) [262]. Hormones of the 
somatotropic system as growth hormone-releasing hormone (GHRH) and GH belong to the 
sleep-promoting SRSs. Taken together, the complex network of cytokines and the 
neuroendocrine system is part of the sleep regulatory/modulatory machinery (sketched in Fig. 
5). In turn, sleep itself affects cytokine expression [107]. 
 
 
 
 
 
 
 
 
Figure 5  Schematic overall model of humoral regulation of sleep organised in a large network. Sleep-
promoting components (green) are inhibited during wakefulness (red) and vice versa. For further 
information see 1.6.2. 
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1.6.3  Functions of sleep 
Sleep is a fundamental brain process [137, 283] but currently it is not possible to determine a 
specific function. Nevertheless, there is no question that sleep serves multiple functions to 
ensure physical and mental health. Sleep has recovery and restorative functions to the brain 
and body that include cellular, endocrine, immune, metabolic, thermoregulatory and 
behavioural processes like learning and synaptic plasticity [167]. 
The detrimental effects of sleep loss corroborate the importance of sleep. Rats that were not 
allowed to sleep died after 2–3 weeks [222]. Sleep deprived humans showed impaired 
cognitive performance, tiredness, metabolic, endocrine and immune dysregulation [8, 128, 
290, 291]. Prevention of sleep altered the numbers of NK-cells, lymphocytes, monocytes and 
enhance levels of HPA hormones and proinflammatory markers such as CRP and the 
cytokines TNFα, IL-1β, IL-6 and IL-17. These sleep-restricted changes of immune functions 
contribute to many disorders such as higher susceptibility to infections, diabetes, impaired 
glucose tolerance, cardiovascular diseases, hypertension, obesity and depression [25, 108, 
109, 121, 292].  
The other way around, bacterial or viral infections, inflammation processes, stress situations, 
or other pathologies that alter cytokine and hormone secretion patterns often lead to 
dysregulated sleep-wake behaviour, e.g. in influenza infection, HIV infection, in 
cardiovascular diseases, diabetes and rheumatoid arthritis [107, 121, 134]. Beneficially, sleep 
is a component of host defense against microbial pathogens, where cytokines play a key role, 
including acute phase response and sickness behaviour. Sleep architecture is therefore altered 
in a manner that supports the development of fever to promote recovery. Thus, non-REM 
sleep is enhanced and fragmented during infection, so that fever can be generated and heat 
loss is reduced. REM sleep is strongly suppressed, since shivering that is needed for 
generation of fever does not occur during REM sleep [107]. The role of sleep for the immune 
response has additionally been illustrated for vaccination effectiveness. Sleep at the night after 
Hepatitis A vaccination strongly enhanced the antibody titer in comparison to a wakeful night 
[140]. Otherwise, the functions of T-helper and regulatory T cells, which are coupled to the 
sleep-dependent circadian rhythm, are modulated by sleep [21]. 
On the mechanistic level many researchers have proposed the theory that synaptic scaling is 
the primordal function of sleep [124, 132, 137, 284], which means the up- or downregulation 
of the strength of synapses to stabilise the activity-dependent changes in neurons and synaptic 
networks. Tononi and Cirelli [284] described in the “synaptic homeostatic hypothesis” the 
function of synaptic downscaling for the benefits for learning/memory consolidation, which 
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belongs to the essential sleep function [166, 270]. Briefly, learning during wakefulness leads 
to long-term potentiation, the total synaptic strength increases, whereas it decreases 
(downscaling) during sleep (SWS). Then only the most robust connections stay intact, with 
benefits for energy and space requirements and memory consolidation. Krueger and Obal 
[132, 137] concluded that SRSs are involved in synaptic scaling, as it was shown for TNFα 
[119, 267].  
 
 
1.7  IL-6 and sleep 
Multiple research in humans and animals pointed to a role for the cytokine IL-6 as a sleep 
modulatory factor. IL-6 and sIL-6R are present in periphery and brain. Although their 
concentrations under normal conditions are very low, they are sufficient to influence brain 
functions [216]. Plasma IL-6 is secreted in a circadian rhythm that correlates with the sleep-
wake cycle. IL-6 peaks in healthy humans during sleep and has low values during the day [13, 
85, 108, 259, 298, 301, 303]. Similarly, IL-6 release increased in rats during their major 
sleeping period (light period) in brain (cortex, hippocampus, hypothalamus), adipose tissue 
and blood [84]. Thus, sleep onset is associated with elevated levels of circulating IL-6. Mainly 
monocytes, adipocytes and muscle cells contribute to the production of IL-6 in blood [224]. 
For IL-6-producing monocytes (humans) a noctural rise has been found [56]. During human 
sleep, IL-6 plasma levels differ between sleep stages. Higher IL-6 levels were measured in 
REM and light sleep but not in deep sleep (SWS) [224, 298]. A negative correlation between 
SWS and IL-6 release became evident. Likewise, daytime IL-6 concentrations are negatively 
correlated to the amount and efficiency (depth) of noctural sleep (SWS) [168, 298]. Sleep 
deprivation in healthy humans led to a change in the circadian pattern of IL-6 plasma levels, 
thus to an undersecretion of IL-6 during the night of sleep loss and to an oversecretion at the 
following day [253, 298, 303]. The recovery night (rebound sleep), with increased amount of 
SWS and delta power, was associated with reduced IL-6 levels [298, 303]. However, when 
sleep restriction was stopped [224] or interrupted by a nap [253], or after a 2-h midafternoon 
nap [304], IL-6 levels again decreased. Even mild sleep restriction from 8 to 6 h/night for 1 
week in healthy humans resulted in elevated daytime IL-6 plasma levels, sleepiness and 
impaired psychomotor performance [302]. Also in rodents, increased levels of IL-6 were 
observed after sleep deprivation in serum as well as in the brain [84, 104]. Taken together, 
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these results indicate that increased IL-6 levels during wakefulness in consequence of sleep 
loss might contribute to the homeostatic sleep pressure. 
In a number of previous studies sleep-wake behaviour after exogenous manipulation of the 
IL-6 system in humans and animals was investigated. In healthy humans a subcutaneous (s.c.) 
injection of recombinant human IL-6 in the evening before sleep, leading to blood 
concentrations comparable to values during bacterial infection, increased the feeling of 
tiredness. Furthermore, IL-6 reduced the amounts of REM sleep and SWS in the first half of 
the night followed by an enhanced SWS during the second half [262]. Recently, an intranasal 
application of human IL-6 to humans has increased slow wave activity of SWS (delta wave 
power) during the late part of the night together with an improvement of sleep-related 
declarative memory. Here, REM sleep was not affected [16]. The outcome from several 
animal studies remain conflicting with regard to the effect of IL-6. Central (i.c.v.) and 
peripheral (i.p.) injection of human IL-6 into rabbits did not alter non-REM sleep and REM 
sleep [202]. However, i.c.v. administration of rat IL-6 to rats before the dark phase caused an 
initial increase followed by subsequent suppression of non-REM sleep, and sleep 
fragmentation in a dose-dependent manner without changes in REM sleep amount. But 
antagonising IL-6 via anti-rat antibodies did not affect sleep-wake behaviour [99]. 
Remarkably, mice deficient for IL-6 (IL-6 KO) displayed normal non-REM sleep but 30% 
more REM sleep. After sleep deprivation, IL-6 KO mice required more time to obtain the 
same non-REM sleep amount as wildtype mice [174]. To bacterial LPS challenge, normal 
wildtype mice responded with enhanced non-REM sleep, that was slighter in IL-6 KO mice 
[175]. This suggests that IL-6 may be a modulator of non-REM sleep during 
sickness/pathologies, in which IL-6 is elevated. 
Besides, IL-6 is a modulator of the neuroendocrine system, such as the HPA axis, that 
influences sleep (see 1.1.) [262, 286]. In clinical human studies an interesting constellation 
between peripheral IL-6 and cortisol levels has been observed. A hypersecretion of IL-6 
accompanied by relatively high cortisol levels (activation of the HPA) led to poor sleep and 
fatigue, as it is the case e.g. in chronic insomnia or in elderly people (aging). On the other 
hand, elevated IL-6 and low cortisol levels were associated with sleep and sleepiness [182, 
300, 301, 303]. IL-6 levels are elevated in disorders and pathologies associated with excessive 
daytime sleepiness (EDS) such as insomnia, narcolepsy, sleep apnea, obesity, aging [34, 39, 
121, 200, 297, 298, 300]. Examples for chronic insomnia and elevated IL-6 levels include 
several psychological disorders such as depression, alcoholism and schizophrenia [1, 86, 108, 
149, 176, 225]. 
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Only a few studies elucidating the effect of IL-6 on sleep addressed the different receptors of 
the IL-6 signalling pathways. Cirelli et al. [46] found a downregulation of the rat IL-6R in the 
cerebral cortex during wakefulness via a gene array study. Dimitrov et al. [56] discriminated 
between components of IL-6 classic and trans-signalling during normal human sleep 
behaviour. This publication revealed rising plasma concentrations of the shed variant of the 
sIL-6R during sleep with a maximum after awakening in the morning, which is paralleld by 
elevated noctural IL-6 levels. These findings implicate that sleep enhances IL-6 trans-
signalling. The normally high amount of REM sleep during late sleep correlated with this high 
sIL-6R amount, suggesting a putative connection of IL-6 trans-signalling and REM sleep. 
 
 
1.8  Aim of this work 
Numerous previous studies implicated the cytokine IL-6 in sleep modulation. Since the 
peripheral human sIL-6R is upregulated during sleep, which is regulated by the brain, it is the 
aim of this study to determine the role of IL-6 trans-signalling within the CNS on sleep-wake 
behaviour. Therefore the effect of IL-6/sIL-6R on sleep was investigated in vivo by 
intracerebroventricularly (i.c.v.) injection of the designer cytokine Hyper-IL-6 (agonist of 
trans-signalling) into rats and subsequent EEG/EMG recoding. Additionally, transgenic mice 
were generated, that overexpress the inhibitor of IL-6 trans-signalling sgp130-Fc within the 
brain under an astroycte-specific promoter. In the future, these mice will be investigated in 
terms of sleep and learning behaviour.  
IL-6 mostly exerts a pathophysiological role in the periphery and the CNS via trans-
signalling. Thus, the constructed transgenic brain-specific sgp130-Fc mice could be subjected 
to reasearch models of peripheral and central inflammation.  
In summary, these experiments will help to define the relevance of IL-6 trans-signalling in the 
regulation/modulation of sleep and in the coordination of neuroinflammatory processes. 
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2  Material and Methods 
2.1  Material 
2.1.1  Chemicals 
General buffer chemicals were purchased by the companies Carl Roth (Karlsruhe), Sigma-
Aldrich (Deisenhofen), Merck (Darmstadt) and Serva (Heidelberg). The used water (Aqua 
bidest) was deionised and if needed autoclaved or sterile filtered. 
 
2.1.2  Radiochemicals 
Deoxyadenosin-5´-triphosphate, [α-32P], 3000 Ci/mmol (MP Biomedicals GmbH, Eschwege). 
 
2.1.3  Plasmids and vectors 
pmax–GFP (Amaxa GmbH, Köln); 
pGfa2–LacZ [29]; 
p409–sgp130-Fc (Jürgen Scheller); 
pCR-script–sgp130-Fc_optimised (GENEART, Regensburg); 
pTZ–PEPCK–βglob.intron–opt_sgp130Fc [220]; 
pGfa2–sgp130-Fc_optimised–mP1 (this work); 
pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-blobin (this work). 
 
2.1.4  Primers 
polyA rabbit β-globin forward (for cloning):  
5’-GAC TGA ATT CGA TCT TTT CCC TCT GCC-3’ 
polyA rabbit β-globin reverse (for cloning):  
5’-GAC TGC GGC CGC GTC GAG GGA TCT CCA TAA G-3’    
2nd intron rabbit β-globin forward (for cloning) :  
5’-GTC GTC GAC AGA TCT CGA TCC TGA GAA CTT CAG-3’ 
2nd intron rabbit β-globin reverse (for cloning):  
5’-GATCAAGCTT GATTCTTGCC AAATGATG-3’ 
sgp130-Fc-screen forward: 5’-GAG TTC AGA TCC TGC GAC-3’ 
sgp130-Fc-screen reverse: 5’-TCA CTT GCC AGG AGA CAG-3’ 
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β-globin (mouse) forward:  
5’-CCA ATC TGC TCA CAC AGG ATA GAG AGG GCA GG-3’  
β-globin (mouse) reverse:  
5’-CCT TGA GGC TGT CCA AGT GAT TCA GGC CAT CG-3’ 
sgp130-Fc-screen-new forward: 5’-CTG TCC TCC TTG TCC TGC TC-3’ 
sgp130-Fc-screen-new reverse: 5’-ATG TCA CCT CAG GGG TTC TG-3’ 
Oligo d(T): 5’-TTT TTT TTT TTT TTT TTT-3’ 
Primers were synthetised by Metabion GmbH (Martinsried). 
 
2.1.5  Recombinant Cytokines 
human IL-6: prepared and purified as described in [289]; 
Hyper-IL-6:  fusion protein of human soluble IL-6 receptor connected by a flexible peptide 
linker; prepared and purified as described in [70]; 
sgp130-Fc :  dimer of soluble gp130 fused to the Fc-portion of a human IgG antibody; 
prepared and purified as described in [115]; kindly provided by Steffi Schnell 
(Institut of Biochemistry, Christian-Albrechts-University Kiel).  
 
2.1.6  Antibodies 
2.1.6.1  Primary antibodies 
mouse anti-human gp130 B-P4 (Diaclone, Besancon, France): diluted 1:1,000 in 5% low fat 
milk powder/TBS for Western blot analysis; 
mouse anti-human IL-6 receptor clone 14-18 [41]: diluted 1:5,000 in 5% low fat milk 
powder/TBS for Western blot analysis; 
rabbit anti-phospho-STAT3 (Cell Signaling Technology, New England Biolabs GmbH, 
Frankfurt/Main): diluted 1:2,000 in 5% BSA/TBS for Western blot analysis; 
mouse anti-STAT3 (Cell Signaling Technology, New England Biolabs GmbH, 
Frankfurt/Main): diluted 1:2,000 in 5% low fat milk powder/TBS for Western 
blot analysis. 
 
2.1.6.2  Secondary antibodies 
Goat anti-mouse IgG peroxidase (POD) conjugate (Pierce, Fisher Scientific GmbH, 
Schwerte): diluted 1:10,000 in 1% low fat milk powder/TBS for Western blot 
analysis; 
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Goat anti-rabbit IgG peroxidase (POD) conjugate (Pierce, Fisher Scientific GmbH, Schwerte): 
diluted 1:10,000 in 1% low fat milk powder/TBS for Western blot analysis. 
 
2.1.7  Cell lines 
U251:  human astroglioma cell line (ATCC, Rockville, MD, USA), adherent cells; 
Ba/F3-gp130: murine peripheral blood pre-B-cell line, stably transfected with cDNA 
encoding human gp130 [207], suspension cells; 
Ba/F3-gp130-IL-6 receptor: murine peripheral blood pre-B-cell line, stably transfected with 
cDNAs encoding human gp130 and murine IL-6 receptor [79], suspension 
cells. 
 
2.1.8  Mouse strains 
C57BL/6N (Charles River Laboratories, Germany, Bad Sulzfeld); 
pepck–sgp130-Fc (systemic expression of sgp130-Fc, [220]); 
gfa2–sgp130-Fc (astrocyte-specific expression of sgp130-Fc, this work). 
 
2.1.9  Standard buffers 
TBS:  50 mM Tris-HCl, pH 7.6, 200 mM NaCl; 
TBS-T: 50 mM Tris-HCl, pH 7.6, 200 mM NaCl, 0.05% Tween-20; 
PBS: 250 mM NaCl, 20 mM KCl, 48 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4; 
PBS-T:  250 mM NaCl, 20 mM KCl, 48 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4, 
0.05% Tween-20. 
 
 
2.2  Molecular biological methods 
2.2.1  Agarose gel electrophoresis 
DNA was separated on an agarose gel in 0.5 x TBE buffer (45 mM Tris, 45 mM boric acid,  
1 mM EDTA, pH 8) at 70–100 V (gel chambers by BioRad Laboratories GmbH, München). 
Depending on the size of the DNA fragment 0.7–2% of agarose was used. Before loading the 
DNA sample onto the gel, 1/6 volume of 6 x loading dye (10 mM Tris-HCl, pH 7.6, 0.03% 
bromphenol blue, 0.03% xylene cyanol, 60% glycerol, 60 mM EDTA) was added. The DNA 
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intercalating substance ethidiumbromide (0.5 µg/ml) was applied to the gel, to visualise the 
DNA under UV light (GelDoc 2000, BioRad Laboratories GmbH, München). For estimating 
the band size of DNA fragments, a 1 kb DNA marker was used (Fermentas, St. Leon-Rot). 
 
2.2.2  Determination of nucleic acid concentrations 
To measure the concentration of DNA or RNA, UV spectrophotometry (Ultrospec 3000, 
Amersham Pharmacia Biotech Europe GmbH, Nümbrecht) was used. Concentrations and 
purity were determined by measuring absorbances at 260 nm, 280 nm and 320 nm.  
 
2.2.3  Cloning 
Steps involved in cloning of DNA constructs and generation of new vectors/plasmids, such as 
isolation of plasmids, restriction of DNA, dephosphorylation of vector DNA, purification of 
DNA fragments via agarose gel extraction, PCR, ligation, transformation of E.coli, are 
described below. 
 
2.2.4  Plasmid DNA Isolation 
Plasmid DNA was isolated from 100-ml liquid bacteria cultures (in LB medium including an 
antibiotic) using the NucleoBond® Midi AX 100 Kit (Macherey-Nagel, Düren) according to 
the manufacturer’s protocol. 
 
2.2.5  Enzymatic restriction of DNA 
The DNA was incubated with appropriate amounts of restriction enzymes (Fermentas, St. 
Leon-Rot) in the recommended buffer for 2 h or overnight at 37°C. Restriction was 
terminated by addition of 6 x DNA loading dye (10 mM Tris-HCl, pH 7.6, 0.03% bromphenol 
blue, 0.03% xylene cyanol, 60% glycerol, 60 mM EDTA) and loaded on an agarose gel. For 
further preparation, the resulted digested DNA fragment was eluted from the agarose gel 
(2.2.8).  
 
2.2.6  Vector dephosphorylation 
To avoid self-ligation of restricted vector/plasmid DNA, the 5’-phosphate groups were 
dephosphorylated enzymatically. The restriction reaction mixture was incubated with 1 U 
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Calf Intestinal Alkaline Phosphatase (CIAP, 1U/µl, Fermentas, St. Leon-Rot) for 60 min at 
37°C. 
 
2.2.7  Polymerase Chain Reaction (PCR) [183] 
During PCR, a target DNA sequence between two oligonucleotid primers is amplified 
exponentially. The recombinant Taq DNA-Polymerase (Fermentas, St. Leon-Rot) was utilised 
in a screening PCR for identification of sgp130-Fc-positive transgenic mice. DNA 
amplification for a cloning strategy was achieved using the Pfu DNA-Polymerase (Fermentas, 
St. Leon).  
 
PCR reaction mix: 
10 x Taq-Polymerase buffer    5 µl 
dNTP mix (10 mM)     1 µl 
MgCl2 (25 mM)     4 µl 
forward primer (100 pmol) 0.5 µl 
reverse primer (100 pmol) 0.5 µl 
Taq-Polymerase (5 U/µl)    1 µl 
DNA template    10–200 ng  
water           ad 50 µl 
 
Standard PCR temperature programme (equipment: Robo Cycler Gradient; Stratagene, La 
Jolla, USA): 
 
initial denaturation   94°C  2  min  1 cycle 
 
denaturation   94°C  1 min 
primer annealing  55–57°C 1 min  30 cycles 
elongation   72°C  1 min 
 
final elongation  72°C  5 min  1 cycle 
 
The annealing temperature depends on the melting temperature of the primer pair. 
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2.2.8  Purification of DNA fragments from agarose gels 
DNA fragments were cut out with a scalpel and purified from agarose gels using the 
PureLinkTM Quick Gel Extraction Kit by Invitrogen Corporation (Karlsruhe) following the 
manufacturer’s protocol. 
 
2.2.9  Precipitation of DNA 
After purification of DNA from an agarose gel (2.2.8) it is possible to further purify, 
concentrate or change the buffer of the DNA solution. An ammoniumacetat/ethanol 
precipitation of the transgene-containing DNA cassette was applied, needed for the 
pronucleus microinjection to generate transgenic mice (2.5.2). For precipitation, 1/10 volume 
of 7 M ammomium acetate and 2 volumes of 96% ethanol were added to the DNA solution 
and mixed. After centrifugation (20 min, 16,000 x g, 4°C) the DNA pellet was washed with  
1 ml 70% ethanol and centrifuged again (10 min, 16,000 x g, 4°C). The DNA pellet was dried 
at 50°C or during vacuum centrifugation before it was dissolved in an appropriate solvent like 
TE buffer (5 mM Tris-HCl pH 7.4, 0.1 mM EDTA) as requested for DNA microinjection 
(2.5.2) to a DNA concentration of 30 µg/ml. The DNA solution was additionally cleared by 
centrifugation (10 min, 16,000 x g, 4°C). 
 
2.2.10  Ligation 
For ligation of the DNA fragment of interest into a vector, 50 ng vector DNA and a 3–5 fold 
molar excess of insert DNA were incubated with 1 U T4 Ligase (Fermentas, St. Leon-Rot) in 
ligation buffer (supplemented, Fermentas, St. Leon-Rot) for 1 h at room temperature. The 
reaction mixture was used directly for transformation of E. coli (2.2.12). 
 
2.2.11  Generation of chemo-competent E. coli 
To prepare chemo-competent E. coli XL1-Blue (Stratagene, La Jolla, USA) the calcium 
chloride method was used. Therefore the bacteria were grown to an OD595nm of 0.6 and 
subsequently chilled on ice at 4°C. The cells were centrifuged (3,000 x g, 4°C) and 
resuspended in 50 mM CaCl2. After a second centrifugation step and resuspension in 50 mM 
CaCl2 supplemented with 10% glycerin, the cells were aliquoted and snap frozen in liquid 
nitrogen. The competent bacteria were stored at –80°C. 
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2.2.12  DNA Transformation of E. coli 
Chemo-competent E. coli XL1-Blue bacteria were transformed by the heat-shock method. 
Bacteria were thawn on ice. Fifty µl of competent E. coli XL1-Blue and 10 ng plasmid or 5 µl 
of ligation mixture were incubated on ice for 5 min. After a heat-shock of 90 seconds at 42°C 
the bacteria were chilled on ice for 5 min. Thereafter 1 ml LB medium without antibiotics was 
added and the bacteria were incubated for 1 h at 37°C under continous shaking. The 
transformed bacteria (100–400 µl) were plated onto LB agar plates containing the appropriate 
antibiotic and incubated overnight at 37°C. For isolation of a transformed plasmid DNA via 
the NucleoBond Kit (Macherey-Nagel, Düren, 2.2.4), a single E. coli colony was picked from 
the plate and grown in liquid cultures at 37°C overnight. 
 
“Luria Bertani” (LB) medium: 10 g/l NaCl, 5g/l yeast extract, 10 g/l tryptone 
 
LB agar plates:  10 g/l NaCl, 5g/l yeast extract, 10 g/l tryptone, 15 g/l agar agar 
 
The autoclaved medium was supplemented, if required, with antibiotics: ampicillin  
(50 µg/ml) or kanamycin (30 µg/ml, both from Carl Roth, Karlsruhe).   
 
2.2.13  DNA Sequencing 
Sequencing of DNA was performed by the company Seq-Lab (Göttingen). The DNA (0.7 µg) 
and 20 pmol sequencing primer were diluted in 7 µl water. 
 
2.2.14  Isolation of genomic mouse DNA 
Genomic DNA was isolated from a 0.5-cm-long tail of a 4-week-old mouse, which was cut 
with sterile scissors. The tail was incubated overnight at 55°C, slightly shaked in 600 µl tail-
buffer (50 mM Tris-HCl, 1 mM EDTA, 20 mM NaCl) containing 30 µl 10% SDS and 20 µl 
Proteinase K (20 mg/ml; Fermentas, St. Leon-Rot). Undissolved material was removed by 
centrifugation (5 min, 16,000 x g, 4°C) and DNA was purified by adding 600 ml 
phenol/chloroform/isoamylalcohol (25:24:1; Carl Roth, Karlsruhe) and shaken for 10 min at 
4°C. After a centrifugation step (10 min, 16,000 x g, room temperature) the upper aqueous 
phase was collected and again treated with phenol/chloroform/isoamylalcohol followed by 
mixing and centrifugation according to the same procedure, which was repeated 2 times if 
necessary. After the following extraction step with only chloroform, the DNA of the upper 
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aqueous phase was precipitated with 100 µl 5 M NaCl and 800 µl 96% ethanol. The mixture 
was inverted 20 times, incubated for 20 min at -20°C and centrifuged (20 min, 16,000 x g, 
4°C). The DNA pellet was washed once with 70% ethanol and thereafter dried for 20 min at 
37°C. The DNA was dissolved in 100 µl water, incubated for 10 min at 65°C and overnight at 
4°C. The concentration of DNA was determined by UV spectrophotometry (2.2.2). Genomic 
DNA was used for Southern blot analysis (2.2.17) and PCR (2.2.7).  
As an alternative method a phenol-free kit was used (Gentra Puregene Tissue Core Kit; 
Qiagen, Hilden) according to the manufacturer’s instruction, and the genomic DNA was used 
for PCR (2.2.7). 
 
2.2.15  Isolation of total RNA 
Total RNA from tissue or cells was isolated with the NucleoSpin® RNA II Kit (Macherey-
Nagel GmbH & Co. KG, Düren). Frozen mouse tissue was grinded with pestle and mortar in 
liquid nitrogen. During this procedure, thawing of organs was avoided. The pulverised organs 
were processed immediately or kept at –80°C. The total RNA amount was measured by UV 
spectrophotometry (2.2.2). 
 
2.2.16  Reverse Transcriptase PCR (RT-PCR) 
During the reverse transcription (RT) reaction, mRNA is translated into a single stranded 
cDNA followed by a conventional PCR using gene-specific primers. RevertAid M-MuLV 
Reverse Transcriptase (Fermentas, St. Leon-Rot) was employed according to the 
manufacturer’s protocol. Oligo(dT) primers were used, which target the 3’ poly(A) mRNA 
tail. For RT reaction 1.5 µg RNA and for further PCR reaction (2.2.7) 1 µl cDNA were used. 
 
2.2.17  Southern blot 
2.2.17.1  Electrophoretic separation of digested genomic DNA 
Ten micrograms of genomic mouse DNA were digested with the restriction endonuclease 
EcoRV overnight at 37°C. Afterwards the generated DNA fragments were separated on a 
0.7% agarose gel at 90 V. 
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2.2.17.2  Preparation of the Agarose gel and blotting procedure 
After electrophoresis the gel was treated with 0.25 M HCl for 15 min (depurination), 2 x  
20 min with a denaturation solution (0.5 M NaOH, 1.5 M NaCl) and finally with a 
neutralisation solution (1 M Tris-HCl, pH 8, 1.5 M NaCl) for 10 min. After washing the gel in 
10 x SSC (1.5 M NaCl, 0.15 M sodium citrate, pH 7) for 5 min, the capillary blot was 
assembled according to Sambrook et al. [239]. The transfer buffer 10 x SSC was used. During 
blotting, the DNA fragments were transferred and immobilised onto a positive charged nylon 
membrane (Hybond-N+, Amersham Biosciences Europe GmbH, Freiburg). After the transfer 
process the membrane was washed in 5 x SSC for 15 min and dried at 65°C. The DNA was 
crosslinked to the membrane by radiation with 120 mJ UV light. 
 
2.2.17.3  Hybridisation of the membrane 
The α-32P-dATP-labelled probes, which contain the DNA sequence of interest, were 
generated using the Prime-It II Random Primer Labeling Kit (Stratagene, La Jolla, USA) 
according to the manufacturer’s instruction in a reaction volume of 50 µl. To remove unbound 
nucleotides the probes were purified via ProbeQuantTM G-50 Micro Columns (Amersham 
Biosciences Europe GmbH, Freiburg) according to the manufacturer’s instructions. 
To avoid unspecific binding of the probe, the membrane was prehybridised for 1 h at 65°C in 
prewarmed hybridisation solution (500 mM NaPi, pH 7.2, 7% SDS, 1% BSA, 1 mM EDTA) 
under constant rolling. The radioactive-labelled probe was incubated for 5 min at 95°C to 
obtain single-stranded probes and then put on ice for 5 min. For hybridisation, the membrane 
was incubated with the probe (50 µl) in 20 ml fresh prewarmed hybridisation solution over- 
night at 65°C under constant rolling. 
To remove unspecifically bound probes, the membrane was washed with stringent washing 
buffers: 2 times for 15 min with 2 x SSC, 0.1% SDS (high stringency); 2 times for 10 min 
with 0.1 x SSC, 0.1% SDS (moderate stringency) at 65°C under rolling conditions. Binding of 
the probe to the desired target sequence was visualised by exposing the membrane on a Kodak 
BioMax MS X-ray film (Amersham Biosciences Europe GmbH, Freiburg) for several days at 
–70°C. The film was developed until bands were seen visually and fixed in solutions by 
Tenenal (Norderstedt).  
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2.2.18  Northern blot 
2.2.18.1  Electrophoresis of RNA 
To avoid RNA degradation all solutions and water were treated with 0.05% DEPC 
(diethylpyrocarbonate; Carl Roth, Karlsruhe) overnight at 37°C. DEPC inactivates RNAses 
by derivatisation of histidine residues. Subsequently the treated solutions were autoclaved, 
whereupon DEPC breaks down to CO2 and ethanol.  
Total RNA was separated by electrophoresis under denaturating conditions on a 1% agarose 
gel containing 7% formaldehyde. The gel was prepared as follows. One gram of agarose was 
dissolved in 62 ml DEPC treated water by boiling, then cooled down to 60°C. Thereafter  
20 ml 5 x MOPS buffer (0.1 M MOPS, pH 7.0, 40 mM sodium actetate, 5 mM EDTA,  
pH 8.0), 18 ml formaldehyde (37%) and 1 µl ethidiumbromide were added. Five micrograms 
of RNA in a volume of 5 µl were mixed with 15 µl RNA sample buffer, heated to 65°C for  
15 min and cooled on ice. Before loading the RNA onto the gel, 2 µl of RNA loading buffer 
was added. The gel was running in 1 x MOPS buffer at 75 V.  
 
2.2.18.2  Preparation of the Agarose gel and blotting procedure 
After electrophoresis the gel was washed overnight in DEPC-treated water under gentle 
shaking to remove the formaldehyde. Under UV light (GelDoc 2000, BioRad Laboratories 
GmbH, München) the 2 bands of 28S and 18S rRNA should be visible as an indicator of 
intact RNA. Before the transfer onto the nylon membrane (Hybond-N+, Amersham 
Biosciences Europe GmbH, Freiburg), the gel was washed in DEPC-treated 50 mM NaOH for 
30 min and finally in 20 x SSC (3 M NaCl, 0.3 M sodium citrate, pH 7) for 45 min under 
gentle shaking.  
The following steps of Northern blotting up to exposition on a X-ray film were the same as 
for Southern blotting (2.2.17.2–3.), but for transfer 20 x SSC was used. 
 
 
2.3  Protein biochemical methods 
2.3.1  SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) [139] 
Proteins were separated on 10% SDS polyacrylamide gels at 120–160 V using the Mini-
Protean III System (BioRad Laboratories GmbH, München). The gel casting frames, stands 
and running chambers were assembled according to the manufacturer’s protocol. Before 
loading the samples onto the gel, they were mixed with 4 x SDS gel loading buffer and heated 
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to 95°C for 5 min. Estimation of protein molecular weight occurred via the Prestained 
Molecular Weight Marker (Fermentas, St. Leon-Rot). Gel run was stopped when the blue 
bromphenol blue line reached the end of the gel and Western blot analysis (2.3.2) proceeded. 
 
10% running gel:   
3.870 ml water, 2.55 ml 1.5 M Tris-HCl, pH 8.8, 0.1 ml 10% SDS, 3.33 ml 30% 
acrylamid/bisacrylamid 29:1, 0.1 ml 10% ammoniumpersulfat, 0.01 ml TEMED 
 
4% stacking gel:   
3.725 ml water, 0.625 ml 0.5 M Tris-HCl, pH 6.8, 0.05 ml 10% SDS, 0.67 ml 30% 
acrylamid/bisacrylamid 29:1, 0.025 ml 10% ammoniumpersulfat, 0.005 ml TEMED 
 
SDS running buffer:  192 mM glycine, 25 mM Tris-HCl, pH 8.3, 0.1% SDS 
 
4 x SDS gel loading buffer:  
240 mM Tris-HCl, pH 6.8, 20% β-mercaptoethanol, 8.0% SDS, 40% glycerol, 0.2% 
bromphenol blue 
 
2.3.2  Western blot analysis and immunochemical detection of proteins 
Proteins from a SDS gel were transferred onto a PVDF Hybond-P membrane (Amersham 
Biosciences Europe GmbH, Freiburg) by blotting via a “Trans-Blot SD Semi-Dry Transfer 
Cell” (BioRad Laboratories GmbH, München) at 20 V for 60 min. The membrane was 
activated before the blotting procedure by incubation steps in methanol, water and transfer 
buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 20% methanol) for 5 min each. The 
blotting sandwich was assembled according to the manufacturer’s instructions.  
The membrane was then blocked in 5% low fat milk powder dissolved in TBS for 1 h at room 
temperature. After 3 washing steps for 10 min each with TBS-T, the membrane was incubated 
overnight at 4°C with the primary antibody (titer and dilution buffers: 2.1.6.1). Afterwards 
unbound antibodies were removed by repeated washing in TBS-T (3 times, 10 min, room 
temperature) before the secondary POD conjugated antibody (see 2.1.6.2) was applied and 
incubated for 1 h at room temperature. Subsequently the membrane was washed again in 
TBS-T (3 times, 10 min) and once in TBS. Immunoreactive bands onto the membrane were 
detected using the “ECL Plus Western Blotting Detection Reagents” (Amersham Biosciences 
Europe GmbH, Freiburg). Therefore the membrane was soaked for 2 min in the POD 
2  Material and Methods   
  28 
substrate solution and exposed to a chemiluminescent sensitive “Hyper ECL” film 
(Amersham Biosciences Europe GmbH, Freiburg). Alternatively, chemiluminescence was 
detected by the Luminescent Image Analyzer LAS-1000 CH (FUJIFILM Europe GmbH, 
Düsseldorf).  
For reprobing the membrane additionally with a different antibody, the blot was stripped in 
solution I (0.5 M NaCl, 0.5 M acetic acid) for 40 min and in solution II (100 mM Tris-HCl, 
pH 8.0) for 40 min at room temperature. After a short washing step in TBS, the membrane 
was blocked again and proceeded as described above. 
 
2.3.3  Immunoprecipitation (IP) with Protein A sepharose 
This method was used to precipitate sgp130-Fc from cell culture supernatants and from 
sgp130-Fc transgenic mouse sera. Protein A is able to bind to Fc-portions of antibodies, in 
this case to the Fc-portion of sgp130-Fc [115]. To precipitate sgp130-Fc from transfected 
U251 cell supernatant, 500 µl of cell-free conditioned medium was incubated with 50 µl 
Protein A sepharose (50% slurry in PBS, GE Healthcare, München) overnight under 
continous rolling at 4°C. The next day the mixture was centrifuged (5 min, 16,000 x g, 4°C) 
and the Protein A sepharose pellet was washed 3 times with IP washing buffer A (10 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% NP-40, 2 mM EDTA) and twice with IP washing 
buffer B (10 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.2% NP-40, 2 mM EDTA). After the last 
centrifugation step, the Protein A sepharose pellet was heated at 95°C in 50 µl of 4 x SDS gel 
loading buffer for 5 min. After SDS-PAGE (2.3.1) and Western blotting (2.3.2) of 20-µl 
samples, precipitated sgp130-Fc was detected using a monoclonal antibody against human 
gp130 (B-P4, Diaclone, Besancon, France). Via the same procedure, sgp130-Fc was 
precipitated from mouse serum (40 µl) and from supernatant of primary transgenic murine 
astrocytes (1 ml) using 50 µl Protein A sepharose solution including 10 x IP buffer (0.25 M 
Tris-HCl, pH 7.5, 5% Triton X-100, 5% NP-40) filled up with PBS to 1.5 ml. 
For coimmunoprecipitation of Hyper-IL-6 with sgp130-Fc of transgenic mouse brain 
homogenates, 40 µl of brain homogenate was incubated with 100 µl 10 x IP buffer (0.25 M 
Tris-HCl, pH 7.5, 5% Triton X-100, 5% NP-40), 4 µl Hyper-IL-6 (100 ng/µl) and 856 µl PBS 
overnight under continous rolling at 4°C. For pulldown of sgp130-Fc, 50 µl Protein A 
sepharose was added the next day and again incubated for 4 h or overnight under rolling 
conditions at 4°C. Subsequently the Protein A sepharose was washed and treated as described 
above. Coprecipitated Hyper-IL-6 was detected by Western blotting by a monoclonal 
antibody against the human IL-6 receptor (clone 14-18, [41]). 
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2.3.4  Cell lysis 
Eukaryotic cells (rat primary astrocytes and microglia, mouse primary astrocytes; all 
adherent) were washed in ice-cold PBS, removed by a cell scraper and transferred to a 1.5 ml 
plastic tube. After centrifugation (30 s, 16,000 x g, 4°C) the cell pellet was snap frozen in 
liquid nitrogen. Subsequently the cell pellet was lysed in lysis buffer (100 µl/ 0.5 x 106 cells) 
for 2 h at 4°C. Cell debris was removed by centrifugation (15 min, 16,000 x g, 4°C) and the 
cell lysate (supernatant) was stored at –20°C. 
Alternatively, when cell lysates were only subjected to SDS-PAGE and Western blot analysis, 
the cultured cells were lysed directly in hot SDS gel loading buffer, transferred after scraping 
in a 1.5 ml plastic tube, vortexed vigorously and heated to 95°C for 10 min. 
 
cell lysis buffer:   
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% Triton X-100, 1 mM 
NaF, 1 mM sodium-ortho-vanadate, 1 tablet/50 ml protease inhibitor complete (Roche 
Diagnostics, Mannheim) 
 
2.3.5  Enzyme-linked immunosorbent assay (ELISA) 
The ELISA for human sgp130 (DuoSet ELISA Development Kit; R&D Systems Europe, 
Abingdon, UK) was performed following the manufacturer’s instructions. Recombinant 
sgp130-Fc [115] in 2-fold serial dilutions starting from 10 ng/ml to 0.3125 ng/ml served as 
standard. Mouse serum was diluted 1:2,000, and brain homogenates were diluted 1:750 and 
1:1,000. 
To perform the murine sIL-6R sandwich ELISA, microtitre plates (Greiner Microlon, 
Solingen, Germany) were coated with goat anti-mouse IL-6R polyclonal antibody AF1830 
(R&D Systems Europe, Abingdon, UK) diluted to 0.8 µg/ml in PBS buffer and incubated 
overnight. After blocking with 5% BSA/PBS for 1–2 h, 100-µl aliquots of brain homogenates 
(1:50; 1:100; 1:500) and standard (mouse IL-6R 1830-SR; R&D Systems) diluted in 1% 
BSA/PBS were added and incubated for 2 h. Bound IL-6R was detected by biotinylated goat 
anti-mouse IL-6R polyclonal antibody BAF1830 (R&D Systems Europe, Abingdon, UK) 
diluted to 0.2 µg/ml (2-h incubation) followed by incubation in the dark for 30 min with 
streptavidin horseradish peroxidase (R&D Systems Europe, Abingdon, UK) diluted 1:200 in 
1% BSA/PBS. After each incubation step the plate was washed 3 times in PBS/0.05% Tween-
20. The soluble peroxidase substrate (BM blue POD; Roche Diagnostics, Mannheim, 
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Germany) for the enzymatic reaction was added and incubated in the dark until colour 
development. The absorbance was read at 450 nm on an SLT Rainbow plate reader (Tecan, 
Maennedorf, Switzerland) after the reaction was stopped by addition of 1.8 M H2SO4.  
 
 
2.4  Cell Culture 
2.4.1  Cell culture media and cultivation 
Cells were usually grown in 10-cm dishes (Cell Tissue Dishes, Sarstedt, Nümbrecht) in 
DMEM High Glucose (4.5 g/l) Medium with L-Glutamine (PAA Laboratories GmbH, Cölbe) 
supplemented with 10% FCS and 1% penicillin/streptomycin at 37°C with 5% CO2 in a 90% 
humified atmosphere (Hera Cell CO2-Incubator, Kendro Laboratory Products GmbH, 
Langenselbold). For maintenance, the culture was split 1:10. Cells were passaged at  
80–90% confluency. Adherent cell lines were therefore detached by 2 ml trypsin/EDTA (PAA 
Laboratories GmbH, Cölbe) for 5 min at 37°C. After centrifugation (5 min, 1,000 x g) the cell 
pellet was gently resuspended in fresh medium.  
 
2.4.2  Transient transfection of U251 cells with Lipofectamine-2000 
Cells grown to confluency of 80–90% were transiently transfected in a 24-well format using 
Lipofectamine-2000 (Invitrogen Corporation, Karlsruhe) according to the manufacturer’s 
instructions. In contrast to the original protocol, only 0.5 µg DNA and 1.5 µl Lipofectamine-
2000 were used for one transfection. 
 
2.4.3  Proliferation assay 
The cell viability test was performed with Ba/F3-gp130 and Ba/F3-gp130-IL-6 receptor cells 
(=Ba/F3-gp130-IL-6R cells). Cells were washed 3 times with sterile PBS and resuspended in 
DMEM Medium (PAA Laboratories GmbH, Cölbe) containing 10% FCS and seeded at 5,000 
cells/well in a 96-well plate in a volume of 100 µl/well. The cells were cultured in presence of 
the cytokines to test for the proliferation capability in different concentrations. After 3 days, 
the cell viability was determined by using CellTiter-Blue Reagent (Promega GmbH, 
Mannheim) according to the manufacturer’s instructions. For measurment, the Lambda Fluoro 
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320 fluorimeter (excitation filter: 560/25 nm; emission filter: 590/35 nm; sensitivity 75; 
Software KC4) was used. 
 
2.4.4  Isolation of primary astrocytes and microglia 
Primary astrocytes and microglia were isolated from 2-days-old rats by Dr. Claudia Röhl and 
Monika Grell at the Institute of Anatomy as described in [229]. Primary murine astrocytes, 
derived from cerebral cortices, were preparated using the same method. For experiments rat 
astrocytes were seeded in 6-well plates in DMEM medium complemented with 10% FCS 
(inactivated at 56°C) in a cell density of 30,000 cells/cm²; murine astrocytes in 75 cm² flasks. 
Microglial cells were seeded in astrocyte-conditioned medium at a density of  
100,000 cells/cm² in a 6-well format. 
 
 
2.5  Generation of transgenic mice 
2.5.1  Animal treatment 
Procedures involving animals and their care were conducted in conformity with national and 
international laws according to home office approved project license 66-6/06 from 9/15/2006. 
Mice were housed in a 12/12 h light/dark rhythm with ad libitum access to standard chow and 
tap water. All mice were maintained under barrier conditions and were pathogen free as 
assessed by regular microbiological screening. The animals were kept at 21°C ± 2°C and 60% 
± 5% humidity in individually ventilated cages (IVC) in the animal facility Viktor-Hensen-
Haus of Medical Faculty of the Christian-Albrechts-Universität zu Kiel. 
 
2.5.2  Pronucleus microinjection of DNA 
A pronucleus microinjection of DNA is a method to produce transgenic animals. The 
transgene DNA was prepared as follows. The vector containing the transgene DNA was 
transformed into E. coli (2.2.12), the DNA vector was isolated (2.2.4) and cutted with 
appropriate restriction enzymes (2.2.5). The DNA fragment comprising the transgene DNA 
was purified from a 1% agarose gel via gel extraction (2.2.8) and subsequent precipitation 
with ammonium acetate and ethanol (2.2.9). 
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The transgene DNA was injected into pronuclei of fertilised oocytes of the hybrid strain 
B6D2/F1. Viable injected oocytes were then transferred into oviducts of pseudopregnant 
foster mothers. The hybrid strain B6D2/F1 was created by a cross of a C57BL/6J (B6) female 
and a DBA/2 (D2) male mouse. B6D2/F1 mice are heterozygous for B6 and D2 alleles at all 
loci in their genome. Advantages of F1 hybrid strains over inbred strains are a larger litter 
size, thus increased fertility, higher resistance to disease, better survival under stress, longer 
life (information by The Jackson Laboratory, Bar Harbor, USA). Therefore the B6D2/F1 
hybrid strain is often used for the generation of transgenic mice. 
The DNA microinjection and implantation into foster mice was accomplished at the 
Biotechnologielabor (BTL) of the University of Heidelberg. 
 
2.5.3  Animal breeding 
The offspring of the foster mothers were analysed for integration of the transgene DNA into 
the chromosomal murine DNA. DNA isolated from tail biopsies (2.2.14) of 3-weeks-old 
animals was screened via PCR (2.2.7) and Southern blotting (2.2.17). Identified transgenic 
founder animals (B6D2/F1) were intercrossed with C57BL/6N mice to establish different 
lines, with regard to transgenic protein expression and activity. After 10 generations of 
backcrossing the genome will be >99% of C57BL/6N-genetic homogenous background and 
include the transgene allele. Thereupon the heterozygous mice can be crossed with each other 
to generate homozygous animals. 
 
2.5.4  Preparation of mouse brain homogenates 
After cervical dislocation, the mouse brain was dissected and snap frozen in liquid nitrogen 
and stored at –80°C. The frozen brain was homogenised in 2 ml TNE buffer (25 mM Tris-
HCl pH 7.4, 150 mM NaCl, 5 mM EDTA supplemented with 1 tablet protease inhibitor 
complete/50 ml TNE (Roche Diagnostics, Mannheim)) by use of a potter. After centrifugation 
(15 min, 1,000 x g, 4°C), the soluble substances contained in the supernatant of the brain 
homogenate were collected and stored at –20°C.  
 
2.5.5  Preparation of mouse blood serum 
Whole blood was collected from a tail vein of living mice or shortly after sacrifice by cardiac 
puncture. After self-coagulation of the blood for 2 h at room temperature or overnight at 4°C, 
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the serum was separated by centrifugation (10 min, 600 x g, room temperature) and stored at 
–20°C. 
 
 
2.6  Sleep Studies on rats 
Recording sleep-wake behaviour of rats, including surgeries and i.c.v. injections, were 
performed at the Washington State University, Department of VCAPP, College of Veterinary 
Medicine, Pullman (WA, USA), in the group of Prof. James M. Krueger, in the animal facility 
(Bustad building). 
 
2.6.1  Animals 
Male Sprague-Dawley rats weighing 300–380 g at the time of surgery were used. Rats were 
kept individually in Plexiglas cages in sound-attenuated, temperature-regulated environmental 
chambers at 23 ± 1°C on a 12-h light: 12-h dark cycle (light on at 5:00 a.m.). Water and food 
were available ad libitum. Institutional guidelines for the care and use of research animals 
were followed and approved by the Institutional Animal Care and Use Committee. 
 
2.6.2  Surgery 
All materials and tools used during surgery and injections were sterilised and autoclaved. 
 
2.6.2.1  Anaesthesia 
For surgery, the rats were anaesthetised by intraperitoneal (i.p.) injection of ketamine  
(87 mg/kg body weight) and xylazine mixture (13 mg/kg body weight). Breathing was 
controlled over the time of surgery. The rats were wrapped in a cloth to avoid hypothermia. 
 
2.6.2.2  Implantation of EEG, EMG electrodes and i.c.v. cannula 
After shaving the head, the rat was placed in a stereotaxic frame (David Kopf instruments) 
and fixed with earbars, toothbar and nosebar. The head skin was desinfected with 10% 
povidone-iodine topical solution followed by skin incision and extirpation of the skull 
membrane with scissors and skull scraper. For hemostasis, the tissue site of bleeding was 
burned with high temperature by a surgerical cautery and treated with the desinfectant 
hydrogen peroxide. These steps were repeated several times until bleeding had stopped. 
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Thereafter a 37% phosphoric Etchant gel was added to remove all traces of tissue and to make 
the skull bone rough. After 5 min the skull was cleaned with water. Stainless steel screw 
electrodes for electroencephalographic (EEG) recordings were implanted over the frontal and 
parietal cortices into holes of the skull burred with a dentist’s drill (0.9 mm diameter drill tip) 
and by hand (1.4 mm diameter drill tip). See Fig. 6 for position of EEG electrodes. The EEG 
electrodes were screwed into the scalp in a depth of 1 mm from the skull surface. To insert 
electromyographic (EMG) electrodes, the skin was separated from the dorsal neck muscle and 
the EMG electrode wire wrapped around the muscle.  
An intracerebroventricular (i.c.v.) cannula (PlasticsOne inc., 22 gauge) was inserted into the 
right lateral ventricle by using stereotaxic equipment. The guide cannula was implanted into a 
drilled hole at the coordinates 0.80 mm posterior, 1.8 mm lateral to the bregma, and 4.5 mm 
ventral from the surface of the skull, according to the rat brain atlas by Paxinos and Watson 
[210]. The size of the internal cannula (for injection procedure) was 30 gauge and extended 
0.5 mm beyond the tip of the guide cannula. The guide cannula and the screws of the EEG 
electrodes were fixed to the skull with dental glue and dental cement. The EEG/EMG wires 
were connected to a pedestal pin (PlasticsOne inc.) and a round headpiece was built with 
dental cement covering all wires, fixing the i.c.v. guide cannula and the pedestal pin. The 
guide cannula was closed with a dummy cap to avoid contamination.  
After surgery the rats were allowed to recover for at least 7–10 days. 
 
 
 
 
 
 
 
Figure 6  Schematic illustration of the positions of EEG electrodes and i.c.v. cannula onto the skull. 
 
 
2.6.2.3  Verification of correct i.c.v. cannula placement 
The correct i.c.v. cannula placement was determined by the gravity method (sudden drop in 
pressure) during implantation. Additionally 3–4 days after surgery the drinking response to 
i.c.v. injection of 200 ng angiotensin II [64] was tested. Only rats responding to angiotensin, 
verifying the correct position of the cannula, were used for experiments.  
EEG electrodes
i.c.v. cannula
Bregma
Lamda
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2.6.3  Injection procedure 
The dummy cap was removed from the rat’s head and the guide cannula was cleaned carefully 
with a 30-gauge needle. An internal cannula was connected to a 10-µl Hamilton syringe by a 
silicon tube. This injection tool was filled with sterile water followed by an air bubble before 
the injection substance solution was drawn up into the tube. The air bubble created a contact 
barrier between the injection substance and the water (Fig. 7). Thus, the syringe was only 
filled with sterile water without contaminations.  
The internal cannula of this injection system was inserted carefully into the implanted guide 
cannula when holding the rat gently but firmly. A volume of 2–4 µl were i.c.v. injected within 
a 1-min period and left in place for an additional minute to allow the solution to flow 
completely into the ventricle. After removing the injection tool and replacing the dummy cap, 
the rat was connected to the EEG/EMG wires for recording. 
 
 
 
 
 
 
 
 
Figure 7  Scheme of the i.c.v. injection tool. For further information see 2.6.3. 
 
 
2.6.4  Setup for sleep-wake recording 
At least 3 days before the experiments of sleep and wake recording, the rats were connected to 
the recording cables for adaptation to the experimental conditions. The recording cables, 
plugged to communicators, were connected to amplifiers. The signals of EEG and EMG were 
converted from analog to digital at a sampling rate of 128 Hz and collected by computers. The 
EEG was filtered below 0.5 Hz and above 30 Hz. EMG activity aided to determine the 
vigilance state. 
 
agent air sterile water
internal i.c.v. cannula silicone tubing 10-µl Hamilton syringe
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2.6.5  Experimental procedure of sleep-wake recording 
Rats were injected i.c.v. with 2 µl pyrogen-free isotonic NaCl (vehicle) at dark onset (prior to 
the dark phase) following 23-h sleep-wake recording as baseline. The next experimental day 
the rats received an i.c.v. injection at dark onset of either 100 ng human Hyper-IL-6 (n=4) or 
500 ng Hyper-IL-6 (n=4), in a volume of 2 µl. EEG and EMG signal recording started 
immediately after injections. 
 
2.6.6  Body core temperature recording 
For temperature measurement, an e-mitter without batteries (Vital View®) was surgically 
implanted into the peritoneal cavity. This was realised before implanting the EEG electrodes 
and i.c.v. cannula during the same surgery. After shaving the stomach and desinfection of the 
skin with 10% povidone-iodine topical solution, the skin, muscle and peritoneal membrane 
was cutted with a blade at a length of 1 cm. Then the sterile e-mitter was placed into the 
peritoneum and could freely moved e.g. within the intestinal loops. Thereafter the muscle and 
the skin was sutured (with Chromic Gut 12``), and the closed wounds were desinfected. 
For temperature recording, the animal cage was placed onto a receiver plate (Vital View®) 
and the signal was routed to a computer. 
 
2.6.7  Analysis of recorded EEG/EMG data 
2.6.7.1  Sleep state scoring 
The states of vigilance were visually scored off-line in 10-s epochs and classified as non-
REM sleep (high voltage EEG waves, predominant EEG in delta range of 0.5–4.0 Hz, no 
body movement), REM sleep (low voltage EEG, dominance in fast theta power of 4.0–9.0 Hz, 
no body movement) or wakefulness (Wake; less regular low voltage fast EEG, frequent body 
movements) according to the criteria of Neckelman and Ursin [189]. The amount of time 
spent in each vigilance state was calculated for 2-h time blocks. The number of transitions 
from one vigilance to another served as indicator of sleep fragmentation. The programme 
“Sleep Sign” was used for analysis. 
 
2.6.7.2  Spectral analysis 
For spectral analysis (frequency analysis), EEG of each artefact-free 10-s epoch scored as 
non-REM or REM sleep was subjected to a Fast Fourier Transformation (FFT) analysis, 
yielding power spectra between 0.5 and 20 Hz with a 0.5 Hz resolution (“Sleep Sign”). EEG 
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power in REM and non-REM sleep was expressed as percentage of individual maximum EEG 
power in non-REM sleep to correct for individual differences in the absolute power [73]. 
 
2.6.7.3  Statistical analysis 
Values are means ± S.E.M. For comparison of duration of each vigilance state and numbers of 
transitions between the baseline and experimental day, two-way analyses of variance 
(ANOVA) for repeated measures (factors: treatment and time effect) were calculated. A α-
level of P<0.05 was considered to be significantly different. As post-hoc analysis the Tukey 
test was used. The same statistical analysis method was used for comparison of EEG power 
spectra (factors: treatment and frequency effect).  
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3  Results 
3.1  Role of Hyper-IL-6 for sleep in rats 
This chapter describes the experiments and results investigating the effect of 
intracerebroventricularly (i.c.v.)-injected Hyper-IL-6 on sleep-wake behaviour in rats. By 
means of Hyper-IL-6 (see 1.4), which activates almost all cells of the brain in contrast to IL-6 
alone, the IL-6 trans-signalling pathway could be investigated exclusively. 
 
3.1.1  Activity test of used cytokine samples 
Since construction of the designer cytokine Hyper-IL-6 by Fischer et al. [70], several studies 
have indicated the specific binding to the receptor gp130, with no report showing cellular 
activation independent of gp130. In order to avoid non-specific side effects by the cytokine 
Hyper-IL-6 itself within the rat brain, its specificity was tested again before i.c.v. injection 
into rats with subsequent sleep recording. The biological activity of relevant Hyper-IL-6 
samples was verified in a primary rat brain-derived cell-based analysis. Hyper-IL-6 is known 
to be a potent activator of STAT3-dependent gene transcription [221]. Therefore primary rat 
astrocytes and microglia cells (2.4.4) were treated with 50 ng/ml Hyper-IL-6 and IL-6 for 20 
minutes after overnight starvation of confluent cells. Equal amounts of cell lysates (2.3.4) 
were applied to SDS-PAGE (2.3.1) and Western blot detection (2.3.2) of Y705-
phosphorylated STAT3 proteins. The Western blot analysis (Fig. 8) revealed a specific strong 
reaction of primary rat astrocytes and microglia to Hyper-IL-6, presented as activation of 
transcription factor STAT3 by phosphorylation via gp130 stimulation. Unstimulated cells 
showed very week or not any phosphorylated STAT3 (negative control). IL-6, which only can 
signal through the membrane-bound IL-6 receptor, induced a very week signal intensity of 
phosphorylated STAT3 in the range of the unstimulated samples. This might point to a very 
low presence of the IL-6R on the membrane of rat astrocytes and microglia, if at all. As a 
loading control, STAT3 levels were determined showing comparable amounts of STAT 
protein in all samples.  
In addition, after use of Hyper-IL-6 for the i.c.v. injection into rats, residual samples were 
retested for their biological activity in cell-based proliferation (viability) assays (2.4.3).  
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Figure 8  Detection of phosphorylated STAT3 (P-STAT3) after stimulation of primary rat astrocytes and 
microglia with Hyper-IL-6 and IL-6 (50 ng/ml each) via Western blotting. For comparison, 
STAT3 was detected. Unstimulated cells served as negative control. 
  
 
The ability of Hyper-IL-6 to elicit proliferation of different Ba/F3 cell lines was utilised. The 
original Ba/F3 cell line, which is a murine peripheral blood pre-B cell line, grows IL-3-
dependent. After stable transfection with human gp130 (Ba/F3-gp130 cells), cell growth has 
become dependent on IL-3 or Hyper-IL-6 [207]. Ba/F3 cells stably transfected with both 
gp130 and IL-6R are IL-3- or IL-6-dependent [79].  
Ba/F3 cells that express gp130 on its membrane but not the IL-6R (Ba/F3-gp130 cells) and 
cells that express both gp130 and the membrane-bound IL-6R (Ba/F3-gp130-IL-6R cells) 
were cultured in presence of Hyper-IL-6 and IL-6 in different concentrations to monitor the 
cell viability after 3 days. Ba/F3-gp130 cells cannot respond to IL-6 alone and therefore they 
did not grow (Fig. 9A), because the lack of the membrane-bound IL-6 receptor excludes 
classic signalling. Hyper-IL-6, which only needs gp130 to bind to and to signal via IL-6 trans-
signalling, maintained cell proliferation and thus viability of Ba/F3-gp130 cells. Ba/F3-
gp130-IL-6R cells could respond to Hyper-IL-6 as well as to IL-6 (Fig. 9B). This proliferation 
assay revealed that the cytokine Hyper-IL-6 used for the rat sleep study was biologically 
active.  
Taken together, these data again confirmed nicely the high specificity and wide reactivity of 
Hyper-IL-6. 
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Figure 9  Proliferation assay measuring cell viability (as fluorescense) after stimulation of Ba/F3-gp130 cells 
(A) and Ba/F3-gp130-IL-6R cells (B) with Hyper-IL-6 (closed circles, thick line) and IL-6 (open 
circles, thin line). Samples were retested after use for i.c.v. injection into rats to ensure biological 
activity. 
 
 
3.1.2  Effect of i.c.v. injection of Hyper-IL-6 on sleep-wake behaviour 
In order to inject the cytokine Hyper-IL-6 into the brain of a rat, an i.c.v. cannula (22 gauge) 
was surgically inserted into the right lateral ventricle. EEG electrodes were implanted over the 
cortices and EMG electrodes in the dorsal neck muscle for sleep recording (2.6.2).  
All operated animals reacted to i.c.v. administration of angiotensin II with a drinking 
response, thus proving the correct placement of the i.c.v. guide cannula, so that these rats 
could be used for experiments. The functionality of the implanted EEG/EMG electrodes to 
record brain waves and muscle activity respectively was tested successfully. 
The study of Hogan et al. [99] (see 1.7) was used as a guideline, where IL-6 was injected 
before the dark period (dark onset) with subsequent EEG/EMG recording for 23–24 h. To 
investigate the effect of Hyper-IL-6, a comparable experimental set-up was chosen, which is 
illustrated in Fig. 10. After surgery, recovery and adaptation to conditions of connection with 
EEG/EMG recording wires in an environmental chamber, the rats were i.c.v. injected with  
2 µl of saline shortly before the dark period (dark onset), followed by recording of EEG/EMG 
signals for 24 h (2.6.3; 2.6.4; 2.6.5). These signals represented the baseline sleep (for each 
individual rat). After 24 h of i.c.v. application of saline, Hyper-IL-6 was administered (i.c.v.), 
again at dark onset, and EEG/EMG recording succeeded for more than 24 h. Two different 
dosages of Hyper-IL-6 were analysed for their effect on sleep architecture. One group of 4 
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rats were treated with a low dose of 100 ng Hyper-IL-6 per rat and another group of 4 animals 
with a high dose of 500 ng/rat. In parallel the body core temperature was recorded, which is 
described in section 3.1.4.  
  
 
 
 
 
 
 
Figure 10  Scheme of experimental sleep study set-up. Black bars indicate dark period. 
 
 
After i.c.v. exposure to the cytokine Hyper-IL-6, a modified or abnormal behaviour of the rats 
was not observed visually during the sleep study. Examples of recorded EEG/EMG waves are 
shown in Fig. 11.  
 
 
 
 
 
 
 
 
 
 
Figure 11 Example of a 10-s EEG/EMG record for each sleep-wake state. These signals were taken from an 
animal after i.c.v. injection of 100 ng Hyper-IL-6. 
 
 
The EEG/EMG signals were scored in 10-s epochs to identify the amount of time the rats 
spent in each of the sleep states and the number of changes between different stages 
(transitions), calculated for 2-h time blocks, according to the specific patterns of electric brain 
signals (2.6.7.1). The resulting diagrams for a time period of 24 h after i.c.v. injection of 
saline and Hyper-IL-6 into rats (Fig. 12) revealed a clear circadian rhythm of the sleep-wake 
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behaviour. Thus, the dark period was dominated by physical activity, the light period by 
sleep. This is reflected in the highly significant ANOVA time effects (P<0.0001) within the 
recording time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Effects of i.c.v. injection of 100 ng and 500 ng recombinant Hyper-IL-6 (closed circles, thick 
lines) and pyrogen-free isotonic saline (open circles, thin lines) into rats on Wake (A, B), non-
REM sleep (C, D), REM sleep (E, F) and transition of states (G, H). Values are means ± S.E.M. 
(n=4). Asterisks denote significant treatment effect. Horizontal black bars indicate the dark period. 
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The i.c.v. administration of the low dose of Hyper-IL-6 (100 ng) did not alter sleep in terms of 
Wake (Fig. 12A), non-REM sleep (Fig. 12C), REM sleep (Fig. 12E) and transitions between 
the states (Fig. 12G). Treatment of 500 ng Hyper-IL-6 did not change the amounts of Wake 
(Fig. 12B) and non-REM sleep (Fig. 12D), but significantly increased the amount spent in 
REM-sleep (Fig. 12F; ANOVA results: treatment effect, F(1,33)=7.559, P=0.0096; 
interaction “treatment x time”, F(10,33)=2.015, not significant). For the time points 18 and  
20 h during the light period, the post-hoc performed Tukey test (multiple pairwise 
comparisons of treatments) for each 2-h time blocks revealed statistical increase. The 
transitions between sleep states after the application of 500 ng Hyper-IL-6 did not statistically 
increase (Fig. 12H; ANOVA results: treatment effect, F(1,36)=2.907, P=0.0968; interaction 
“treatment x time”, F(11,36)=0.8848, not significant).  
The question arose whether the observed REM sleep-promoting effect of 500 ng Hyper-IL-6 
continued in the second dark period of the following day (24–34 h postinjection). Therefore 
the contributing EEG data were scored (Fig. 13) and these 12 h of the second dark were 
compared with the first 12 h after saline injection, since EEG after saline treatment was 
recorded only for one day. The amount of REM sleep of the second dark period after 500 ng 
Hyper-IL-6 i.c.v. injection into rats did not differ statistically from saline baseline (ANOVA 
results: treatment effect: F(1,30)=0.163, not significant; interaction “treatment x time”: 
F(5,30)=0.83, not significant). The same finding applied to non-REM sleep and transitions 
between the states (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 13  Effects of i.c.v. injection of 500 ng Hyper-IL-6 (closed circles, thick line) and saline (open circles, 
thin line) into rats on REM sleep including the second dark period. Values are means ± S.E.M. 
(n=4). Asterisks denote significant treatment effect. Horizontal black bars indicate the dark period.  
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3.1.3  Effect of Hyper-IL-6 on EEG power spectrum 
EEG signals consist of many different frequencies in various amounts. A power spectral 
analysis shows how the power of an EEG wave (power density) is distributed with frequency. 
Power density differs among sleep states and varies over a wide range of frequencies [73]. 
EEG signal epochs defined as non-REM sleep show a higher power density of the delta 
frequency band (0.5–4 Hz); REM sleep waves of the theta frequency band (5–9 Hz). A 
spectral analysis (2.6.7.2) of 24-h EEG signals derived from rats receiving an i.c.v. injection 
of 500 ng Hyper-IL-6 and saline respectively is depicted in Fig. 14, determined for light and 
dark period separately. It displayed no effect of Hyper-IL-6 on EEG spectra for non-REM 
sleep (Fig. 14A). For REM sleep no shift in theta peak frequency was present but a 
significantly reduced relative power density (Fig. 14B; ANOVA results: treatment effect, 
F(3,126)=17.09, P<0.0001; frequency effect, F(20,126)=6.173, P<0.0001, interaction 
“treatment x frequency”, F(60,126)=0.7095, not significant). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14  Effect of i.c.v. injection of 500 ng Hyper-IL-6 (red line) and pyrogen-free isotonic saline (green 
line) into rats on EEG power spectra obtained from non-REM (A) and REM epochs (theta peak 
frequency, B) shown for light (dashed line) and dark period (solid line) respectively. Mean values 
are shown. The black bar with the asterisk indicates a significant treatment effect (ANOVA).  
 
 
 
 
Frequency [Hz]
11
*
4 5 6 7 8 9 10
0.00
0.25
0.50
0.75
1.00
REM sleep –
theta peak frequency
non-REM sleep
Frequency [Hz]
R
el
at
iv
e 
po
w
er
de
ns
ity
0 5 10 15 20
0.0
0.5
1.0
1.5
2.0
2.5
25
A B
3  Results   
  45 
3.1.4  Effect of Hyper-IL-6 on body core temperature 
As the cytokine IL-6 has been shown to be pyrogenic [99, 142, 202, 236], it was tested if 
Hyper-IL-6 also was able to induce fever. The body core temperature was measured by a so-
called e-mitter that was surgically placed into the peritoneal cavity (2.6.6). After i.c.v. 
injection of 500 ng Hyper-IL-6, the body temperature did not significantly differ from saline 
treatment (Fig. 15).  
 
 
 
 
 
    
 
 
 
 
Figure 15  Body core temperature after i.c.v. injection of saline (open circles) and 500 ng Hyper-IL-6 (closed 
circles) into rats (n=4). Values are means ± S.E.M.  
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3.2  Central blockade of IL-6 trans-signalling in gfa2–sgp130-Fc transgenic 
mice  
This chapter involves the generation and first characterisation of mice, transgenic for the 
antagonistic protein of the IL-6 trans-signalling pathway sgp130-Fc (see 1.4) under the brain-
specific promoter gfa2. 
 
3.2.1  Cloning of the transgene vector for gfa2–sgp130-Fc mice 
To generate transgenic mice expressing sgp130-Fc within the brain, sgp130-Fc was set under 
transcriptional control of the human gfa2 promoter. Gfa2 is a 2.2 kb promoter fragment of the 
glial fibrillary acidic protein (GFAP) that is specifically active in astrocytes. It is activated 
from embryonic day 12.5 [29]. Genes under control of the human gfa2 promoter were 
successfully used in the past to generate various different transgenic mouse strains [30], 
including TGFβ [77] and tau [71]. 
The cDNA for sgp130-Fc was codon-optimised by the company GENEART (Regensburg) to 
achieve high and stable expression rates [220]. Thus, e.g. only the most frequent codons of the 
mammalian genome appeared in the cDNA.  
For construction of an appropriate sgp130-Fc DNA vector, the expression vector pGfa2–
LacZ–mP1 [29] served in a first approach as a backbone (Fig. 16). The lacZ cDNA was 
removed by restriction with the enzyme BamHI and replaced with the sgp130-Fc cDNA, 
which was excised before with BglII from the vector p409–sgp130-Fc (Jürgen Scheller), 
resulting in the expression vector pGfa2–sgp130-Fc_optimised–mP1. This was possible since 
BglII and BamHI produce compatible sticky ends (5’-GATC-3’), but these endonuclease 
recognition sites were destroyed after ligation. A segment of murine protamine 1 (mP1) 
including an intron for efficient expression [32] and a polyadenylation site (PolyA) that 
enhance mRNA stability [238], was located downstream of the sgp130-Fc cDNA. 
In a second cloning approach, the sgp130-Fc-containing vector pCR-script–sgp130-
Fc_optimised (GENEART, Regensburg) served as backbone plasmid (Fig. 17). The cDNAs 
for the polyadenylation site and the second intron of rabbit β-globin were amplified via PCR 
from the vector pTZ–PEPCK–βglob.intron–opt_sgp130-Fc [220] with addition of the 
appropriate endonuclease restriction sites for insertion into the plasmid pCR-script–sgp130-
Fc_optimised as shown detailed in Fig. 17. The BglII/BamHI fragment derived from the 
vector pGfa2–LacZ–mP1 [29] comprising the gfa2 promoter was ligated into the BglII opened 
vector pCR-script–intron_β-globin–sgp130-Fc_optimised–polyA_β-globin, with loss of the 
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BamHI/BglII restriction sites between promoter and intron. In the resulting expression 
plasmid pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-globin, the intron 
was located upstream of the sgp130-Fc-encoded sequence. This location of an intron should 
yield to a more potent increased expression of the gene [209]. Also this type of composition 
of a transgene expression cassette provided an optimal expression efficiency for the vector 
pTZ–PEPCK–βglob.intron–opt_sgp130-Fc used for generation of sgp130-Fc transgenic mice 
with systemic protein expression [220].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Cloning scheme of the vector pGfa2–sgp130-Fc_optimised–mP1. The intron is located 
downstream of the sgp130-Fc cDNA. 
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Figure 17 Cloning scheme of the vector pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-
globin. The intron is located upstream of the sgp130-Fc cDNA. 
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3.2.2  Protein expression of sgp130-Fc in cell culture 
Both expression vectors, pGfa2–sgp130-Fc_optimised–mP1 and pCR-script–gfa2–intron_β-
globin–sgp130-Fc_optimised–polyA_β-globin, were transiently transfected (2.4.2) into U251 
cells to test the strength of sgp130-Fc expression in vitro. U251 is a human astroglioma cell 
line that provided an ideal model for the astrocyte-specific GFAP promoter gfa2-driven 
sgp130-Fc protein expression. As a control the plasmid pmax-GFP (for green fluorescent 
protein) was transfected with about 50% transfection efficiency. Given that sgp130-Fc is a 
soluble, secreted protein, the cell supernatants 3 days after transfection were subjected to 
immunoprecipitation with protein A sepharose (2.3.3), SDS-PAGE (2.3.1) and Western blot 
analysis (2.3.2). Protein A sepharose has the ability to bind Fc-portions. Sgp130-Fc was 
detected by the antibody B-P4 at a size of 130 kDa in the Western blot (Fig. 18), where 
recombinant purified sgp130-Fc served as a positive control. The vector that located the 
intron upstream of sgp130-Fc (pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–
polyA_β-globin) showed stronger expression rates than the vector with the intron cloned 
downstream of sgp130-Fc (pGfa2–sgp130-Fc_optimised–mP1). Hence, the expression vector 
pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-globin was chosen for the 
generation of gfa2–sgp130-Fc transgenic mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18  Protein expression of sgp130-Fc in U251 astroglioma cells. Transfected cells with different vector 
constructs were detected in medium supernatants after immunoprecipitation with protein A 
sepharose via Western blotting using the anti-gp130 antibody B-P4. 
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3.2.3  Generation of astrocyte-specific gfa2–sgp130-Fc transgenic mice 
3.2.3.1  DNA microinjection into pronuclei 
The gfa2–sgp130-Fc expression cassette, illustrated in Fig. 19A and B, was restricted by BglII 
and NotI from the vector pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-
globin. This transgene-coding DNA fragment was purified and injected into pronuclei of 
fertilised mouse oocytes as described in 2.5.2. A total of 328 oocytes were transferred into 12 
foster mothers, which gave birth to 151 alive animals. The offspring were then analysed for 
integration of the transgene cDNA cassette into the genome to identify founder animals.  
 
  A                                                                                      B    
 
 
 
 
 
 
 
 
Figure 19 Organisation of the gfa2–sgp130-Fc_optimised cDNA expression cassette with all relevant 
regions, restriction and primer binding sites (A). The BglII/NotI restricted fragment of the 
expression vector (pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-globin) 
shown on a 1% agarose gel contained the gfa2–sgp130-Fc expression cassette for generation of 
transgenic mice (B). 
 
 
3.2.3.2  Identification of founder animals transgenic for sgp130-Fc 
A transgene integrates randomly into the mouse genome mostly at a single site with numerous 
copies as concatemers (up to 50 or more) [31, 48, 208]. The genomic mouse DNA (2.2.14), 
isolated from tail biopsies of the offspring of the foster mothers, was genotyped via PCR 
(2.2.7) and Southern blotting (2.2.17). The PCR screening, using sgp130-Fc-screen primers 
(2.1.4) that span 699 bp between sgp130 and the Fc-part of the transgenic DNA construct, 
identified 18 transgenic founder animals (Fig. 20). Founder mice were heterozygous for 
sgp130-Fc under transcriptional control of the brain-specific gfa2 promoter. As a positive 
control DNA of a transgenic sgp130-Fc mouse under control of the PEPCK promoter 
(systemic expression) [220] was used.  
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Figure 20 Identification of gfa2–sgp130-Fc founder animals via PCR analyses and separation on a 1.5% 
agarose gel. The offspring of 151 mice by 12 foster mothers resulting from DNA pronucleus 
microinjection were tested. Sgp130-Fc-specific primers amplified a 699 bp product (scheme at the 
bottom, left). Numbers designate founder names. M indicate the DNA marker (1 kb Generuler). 
The symbol +  denotes the positive control,  – the negative water control. 
 
 
The PCR-based data of identified founder animals were additionally verified by Southern blot 
analysis, as presented in Fig. 21. The α-32P-dATP-labelled probe contained a sgp130-Fc 
cDNA fragment of 2,016 bp, resulting from the restriction of the gfa2–sgp130-Fc_optimised 
expression cassette with the endonuclease EcoRV (see Fig. 19A). For 14 out of 18 founder 
mice the integration of the sgp130-Fc transgene could be confirmed. The differences in signal 
intensity generally reflect the different copy numbers of the transgene integrated into the 
genome. 
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Figure 21 Verification of gfa2–sgp130-Fc founder animals via Southern blot analysis. Ten micrograms of 
genomic DNA were digested with EcoRV, loaded on an agarose gel, transferred onto a nylon 
membrane and hybridised with a radioactive-labelled probe consisting of sgp130-Fc cDNA (2,016 
bp). Founder mice are designated as numbers. Positive signals are marked in red. M indicate the 
DNA Marker (1 kb Generuler), + the positive control, – the negative water control.  
 
 
3.2.3.3  Backcrossing and general genotyping 
Founder mice were crossbred onto a C57BL/6N background (2.5.3) to establish different 
transgenic lines. Backcrossing is mandatory to produce animals at a genetic homogenous 
background, since the offspring after pronucleus microinjection (founder mice) belonged to 
the hybrid strain B6D2/F1, which is a cross of C57BL/6 and DBA/2 (2.5.2). Foremost after 
10 generations the genome will have reached a >99% C57BL/6N-specific background. 
Because at least 14 animals had been identified as founder mice (3.2.3.2), the number of lines 
was reduced. Lines were excluded that produced no or a low litter size after the first backcross 
and/or did not express the sgp130-Fc protein within the brain in relatively high amounts (see 
3.2.4.1). Finally, the transgenic lines designated as 5.2, 15.5 and 19.1 were continued. 
The offspring was genotyped to identify transgenic animals via the following scheme in Fig. 
22. First the quality of the isolated genomic mouse DNA (2.2.14) was checked in a PCR 
(2.2.7) for the housekeeping gene β-globin (494 bp). The transgene-specific PCR was 
performed using the “sgp130-Fc-screen” primers that produced a 699 bp product or, from 
backcross 5 on, with the “sgp130-Fc-screen-new” primers resulting in a 176 bp product. Both 
primer pairs span the boarder of sgp130 and the Fc-part of the cDNA. Untill backcross 3 the 
PCR results were additionally verified via Southern blotting (2.2.17) using α-32P-dATP-
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radioactive-labelled sgp130-Fc-specific probe of the EcoRV restricted gfa2–sgp130-
Fc_optimised cDNA fragment (2,016 bp; see Fig. 19A). While writing this thesis the 
backcross was progressed to number 8.  
 
 
                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 General genotyping scheme for the identification of gfa2–sgp130-Fc transgenic mice. See 3.2.3.3 
for details. 
 
 
Identification of homozygous mice, which e.g. could be used for the preparation of primary 
astrocytes, was determined by Southern blot analysis comparing the relative copy number of 
the integrated transgene between transgenic littermates. While heterozygous animals carry the 
transgene on one allele, homozygous mice contain the transgene on both alleles. This fact is 
reflected in signal intensity twice as strong for a homozygous littermate as for a heterozygous 
on the Southern blot, as far as equally amounts of genomic DNA have been loaded onto the 
agarose gel. The identification of homozygous sgp130-Fc mice is represented in Fig. 23.  
β-globin PCR (housekeeping gene)
sgp130-Fc PCR (transgene)
Southern blot (sgp130-Fc probe)
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Figure 23 Identification of homozygous transgenic gfa2–sgp130-Fc mice via Southern blotting (upper 
panels) shown for 2 animals of 2 different litters. The correspondent agarose gel (lower panels) 
displayed that equal genomic DNA amounts were loaded. Symbol M indicates the 1kb Generuler, 
+/- indicates heterozygous, +/+ indicates homozygous animals. 
 
 
3.2.4  Expression analyses of sgp130-Fc in transgenic gfa2–sgp130-Fc mice 
3.2.4.1  Brain-specific expression of transgenic sgp130-Fc on protein level 
Sgp130-Fc expression is targeted specifically to astrocytes by use of the gfa2 promoter. 
Detection of a transgene on DNA level does not necessarily lead to strong protein expression. 
Therefore the protein expression of sgp130-Fc within the brain of founder animals was 
examined. For this purpose it was ensured that the founder animals produced sufficient 
transgenic offspring, since the founder mice had to be sacrificed for production of whole brain 
homogenates. The brain was homogenised in a volume of 2 ml TNE buffer (2.5.4), and 10 µl 
of the soluble fraction was applied to SDS-PAGE (2.3.1) followed by detection of sgp130-Fc 
protein (130 kDa) in Western blot analysis (2.3.2) with the monoclonal antibody B-P4 raised 
against the human gp130. The highest protein amount was detected in founder animals 19.1, 
12.3 and 5.2, a moderate sgp130-Fc content in founders 5.2, 8.5 and 14.4, and a lower 
concentration in founder 18.5 (Fig. 24). All those protein bands correlated with the DNA band 
intensities of the transgene seen by Southern blotting, thus with their copy numbers (see  
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Fig. 21). Sgp130-Fc protein expression within the brain was absent in the founder mice 11.5 
and 18.4, but by contrast they showed moderate and high copy numbers of the transgene in 
Southern blot analysis. Interestingly, founder 15.5 that displayed an obvious low copy 
number, expressed rather a high protein amount of sgp130-Fc. 
 
 
 
 
 
 
 
 
 
Figure 24 Detection of sgp130-Fc proteins in brain homogenates of different founder mice (designated as 
numbers) via Western blot analysis using the monoclonal anti-gp130 antibody B-P4. The wildtype 
C57BL/6N mouse did not express sgp130-Fc (negative control). Recombinant sgp130-Fc was 
included as positive control. 
 
 
In addition, the amount of sgp130-Fc protein in brain homogenates was quantified by gp130 
sandwich ELISA (2.3.5, Fig. 25), which confirmed the Western blot results. The highest 
protein levels of sgp130-Fc over 1 µg/ml of brain homogenate were measured in the founder 
mice 19.1 and 12.3. The founder mice 5.2 and 15.5, which expressed sgp130-Fc at about  
750 ng/ml of brain homogenate, were chosen additionally to founder 19.1 to establish 
different mouse lines. During the backcross breedings, the presence of sgp130-Fc was 
continuously analysed to avoid production of subsequent generations without transgenic 
protein production. Expression of transgenic proteins may vary through generations up to 
cessation of activity [208].  
The levels of the endogenous murine sIL-6R (msIL-6R), the crucial component of IL-6 trans-
signalling that should be inhibited by sgp130-Fc, were determined by msIL-6R sandwich 
ELISA (2.3.5) of brain homogenates of some founder animals. Founder mice displayed 
amounts of endgenous msIL-6R in the range of 10–15 ng/ml brain homogenate (Fig. 26).  
Blockade of IL-6 trans-signalling strictly relies on a molar excess (at least 10-fold) of sgp130-
Fc [115]. Therefore the molar ratios of sgp130-Fc versus msIL-6R were calculated from their 
protein levels measured by ELISA (Fig. 25, Fig. 26). The molar values are shown in Table 1.  
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Figure 25 Sgp130-Fc protein levels in brain homogenates of different founder mice (designated as numbers 
on x-axis) measured via gp130 ELISA. Data represent mean values ± S.D. Values were measured 
in quadruplets; but 18.4 and 12.3 in duplets.  
 
 
 
 
 
 
 
 
 
Figure 26 Endogenous protein levels of murine sIL-6R in brain homogenates of founder mice (designated as 
numbers on x-axis) and wildtype C57BL/6N measured via msIL-6R sandwich ELISA. Data 
represent mean values ± S.D. Values were calculated of 3 different sample dilutions.  
 
 
Table 1 Protein levels of sgp130-Fc in brain homogenates of gfa2–sgp130-Fc founder mice measured via 
gp130 ELISA and calculated molarities. Shown are mean values. Protein levels were measured in 
quadruplets; but 18.4 and 12.3 in duplets. Molar relations of sgp130-Fc to msIL-6R were 
calculated for 15 ng/ml msIL-6R (1 M sgp130-Fc=130,000 g/l; 1 M sIL-6R=80,000 g/l). See 
3.2.4.1 for further details. 
  
founder 5.2 8.5 11.5 14.4 15.5 18.5 19.1 18.4 12.3 
sgp130-Fc 
[ng/ml] 745.71 588.91 0 581.49 710.62 263.47 1241.98 121.72 1145.08 
sgp130-Fc 
[mol/l]  
5.736 
×10-9 
4.530 
×10-9 0 
4.473 
×10-9 
5.466 
×10-9 
2.027 
×10-9 
9.554 
×10-9 
9.363 
×10-10 
8.808 
×10-9 
molar factor 
sgp130-Fc : 
msIL-6R 
30.59 24.16 0 23.86 29.15 10.81 50.95 4.99 46.98 
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For calculation of the molar relation of sgp130-Fc versus msIL-6R in each founder animal, an 
endogenous level of msIL-6R within brain homogenates at 15 ng/ml (1.875 ×10-10 M) 
measured by ELISA (Fig. 26) was considered to be present in all transgenic brain samples. 
Thus, theoretically this amount of msIL-6R could be bound by IL-6, which has to be inhibited 
by sgp130-Fc. Table 1 revealed a 10- to 50-fold molar excess of sgp130-Fc within brain 
homogenates of the various founder mice, with exception of the founders 11.5 and 18.4 that 
expressed only low or no levels of transgenic protein. 
Because sgp130-Fc is a soluble protein, its secretion by transgenic astrocytes derived from 
heterozygous mice was examined. For isolation of primary astrocyte cultures, a newborn 
transgenic mouse pub was needed. Therefore heterozygous mice were bred to homozygousity 
(see Fig. 23). As the identified homozygous animals were both male, one was mated with a 
female wildtype C57BL/6N mice resulting in a sgp130-Fc heterozygous uniform litter (line 
14.4, 2nd backcross). Two-days-old (P2) animals were dissected to isolate cortical astrocytes 
for primary cultures (2.4.4). The primary transgenic astrocytes grew 1 week in 75 cm²-flasks 
in medium either with or without FCS, before the supernatant/medium was used for SDS-
PAGE (2.3.1) followed by Western blot detection (2.3.2) of secreted sgp130-Fc (130 kDa) via 
the anti-gp130 antibody B-P4. Supernatant was used directly (30 µl) or after 
immunoprecipitation (IP) with protein A sepharose that binds to the Fc-part of sgp130-Fc  
(1 ml medium for IP, 50% loaded onto SDS gel, 2.3.3). Additionally, as positive controls, cell 
lysate (2.3.4) of transgenic astrocytes (approximately 500,000 cells) and recombinant purified 
sgp130-Fc was used. Medium of primary wildtype rat astrocytes after IP served as negative 
control. The Western blot analysis (Fig. 27) clearly showed the protein expression of sgp130-
Fc and secretion into the medium by primary cortical astrocytes of transgenic gfa2–sgp130-Fc 
mice.  
 
 
 
 
 
 
 
Figure 27 Secretion of sgp130-Fc by transgenic murine primary astrocytes (line 14.4, 2nd backcoss) detected 
via Western blotting using the monoclonal anti-gp130 antibody B-P4. Medium supernatants (SN) 
were used directly or after IP with protein A sepharose. As negative control served medium of 
primary wildtype rat astrocytes after IP . Recombinant sgp130-Fc was included as positive control. 
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3.2.4.2  Biological activity of transgenic sgp130-Fc 
The specific ability of Hyper-IL-6, which is the fusion protein of human IL-6 and human 
soluble IL-6 receptor (sIL-6R) connected by a flexible peptide linker [70], to bind gp130 was 
employed to prove the functionality of the transgenic sgp130-Fc protein. Therefore, 
transgenic and wildtype brain homogenates (40 µl) were coimmunoprecipitated with Hyper-
IL-6 (400 ng) and protein A sepharose for pulldown by centrifugation (2.3.3). Binding of 
precipitated proteins was monitored by SDS-PAGE (2.3.1) followed by Western blotting 
(2.3.2) via an monoclonal antibody recognising the human sIL-6R part of Hyper-IL-6  
(80 kDa), named clone 14-18 [41], and the sgp130-Fc-detecting antibody B-P4 (130 kDa). 
The principle of this binding test including the subsequent Western blot analysis of the 
coimmunoprecipitated samples, achieved with recombinant purified sgp130-Fc (400 ng) and 
Hyper-IL-6 (400 ng), are illustrated in Fig. 28A and B.  
The Western blot analyses of coimmunoprecipitated brain homogenates from astrocyte-
specific sgp130-Fc-expressing mice (lines 5.2, 15.5, 19.1; 1st backcross) indicated that the 
transgenically expressed sgp130-Fc protein was able to bind and precipitate its ligand IL-
6/sIL-6R (Hyper-IL-6) revealing its biological activity (Fig. 29). Wildtype brain homogenate 
(of non-transgenic littermate) did not show protein signals after coimmunoprecipitation for 
sgp130-Fc (negative control), as well as for Hyper-IL-6 that did not bind unspecifically to the 
protein A sepharose. 
 
A                                                                          B 
 
 
 
 
 
 
 
 
Figure 28 Principle of coimmunoprecipitation of Hyper-IL-6 with sgp130-Fc. Schematic principle of 
coimmunoprecipitation (A), principle of Western blot analysis of a coimmunoprecipitation using 
recombinant proteins of sgp130Fc and Hyper-IL-6 (B). Sgp130-Fc was pulled down after 
incubation of Hyper-IL-6 with protein A sepharose that binds to the Fc-portion. Bound Hyper-IL-6 
was detected by a monoclonal antibody raised against human sIL-6R (clone 14-18), and sgp130-Fc 
via the monoclonal anti-gp130 antibody B-P4.  
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Figure 29 Western blot analysis after coimmunoprecipitation of Hyper-IL-6 with brain-derived sgp130-Fc of 
gfa2–sgp130-Fc mice. Sgp130-Fc in brain homogenates of transgenic mice (3 different lines after 
1st backcross; designated as numbers) and wildtype (non-transgenic) were incubated with Hyper-
IL-6 and for pulldown with protein A sepharose that binds to the Fc-portion of sgp130-Fc. Bound 
Hyper-IL-6 was detected by a monoclonal antibody raised against human sIL-6R (clone 14-18), 
and sgp130-Fc via the monoclonal anti-gp130 antibody B-P4.  
 
 
3.2.4.3  Differential tissue expression of transgenic sgp130-Fc on RNA level 
The GFAP promoter gfa2 directs expression almost exclusively to astrocytes of the CNS. 
However, outside of the brain expression of transgenes driven by this promoter has been 
reported to a weak extent [30, 271]. For the generated gfa2–sgp130-Fc mice, the tissue-
specific expression of sgp130-Fc mRNA was explored in the organs brain, liver, kidney, 
spleen and lung by Northern blot analysis using a radioactive-labelled sgp130-Fc-specific 
probe (2.2.18). Beside the gfa2–sgp130-Fc mice (line 12.3, 1st backcross), transgenic sgp130-
Fc mice under control of the PEPCK promoter (pepck–sgp130-Fc mice [220]) and wildtype 
C57BL/6N were examined. The Northern blot analysis (Fig. 30) indicated that the sgp130-Fc 
expression profile did not overlap between gfa2– and pepck–sgp130-Fc transgenic mice. The 
expression of sgp130-Fc mRNA was clearly restricted to the brain in gfa2–sgp130-Fc mice, 
but very faint amounts also appeared in spleen and lung. The pepck–sgp130-Fc mice 
transcribed sgp130-Fc mRNA mainly in liver and kidney with some amounts in lung, 
consistent with the finding of Rabe et al. [220]. The wildtype mouse strain did not display any 
presence of human sgp130-Fc mRNA. The total RNA was proven to be of optimal quality, 
indicated by the distinct RNA bands for 28S and 18S rRNA of the RNA agarose gel carried 
out before the blotting procedure. 
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Figure 30 Analysis of sgp130-Fc mRNA expression via Northern blotting. Five micrograms of total RNA of 
different organs of heterozygous gfa2–sgp130-Fc mouse line 12.3 (astrocyte-specific, 1st 
backcross), homozygous pepck–sgp130-Fc mouse line opt3 (liver-specific) and wildtype 
C57BL/6N strain (negative control) were separated on a 1% agarose/formaldehyde gel (lower 
panel), transferred onto a nylon membrane and hybridised with α-32P-dATP-radioactive-labelled 
sgp130-Fc-specific probe (upper panel).  
 
 
In addition, the mRNA expression of sgp130-Fc was monitored via RT-PCR (2.2.16) using 
the same RNA samples as for Northern blotting (see above). Even very small amounts of 
mRNA can be amplified via this sensitive method. The results of the RT-PCR (Fig. 31) with 
sgp130-Fc-specific primers (“sgp130-Fc-screen”) led to a 699 bp product and confirmed the 
findings obtained by Northern blot analysis. However, the generated gfa2–sgp130-Fc mouse 
also showed very low expression of sgp130-Fc in lung and spleen, and additionally in liver 
and kidney. Nevertheless, the most intense sgp130-Fc mRNA signal for this mouse strain 
remained within the brain. 
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Figure 31 Analysis of sgp130-Fc mRNA expression via RT-PCR. Total RNA (1,5 µg) of different organs of 
heterozygous gfa2–sgp130-Fc mouse line 12.3 (astrocyte-specific, 1st backcross), homozygous 
pepck–sgp130-Fc line opt3 (liver-specific) and wildtype C57BL/6N strain (negative control) was 
transcribed to cDNA (RT), 1 µl cDNA assessed to PCR (25 cycles) and 10 µl loaded onto a 1% 
agarose gel.  
 
 
3.2.4.4  Transgenic sgp130-Fc protein in the serum 
Although expression of sgp130-Fc, under specific transcriptional control of the astrocyte-
specific promoter gfa2, indeed could be assigned mainly to astrocytes of the transgenic 
murine brain, small amounts of sgp130-Fc mRNA were detected in organs outside of the 
brain (see 3.2.4.3, 3.2.4.1). Therefore, transgenic protein expression in sera of gfa2–sgp130-
Fc founder animals were investigated. Forty µl of serum (2.5.5) of different founder mice 
were tested after IP with protein A sepharose (2.3.3) in Western blot analysis detecting 
sgp130-Fc by the antibody B-P4 (2.3.2), after loading 50% of IP-precipitate onto the SDS gel 
(2.3.1). The strain C57BL/6N served as negative control. A serum sample of pepck–sgp130-
Fc line 4 strain, which expressed low sgp130-Fc levels in serum (0.55 µg/ml) [219], was 
included as a positive control. Varying amounts of precipitated sgp130-Fc were detected 
within the serum of several gfa2–sgp130-Fc founder mice (Fig. 32).  
 
 
 
 
 
 
Figure 32 Detection of transgenic sgp130-Fc protein in the serum of several gfa2–sgp130-Fc founder mice 
after IP with protein A sepharose by Western blotting using the monoclonal anti-gp130 antibody 
B-P4. Serum of C57BL/6N served as negative control, serum of pepck–sgp130-Fc L4 as positive 
control.  
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Additionally, the sgp130-Fc protein concentrations in serum were quantified in gp130 
sandwich ELISA (2.3.5) for several heterozygous mouse lines after the first backcross. Here, 
the positive control consisted of serum from the homozygous pepck–sgp130-Fc mouse line 
opt3 that has been shown to express concentrations between 29–36 µg sgp130-Fc/ml serum 
[220]. In accordance with that outcome, the ELISA (Fig. 33) revealed a concentration of 
approximately 29 µg sgp130-Fc/ml serum for a mouse of this opt3 line. As negative control a 
non-transgenic littermate (wildtype) was utilised.  
 
 
 
 
 
 
 
 
 
 
 
Figure 33 Quantification of sgp130-Fc protein concentrations in the serum of several heterozygous 
transgenic gfa2–sgp130-Fc mice by gp130 ELISA. Several lines after first backcross are 
designated as numbers on the x-axis. A non-transgenic wildtype serum was included as negative 
control and pepck–sgp130-Fc opt3 serum as positive control. Data represent mean values ± S.D. 
(quadruplets).  
 
 
Measurement of sera of gfa2–sgp130-Fc animals indicated that the line 12.3 contained the 
highest sgp130-Fc protein level of about 24 µg/ml serum. Line 5.2 showed a high sgp130-Fc 
concentration of approximately 14 µg/ml serum. The lines 14.4 and 19.1 displayed moderate 
amounts of the transgenic protein with about 9 µg/ml serum, and in line 15.5 a low sgp130-Fc 
content of approximately 700 ng/ ml was present in the serum.  
The sgp130-Fc protein expression of the currently three established gfa2–sgp130-Fc mouse 
lines 5.2, 15.5 and 19.1 within brain and serum was compared. This is exemplified by gp130 
ELISA analyses for a mouse per line (Fig. 34). Blood from the brain (as in capillaries, 
meninges) were removed/replaced by perfusion with 30 ml of PBS buffer. The animals were 
crossed onto a C57BL/6N background to number 5 (line 19.1), 6 (line 15.5) and 7 (line 5.2). 
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The outcome is summarised in Table 2. The data indicate that the sgp130-Fc protein levels in 
serum of gfa2–sgp130-Fc transgenic mice did not correlate with the amount found in the 
brain. The line 19.1 that displayed the highest sgp130-Fc level in brain homogenate (about 
1,900 ng/ml) revealed a moderate concentration in serum (about 6,400 ng/ml). The lines 5.2 
and 15.5 that express comparable sgp130-Fc amounts within the brain homogenates (about 
340 and 360 ng/ml respectively) differed in serum levels of sgp130-Fc. In the serum, line 15.5 
showed a low sgp130-Fc amount (1,100 ng/ml), whereas line 5.2 contained more than a 
fivefold higher sgp130-Fc protein level (8,800 ng/ml).  
 
 
 
 
 
 
 
 
 
Figure 34 Protein levels of sgp130-Fc in brain homogenates and serum after perfusion for a mouse of each 
established gfa2–sg130-Fc line 5.2 (backcross 7), 15.5 (backcross 6) and 19.1 (backcross 5), 
measured by gp130 ELISA. A non-transgenic wildype animal served as negative control. Note the 
different division of y-axes. Data represent mean values ± S.D. (triplets).  
 
 
Table 2 Relative comparison of sgp130-Fc levels between brain and serum of the 3 established gfa2–
sgp130-Fc mouse lines. 
 line 5.2 line 15.5 line 19.1 
sgp130-Fc in 
brain ++ ++ +++ 
sgp130-Fc in 
serum +++ + ++ 
 
                       +++ abundant expression; ++ moderate expression; + low expression 
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3.2.4.5  Transgenic protein expression in gfa2–sgp130-Fc mice in the brain after several 
steps of backcrossing 
It became evident that the absolute sgp130-Fc amounts of the brain changed in the course of 
backcrossing. The gfa2–sgp130-Fc lines 5.2 and 15.5 displayed reduced transgenic protein 
expression in brain homogenates, starting from about 700 ng/ml in the founder mice (3.2.4.1, 
Fig. 25, Table1) and reaching about 350 ng/ml after backcross 6 and 7, respectively (3.2.4.1, 
Fig. 34, Table 3). Conversely, in brain homogenates of line 19.1 after the 5th backcross 
sgp130-Fc levels at about 1,900 ng/ml were detected (3.2.4.4, Fig. 34, Table 3), which 
increased in comparison to the founder animal at about 1,200 ng/ml (3.2.4.1, Fig. 25, Table 
1). 
Considering that a molar excess of sgp130-Fc (at least 10-fold) is needed to counteract IL-6 
trans-signalling [115], molar ratios of the relevant components/molecules were determined 
(Table 3), as before for the founder mice (3.2.4.1, Table 1). Again, 15 ng/ml msIL-6R (1.875 
×10-10 M), the crucial component of trans-signalling was set as the value to relate to. The 
molar amounts of sgp130-Fc were calculated from gp130 ELISA measurements of brain 
homogenates of the 3 established gfa2–sgp130-Fc lines (Table 3). A molar excess of sgp130-
Fc was present in the brain of the transgenic lines: about 14-fold in line 5.2 (7th backcross) 
and 15.5 (6th backcross), and 79-fold in line 19.1 (5th backcross). 
 
 
Table 3 Protein levels of sgp130-Fc in brain homogenates of the 3 established gfa2–sgp130-Fc mouse lines 
5.2 (backross 7), 15.5 (backcross 6) and 19.1 (backcross 5) measured via gp130 ELISA and 
calculated molarities. Values are means. Protein levels were measured in triplets. Molar relations 
of sgp130-Fc to msIL-6R were calculated for 15 ng/ml msIL-6R as measured in ELISA.  
(1 M sgp130-Fc=130,000 g/l; 1 M sIL-6R=80,000 g/l). 
 
tg line L 5.2 L15.5 L19.1 
sgp130-Fc of brain 
homogenate [ng/ml] 340.02 357.19 1938.79 
sgp130-Fc of brain 
homogenate [mol/l] 2.616 ×10
-9 2.748 ×10-9 1.491 ×10-8 
molar factor  
sgp130-Fc : msIL-6R 13.95 14.65 79.54 
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4  Discussion 
4.1  IL-6 trans-signalling and sleep 
4.1.1  Effects of Hyper-IL-6 on sleep-wake behaviour 
Several previous publications have demonstrated the sleep-modulatory properties of IL-6 (see 
1.7). IL-6 responses are transmitted either via the classic or the trans-signalling pathway (see 
1.2, 1.3). This is the first study to systematically investigate the influence of IL-6 trans-
signalling on sleep regulation/modulation in rats by means of the designer cytokine Hyper- 
IL-6. Hyper-IL-6 is the fusion protein of the human IL-6 connected by a flexible peptide 
linker to the human sIL-6R, which mimics the trans-signalling pathway [70].  
As gp130 is ubiquitously expressed, including in the brain [312], Hyper-IL-6 can activate 
virtually all cells within the brain. The cellular response to Hyper-IL-6 in primary rat 
astrocytes and microglia was confirmed in this work by assessing the phosphorylation of the 
transcription factor STAT3 upon Hyper-IL-6 challenge using Western blot analysis (3.1.1, 
Fig. 8). The reactivity of primary rat hippocampal neurons to Hyper-IL-6 was initially shown 
by Sun et al. [273]. The cytokine samples of Hyper-IL-6 utilised in the animal experiments 
were verified to be biologically active and to act specifically via the transmembrane receptor 
gp130 (3.1.1, Fig. 9). To date there has been no publication demonstrating cellular activation 
independent of gp130. The high specificity and wide reactivity of Hyper-IL-6 was 
strengthened in the present work. 
The i.c.v. administration of Hyper-IL-6 (100 and 500 ng) shortly prior to the dark period (dark 
onset), had no impact on non-REM sleep in rats (3.1.2, Fig. 12). Rats that received an i.c.v. 
injection of 500 ng rat IL-6 at dark onset displayed enhanced non-REM sleep initially, that 
reduced thereafter, and a fragmentation of sleep [99]. However, the amount of non-REM 
sleep was not altered by antagonising IL-6 via monoclonal or polyclonal antibodies [99] as 
well as by the lack of IL-6 in IL-6 knock-out mice [174]. Therefore Morrow et al. [174] 
proposed that IL-6 is not involved in the regulation or modulation of non-REM sleep. These 
findings were supported by the present study. In contrast, a subcutanous administration of  
IL-6 to humans revealed an increase of SWS (non-REM sleep) during the second part of the 
sleep period [262]. The route and time of application, the actual doses reaching the brain as 
well as species differences might be the variables leading to different outcomes of the various 
studies. 
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Interestingly, i.c.v. Hyper-IL-6 application (500 ng) had a quantitative (increased amount) and 
qualitative (reduced EEG power density) effect on REM sleep (3.1.2, Fig. 12; 3.1.3., Fig. 14). 
An elevation in REM sleep duration predominately occurred during the light phase, which is 
the main sleeping period for rats. This delayed effect of Hyper-IL-6 18–20 h after injection 
(late part of sleep) might relate to an indirect sleep-promoting effect of Hyper-IL-6, including 
activation of brain cells as astrocytes, glia cells and neurons and subsequent translation of 
further substances mediating the observed REM sleep increase (see 4.1.4). This effect was 
somewhat surprising since IL-6 KO mice show a 30% increase in REM sleep, mainly during 
the light period [174]. In contrast, the effect on non-REM sleep elicited by rat IL-6 injection 
into rats (see above) was not accompanied by changes of REM sleep [99]. In the same way, 
the effects of exogenous IL-6 application on human REM sleep remain ambiguous. Whereas 
one publication displayed suppression of REM sleep after a s.c. injection [262], another study 
did not report changes after an intranasal administration [16]. However, in accordance with 
the present study, some previous reports point to a role of IL-6 and/or sIL-6R for REM sleep. 
It has been found that peripheral circulating levels of IL-6 in humans were higher during 
REM sleep and light sleep, but not in deep SWS [224]. In addition, the human study of 
Dimitrov et al. [56] revealed an association between high amounts of REM sleep, present 
especially at the late part of nighttime sleep, and high levels of the sIL-6R, which is the 
receptor mediating the IL-6 trans-signalling pathway. These results might support the current 
finding herein that Hyper-IL-6 and thus trans-signalling has increased REM sleep during the 
late part of the rat’s sleeping period.  
 
4.1.2  The roles of IL-6 trans-signalling versus classic signalling affecting brain functions 
The cytokine IL-6 is produced within the brain by astrocytes, microglia and neurons [160, 
230, 237, 243, 247, 254, 295]. In addition to this brain-born IL-6, also peripheral circulating 
blood-borne IL-6 can signal the brain to affect CNS function as sleep-wake behaviour. 
Several routes for peripheral cytokines to reach the brain have been delineated so far 
(reviewed in [107, 133, 216]). They can act directly from the blood on brain areas which lack 
the BBB. Such areas are termed circumventricular or periventricular organs. Among them are 
e.g. the pineal gland, the posterior pituitary, the subfornical organ and the median eminence of 
the hypothalamus, and mostly the areas surrounding the ventricles 3 and 4. Crossing the BBB 
via active transport and stimulation of afferent nerves like the vagus nerve are further 
possibilities for cytokines to communicate from the periphery to the CNS. In order to affect 
brain functions even low levels of circulating cytokines are sufficient [216].  
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For the activation by IL-6, the IL-6 receptor in membrane-bound (classic signalling) or 
soluble form (trans-signalling) is required. Whereas the receptor subunit gp130 is 
ubiquitously expressed throughout the body and also in most of the brain areas [312], the 
expression of the IL-6R is highly restricted to distinct cell populations, e.g. hepatocytes and 
lymphocytes ([274], 1.1, 1.3). Within the rat brain, IL-6R mRNA expression has been found 
in some neuronal lineages, like primary sympathetic neurons [157, 160]. In addition, low 
levels of IL-6R mRNA were detected in microglia and astrocytes, but not in oligodendrocytes 
of primary mixed brain cultures of newborn mice [243]. Brain regions in which rat IL-6R 
mRNA transcripts have been found include hypothalamus, hippocampus, neocortex and 
cerebellum [75, 76, 102]. IL-6 mRNA was detected to a minor extent in several other brain 
structures as well [246, 321]. Low levels of IL-6R mRNA were found under basal conditions 
for instance in the ependymal cells of the ventricles, and in areas lacking the BBB like the 
subfornical organ and median eminence [288].  
However, it should be kept in mind that mRNA expression might not reflect protein 
expression onto the cell surface. Recently, Helwig et al. [94] have analysed rat brain slices via 
immunohistochemistry after i.c.v. injection of 100 ng labelled IL-6 and found IL-6R protein 
expression (colocalised with IL-6) in ependymal cells of the third ventricle (periventricular 
tissue) but not within the brain parenchyma. Moreover, the ependymal cells of the ventricles 
and circumventricular organs were activated after i.c.v. application of IL-6 (200 ng) into rats, 
which was detected via in situ hybridisation of brain slices for c-fos mRNA [287]. It was 
further demonstrated that even a systemic IL-6 injection activated sensorial circumventricular 
organs such as subfornical organ and median eminence (of the hypothalamus). These results 
suggest that the circumventricular organs (lacking BBB) provide a route for peripheral IL-6 to 
transmit signals to the brain [287]. Thus IL-6 floating within brain ventricles and peripheral 
IL-6 could signal through the membrane-bound IL-6R via the classic transduction pathway.  
But indeed, it has been shown that many neural cells, e.g. primary rat sympathetic and 
hippocampal neurons, and newborn rat astrocytes, are only responsive to IL-6 in the presence 
of the sIL-6R or to Hyper-IL-6 via trans-signalling ([160-162, 249, 273], see 1.3). Hyper-IL-6 
can thus activate a broader spectrum of target cells within the brain and has been shown to be 
far more potent than IL-6. 
In sum, considering the spatial restriction of the membrane-bound IL-6R, the findings 
mentioned above suggest that IL-6 activity within the brain parenchyma requires the trans-
signalling pathway. Accordingly, the different properties of IL-6 classic and trans-signalling 
might explain the seemingly contradictory effects between exogenous IL-6 and Hyper-IL-6 on 
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sleep behaviour (see 4.1.1). They imply, that IL-6 together with the sIL-6R (mimicked by 
Hyper-IL-6) may affect areas of the brain that would remain unresponsive to IL-6 alone and 
therefore may create different biological outputs such as the herein observed supportive effect 
on REM sleep. 
 
4.1.3  The role of IL-6 trans-signalling in sleep under disease conditions 
The sleep-associated increase of the sIL-6R found in healthy humans [56] seems to be of 
relevance for diseases as well. Under pathological conditions increased levels of both IL-6, 
mainly released by astrocytes [230, 295] and microglia [254], and sIL-6R were observed [1, 
86, 127, 153, 169, 181, 325]. During disease processes an altered sleep behaviour is well 
documented [50, 53, 66, 107, 121, 134, 176, 285], and thus a link to trans-signalling appears 
very likely. The main finding of this project, the association of Hyper-IL-6 with REM sleep, 
is nicely reflected for instance in conditions of major depression and during aging. In these 
cases, sleep architecture is characterised by an increased percentage of REM sleep [15], and 
circulating levels of IL-6 and its soluble receptor (sIL-6R) are elevated [153]. These results 
strengthen the putative involvement of trans-signalling in the modulation of REM sleep 
during disease conditions. In addition, patients suffering from Parkinson’s disease, which is 
associated with elevated IL-6 levels in cerebrospinal fluid, display daytime sleepiness and a 
tendency to more REM sleep at sleep onset [53]. 
Furthermore, expression and activity of the metalloprotease ADAM17 [62], which is 
responsible for the proteolytic generation of the sIL-6R (trans-signalling), is elevated in the 
CNS under some pathological conditions including stroke and multiple sclerosis (MS) [173, 
323]. These processes promote neural progenitor cell migration and contribute to stroke-
induced neurogenesis [173] and might thereby also contribute to altered sleep behaviour 
during disease conditions. 
In this respect, stroke is an interesting case. Stroke is accompanied by a great release of 
glutamate that triggers neurotoxicity. A few hours after stroke in humans, levels of IL-6 rise 
in peripheral blood and cerebrospinal fluid [126, 226, 280]. Interestingly, IL-6 plays a 
neuroprotective role in neurons exposed to glutamate excitotoxicity and thus neuronal 
protection after cerebral ischemia (stroke) [2]. It is well known that sleep loss increases 
cytokines like IL-6 (see 1.6.3; 1.7; [108, 302]). A recent study reported that after cerebral 
ischemia (stroke) in mice, the increased IL-6 mRNA expression caused by experimental sleep 
deprivation contributed to the attenuation of neuronal cell death [314]. This is remarkable 
given that the consequences of chronic sleep loss, including elevated cytokine levels, are 
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normally detrimental. Long-term sleep deprivation may lead to a higher risk developing 
diseases that are mostly associated with aging, e.g. cardiovascular diseases, diabetes or stroke 
(see 1.6.3, [241]). For instance, in a recent human study enhanced circulating levels of IL-1β, 
IL-6, IL-17, CRP and an increased heart rate, which are the risk factors for developing 
cardiovascular diseases were detected after sleep restriction of 5 nights (to 4 h sleep) [292]. 
These examples illustrate well both the protective potential of IL-6 when acutely elevated, 
and the detrimental/degenerative potential when IL-6 is chronically increased during 
pathological conditions, also in connection to the matter of sleep. 
 
4.1.4  Possibilities for REM sleep modulation by IL-6/sIL-6R 
What could be the mechanisms how IL-6/Hyper-IL-6 affects sleep-wake behaviour, 
particularly REM sleep? In general the model of humoral sleep regulation (Fig. 5) also 
accounts for IL-6, and partly for REM sleep (see also 1.6.2). The regulation of REM sleep 
involves a huge network with different generators for the REM sleep signs (e.g. muscle 
atonia, hippocampal theta waves, cortical activation) with multiple neurotransmitters acting 
on various sites of the circuits [52]. Briefly, REM sleep is dependent on a reciprocal 
interaction between monoamine containing REM-off neurons in the brainstem (locus 
coeruleus (noradrenergic) and raphe nucleus (serotonergic)) and cholinergic REM-on neurons 
in the pons (lateral dorsal tegmentum and pedunculopontine tegmentum). During REM sleep 
the aminergic cell activities are drastically reduced or absent (REM-off), whereas the 
cholinergic cell activities are rather high (REM-on; Wake-REM-on) (ratio 0:0.65). During 
wakefulness this ratio is 1:1. When REM sleep is absent the cholinergic REM-on neurons are 
inhibited by the serotonergic and noradrenergic REM-off neurons. At the onset of REM sleep 
the REM-on neurons become disinhibited as the REM-off neuron activity become silent. The 
REM-off cell activity may be inhibited by GABA in dorsal raphe and locus coeruleus nuclei 
[192, 193] and by a reciprocal neuronal activity between serotonergic and GABAergic cells of 
the dorsal raphe nucleus (rev. in [52]). 
It has emerged that neurotransmitters, neuropeptides, hormones, cytokines, etc. interact in a 
complex net with crosslinks at multiple sites and mutual interactions to affect REM sleep and 
are in turn affected by sleep, although there are many open questions. Some speculations and 
hypotheses of mechanisms how the player IL-6 might operate in the modulatory network of 
REM sleep, are discussed below and illustrated in Fig. 35. Importantly, it should be noted that 
release of neurotransmitters or sleep modulatory factors at different sites within the brain and 
networks can result in varying or opposite effects on sleep behaviour, therefore it is difficult 
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to determine the role for a specific local action of IL-6 and thus more experimental research is 
strongly necessary. 
It was supposed that IL-6 could act directly on sleep-wake regulating neurons [99]. Indeed, 
IL-6 was shown to influence neuronal firing rates in some brain regions [125, 316]. Further 
possibilities for an indirect modulation of sleep-wake behaviour by IL-6 include other 
branches of the network. IL-6 is able to alter expression of neurotransmitters involved in 
sleep-wake regulation. For instance, GABA release has been demonstrated to be increased by 
IL-6, which was mediated by prostaglandins [54]. The inhibitory neurotransmitter GABA 
inhibits wake active neurons and promotes non-REM and REM sleep ([192, 193]; rev. in 
[268]). IL-6 might be connected to REM sleep modulation by affecting this transmitter. 
Moreover, IL-6 is involved in glutamatergic neurotransmission, and showed an inhibitory 
effect on the release of glutamate, which is an excitory wake-promoting neurotransmitter [49, 
218]. But in contrast, local activity of glutamate in lateral dorsal tegmentum and 
pedunculopontine tegmentum is needed for initiation of REM sleep. Also serotonin, whose 
action is involved in local inhibition of aminergic REM-off neurons during REM sleep, could 
be influenced by the cytokine IL-6. Several studies indicated the induction of serotonin in the 
brain by IL-6 [10, 309, 310], in turn serotonin was shown to increase IL-6 mRNA in rat 
astrocytes [217].  
Multiple series of evidence ascribe adenosine, which is omnipresent in the brain, as a sleep 
regulatory substance for non-REM and REM sleep, providing a metabolism-dependent 
regulation (rev. in [12, 195, 268]). Both A1 and A2A adenosine receptor subtypes mediate the 
well-documented sleep inducing effect of adenosine. In vitro and in vivo studies in mice 
demonstrated enhanced expression of the neuronal adenosine A1 receptor (hippocampus, 
cortex, astrocyte cultures) and signalling induced by IL-6 [18, 19]. NO may lead to 
accumulation of adenosine as determined in rat forebrain neurons in vivo [235]. Likewise, NO 
has a vital role in REM sleep modulation (rev. in [195]). It has been found that primarily the 
neural NO synthase is responsible for REM sleep production, not the inducible NO synthase 
[42]. To promote REM sleep in brain stem, NO may stimulate acetylcholine release [143], 
may modulate serotonergic activity in raphe [35] and noradrenaline release in 
pedunculopontine area [129]. 
As mentioned above all the sleep modulatory components are interweaved with each other. 
Adenosine is considered an intermediary for the sleep regulatory effects of prostaglandin D2, 
as suggested for non-REM sleep induction at the VLPO [91]. Prostaglandins, which are 
eicosanoids, particularly prostaglandin D2 have been shown to promote both non-REM and 
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REM sleep under normal as well as under some pathological conditions [91]. Similarly, 
prostaglandin E2, which is a major mediator of the fever response, is implicated in sleep 
regulation, too [164]. It has been found that central and peripheral injection of IL-6 increased 
prostaglandin E2 in cerebrospinal fluid, which was inhibited by application of inhibitors for 
cyclooxygenase (an enzyme involved in the synthesis of prostaglandin E2) [57]. The 
cyclooxygenase can also be activated e.g. by NO [122], underlining the complex interplay. 
Another well-described factor for promoting REM sleep is GH, a member of the somatotropic 
axis that regulates tissue metabolism, whose release from the pituitary is stimulated by GHRH 
(rev. in [195, 268]). Exemplary, systemically GH-injected animals and transgenic mice 
overexpressing GH displayed much higher amounts of REM sleep [60, 87]. In rat pituitary 
cells, IL-6 promoted GH expression and secretion [80] and thus could increase REM sleep. 
Likewise, the neuropeptides prolactin and the vasoactive intestinal polypeptide (VIP) also 
belong to the well-known REM sleep-promoting substances (rev. in [268]). Prolactin is 
secreted mostly during the second half of human sleep, which is REM rich [242, 306]. 
Further, a systemic or hypothalamic injection increased REM sleep during the light period 
(sleep) in rats [231]. Contrary, prolactin-deficient mice have reduced REM sleep [196]. IL-6 
has been shown to stimulate the release of prolactin from pituitary cells [3, 227]. Similarly, 
i.c.v. injection of VIP into rats led to enhanced REM sleep [228]. The VIP effect was clearly 
demonstrated to be mediated via prolactin, whose expression can be induced by VIP [185, 
231]. Interestingly, IL-6 together with the sIL-6R induced VIP mRNA expression in 
sympathetic neurons [44]. In turn, VIP was able to potentiate IL-6 production as determined 
in osteoblasts [212]. There is also an indirect connection to cytokines, since VIP together with 
TGFβ promotes differentiation of the IL-17 producing Th17 cells (see below) [317]. 
The transcription factor NF-κB, which is also constitutively expressed in neurons, serves as a 
mediator in sleep-wake regulation [43, 118]. NF-κB is activated by adenosine A1 receptor 
[11] as well as several cytokines and growth factors involved in sleep regulation/modulation 
as IL-1β, TNFα, NGF [43, 144, 155, 319]. In turn, as a feedback loop, NF-κB stimulates 
expression of the adenosine A1 receptor [88, 191], enzymes for syntheses of prostaglandins 
D2 and E2 [9, 190, 318] and a number of sleep modulatory cytokines such as IL-1β and 
TNFα, and NGF [6, 204]. Interestingly, knock-out mice for the p50 subunit of NF-κB spent 
more time in non-REM as well as in REM sleep under normal conditions, but REM sleep was 
reduced after LPS (inductor of NF-κB) challenge [112]. Ihaveri et al. highlighted the role of 
NF-κB in influencing sleep through various sleep regulatory/modulatory substances during 
health and disease [112]. Furthermore, NF-κB is a STAT3 target gene induced by IL-6 [258] 
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and in turn NF-κB also induces IL-6 [145], thus providing an additional possibility to 
influence (REM) sleep. 
Cytokines and growth factors within the brain work together in a large network in synergistic 
or antagonistic manner with overlapping and feedback activities, including IL-6 with its 
downstream and upstream actions. IL-6 is supposed to act downstream of IL-1β and TNFα in 
the cytokine cascade and can build up a negative feeback loop on TNFα [68, 201, 260, 305]. 
In addition, IL-6 in association with TGFβ promotes the development of the IL-17-secreting 
Th17 cells [17, 296]. REM sleep deprivation for 72 h in rats led to inflammation and an 
elevation of IL-17 in blood [322]. In this respect, IL-17 might be a candidate to participate in 
sleep modulation at least under pathological conditions, which has yet to be experimentally 
proven. Induction of REM sleep (and non-REM) was also shown for NGF in rabbits and cats 
[275, 320], which can be triggered by several cytokines [324]. IL-6 in conjunction with sIL-
6R (or Hyper-IL-6) has stimulated synthesis of NGF mRNA and protein release in primary rat 
astrocytes of cortex and hippocampus in a dose-dependent manner, which was strictly 
regulated by the sIL-6R [161, 204]. NGF is associated with other sleep modulatory 
substances. In human microglial cells it was shown that an adenosine-induced NGF mRNA 
and protein release occurred via stimulation of adenosine A2A receptor [92]. 
There are likewise various sleep inhibitory molecules acting on different levels of the sleep 
modulatory machinery. They involve hormones of HPA axis as cortisol, ACTH, CRH [156, 
299], and the non-REM and REM sleep inhibitory cytokines, with IL-4 and IL-10 [136] for 
instance inhibiting NF-κB [47, 311]. 
Moreover, focussing on the overall regulation of sleep, the timing of the sleep-wake cycle is 
coordinated by a circadian control [22, 24]. The secretion of sleep regulatory/modulatory 
components is also controlled by the circadian clock. The circadian master (core) clock is 
located in the SCN of the hypothalamus that receives information via a wide range of 
neurotransmitters and mediators from various regions of the brain [170]. Interestingly, IL-6 
has been detected in the rat SCN [81]. Noteworthy, cytokines are capable of influencing core 
clock or clock-controlled genes. For example, TNFα and IL-1β inhibited expression of some 
clock genes in NIH-3T3 cells, whereas IL-6 showed no effect in that study [40]. In contrast, 
expression of the core clock gene Per1 was induced by IL-6 in a human hepatoma cell line 
[177]. The basic helix-loop-helix transcription factor Dec1 (=Stra13), which is expressed in 
the SCN, belongs to the regulators of the mammalian clock [101]. It suppresses the activation 
of the Per1 promotor [101], the clock-controlled genes Dbp and Rev-erbα and activate the 
core clock gene Cry1 [130]. The expression of Dec1 mRNA in a human NK-cell line 
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increased after stimulation with several cytokines such as IL-2, IL-12, TNFα, TNFβ, and also 
IL-6 [111].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35  Some speculations for REM sleep support by IL-6/sIL-6R operating in the complex REM sleep 
regulatory/modulatory network. IL-6 has been shown to influence the designated substances, but 
not yet in connection to REM sleep and corresponding brain areas. Green marked substances have 
been shown to support REM sleep. Red marked factor is downregulated during REM sleep. 
Circadian control belongs to an overall sleep regulatory mechanism. For further details see 4.1.4.  
 
 
4.1.5  Conclusions 
Taken together, this study defines a REM sleep-promoting role of IL-6 trans-signalling (see 
4.1.1), which might have a crucial meaning for normal sleep-wake behaviour but especially 
for sleep in certain pathologies (see 4.1.3). Regardless, single cytokines never act alone but in 
a complex network associated with other cytokines, neurotransmitters, hormones and cellular 
molecules (see 4.1.4). In this context, IL-6 would be united with the other “sleep factors” in 
the complexicity of REM sleep inducing and maintaining actions. The sleep 
regulatory/modulatory substances presumably influenced by IL-6 might be amplified when 
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IL-6 acts together with the sIL-6R. Thus IL-6/sIL-6R or Hyper-IL-6 could stimulate a broader 
range of cells including areas of REM sleep generation (see 4.1.2). Nevertheless, the 
suggestions that argue the contributed mechanisms for REM sleep modulation by IL-6 should 
be interpreted cautiously, because they have not yet been experimentally proven. 
 
 
4.2  Generation of gfa2–sgp130-Fc transgenic mice: Selective blockade of 
IL-6 trans-signalling in the brain 
IL-6 trans-signalling-mediated responses have been implicated in the pathophysiology of 
inflammatory, autoimmune or degenerative disorders of the periphery and brain, and might be 
involved in sleep modulation (see 1.1, 1.5, 1.7). For further investigations in these research 
fields, transgenic mice (to date 3 lines at heterozygous state on 8th backcross to C57BL/6N) 
expressing sgp130-Fc specifically within the brain were generated and initially characterised.  
Soluble gp130 is the natural inhibitor of IL-6 trans-signalling without affecting the 
membrane-bound IL-6R-triggered responses (classic signalling). The molecular tool sgp130-
Fc (see 1.4) is a dimer of the extracellular portion of human gp130 connected by the constant 
portion of a human IgG1 antibody (Fc). It appeared to be 10-fold more antagonistically active 
than the monomeric sgp130 [115]. Likely sgp130-Fc rather reflects the situation of preformed 
gp130-dimers on living cells [281] that facilitates the ligand/receptor complex formation to 
induce intracellular signalling events (see 1.2, 1.3). Since sgp130-Fc competes with its 
membrane-bound equivalent for binding of IL-6/sIL-6R, a sufficient excess of sgp130-Fc 
(transgenically expressed) is required to block IL-6/sIL-6R-mediated cellular responses 
([115], see 1.4). Human sgp130-Fc is able to inhibit the complex of murine IL-6/sIL-6R, 
because of the special species specificity within the IL-6 receptor system. Murine IL-6 only 
binds the murine IL-6R [293], whereas murine sIL-6R can associate with murine and human 
IL-6 as well as with murine and human sgp130 [115].  
In the present study sgp130-Fc transgenic mice were generated under transcriptional control 
of the human gfa2 promoter. The gfa2 promoter is a 2.2 kb fragment of GFAP (glial fibrillary 
acidic protein) and its expression is mainly restricted to astrocytes, which are the major cell 
population in the CNS [30, 271]. Up to now, the gfa2 promoter has been used successfully in 
several transgenic mice to specifically target gene expression to astrocytes. For instance 
transgenic mice were generated expressing proteins including LacZ [29], TGFβ1 [77], 
somatostatin [250], tau [71], ApoE3, 4 [272], ApoE [257] or angiotensinogen [172]. The 
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gfa2–sgp130-Fc transgene cDNA construct (see 3.2.1, Fig. 17) was inserted by the method of 
microinjection into pronuclei of fertilised oocytes, which randomly incorporated into the 
mouse’s chromosomes. It comprises the 2nd rabbit β-globin intron between promoter and the 
codon-optimised sgp130-Fc cDNA. This type of composition showed a stronger protein 
expression in an astrocytic cell line than the location of the intron behind the sgp130-Fc 
cDNA (3.2.2, Fig. 18), again supporting the finding that the insertion of a heterologous intron 
between promoter and coding region can improve expression [209, 220]. Rabe et al. have 
already demonstrated that the codon-optimised version of the sgp130-Fc cDNA led to a 
higher protein expression [220]. Accordingly, protein expression has additionally increased 
by locating the intron upstream of the sgp130-Fc cDNA [220], as utilised herein.  
The generated gfa2–sgp130-Fc mice of the present project successfully expressed transgenic 
protein in the brain, as shown by Western blot analyses and ELISA. The sgp130-Fc protein 
levels of the founder mice that created the ancestors of different lines (5.2, 15.5, 19.1) ranged 
from about 750 to over 1,000 ng/ml brain homogenate (Fig. 25). A correlation between the 
relative copy numbers detected by Southern blot analyses (Fig. 21) and protein expression 
was not observed. This often reported finding may be attributable to the randomly selected 
site of integration of the transgene, which can affect the pattern and strength of expression 
[30]. Because sgp130-Fc is a soluble protein, its secretion was confirmed. Primary astrocytes 
derived from the cortices of transgenic mice released the transgenic sgp130-Fc into the 
medium (Fig. 27). That additionally identified the cortex as one of the regions of expression.  
The capability of sgp130-Fc to bind the complex of IL-6/sIL-6R that defines its biological 
function was verified by an ex vivo binding/immunoprecipitation test (3.2.4.2, Fig. 29). 
Accordingly, sgp130-Fc present in transgenic brain homogenates precipitated the added 
Hyper-IL-6 (IL-6 coupled to sIL-6R, [70]), revealing the biological activity of the transgenic 
protein. This was expected, because sgp130-Fc of transgenic mice based on the same 
expression construct composition but with a PEPCK promoter, which induce gene expression 
mainly in liver and kidney (protein in circulation), had been shown to be functionally active 
via the same test. The transgene functionality in these mice was additionally reflected e.g. in 
reduced acute phase response after Hyper-IL-6 challenge, due to inhibition of IL-6 trans-
signalling by the transgenic protein sgp130-Fc [220]. Blockade of IL-6 trans-signalling is only 
possible if a molar excess of sgp130-Fc is available. Jostock et al. [115] revealed that a 
fivefold molar excess was sufficient to completely inhibit Hyper-IL-6-mediated cell 
proliferation in BaF/3-gp130 cells (for information to the cells, see 3.1.1). Proliferation of 
BaF/3-gp130 cells induced via IL-6 plus sIL-6R has been blocked by a 10-fold molar excess 
4  Discussion   
  76 
of sgp130-Fc versus sIL-6R [115]. Considering these results one could assume that at least a 
10-fold molar excess of transgenic sgp130-Fc proteins would be sufficient to suppress IL-6 
trans-signalling in the brain of gfa2–sgp130-Fc mice. Molar ratios between sgp130-Fc and 
sIL-6R were calculated from the sgp130-Fc protein levels measured in brain homogenates of 
different founder animals, under determination of the endogenous level of the murine sIL-6R 
(see 3.2.4.1). For the founder mice 5.2, 15.5 and 19.1 a molar excess of sgp130-Fc has been 
calculated to be 29- to 50-fold, thus more than a 10-fold excess (Table 1). Consequently, the 
central blockade of sIL-6R-mediated responses in gfa2–sgp130-Fc mice appears very likely.  
Ultimately, it turned out that in the course of backcrossing the absolute protein amount of 
sgp130-Fc measured in brain homogenates of lines 5.2 and 15.5 was reduced (Fig. 34), 
compared to the corresponding founder mice (Fig. 25). Regardless, these sgp130-Fc levels 
still exceed the 10-fold molar excess that would be theoretically needed to suppress IL-6 
trans-signalling-driven responses ([115], 3.2.4.4, Table 3). There are cases known were 
transgenic expression strongly varied between parental mice and their offspring and even 
under individual animals of a litter (not found in gfa2-sgp130-Fc mice) with no clear trend. 
Explanations for that phenomenon might be possible changes in DNA methylation leading to 
suppression of gene activity or alternatively genomic instability with deletions of some copies 
from tandem arrays or transgene rearrangement. Also cessation of transgene activity has been 
observed once, which never returned in subsequent offspring [208]. Therefore, analyses of 
sgp130-Fc protein levels are necessary in each newborn mouse generation. Moreover, after 
the 10th backcross onto C57BL/6N, transgenic mice can be breed to homozygousity. Since 
homozygous animals carry their transgene on two alleles, an even higher sgp130-Fc protein 
production is expected. 
The expression patterns of sgp130-Fc mRNA of several tissues were assessed by Northern 
blot analyses and the highly sensitive RT-PCR (3.2.4.3, Fig 30, Fig. 31). These methods 
exhibited expression predominantly in the brain but with low amounts present in lung, spleen, 
liver and kidney (the 2 latter only in RT-PCR). Most publications about transgenic mice under 
transcriptional control of a GFAP promoter reported activity of the appropriate transgene 
almost exclusively in astrocytes throughout the brain (rev. in [271]). But apart from astrocytic 
expression, which can also occur in spinal cord astrocytes [71], activity of gfa2-driven 
transgenes has also been directed to neurons of different brain regions, non-myelinating 
Schwann cells and reactive Müller cells in several cases (rev. in [30, 271]. The literature 
pointed out that outside of the brain GFAP promoter-driven genes were individually low 
expressed ectopically in tissues such as liver, heart, lung, kidney, spleen, skeletal muscle and 
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thymus (rev. in [271]). For example in gfa2–angiotensinogen transgenic mice, the transgenic 
protein was mainly localised in astrocytes of all brain regions, but additionally in neurons of 
the subfornical organ. Although angiotensinogen mRNA was found in liver, protein plasma 
levels remained low [172]. These findings of transgenic expression on the mRNA and/or 
protein level (but rather low) outside of the brain are consistent with the herein observed 
expression pattern for the gfa2–sgp130-Fc mouse. Su et al. [271] surmised that ectopic 
expression seems to be more frequent when an intron is located between promoter and the 
synthesised transgene, which was employed herein as well. Considering the presence of 
sgp130-Fc mRNA in liver, the question arose whether transgenic protein would be observed 
in circulation. Indeed, sgp130-Fc protein was detected in sera of all of the three established 
transgenic mouse lines, but at varying levels (3.2.4.4, Fig. 33, Fig. 34). It became evident that 
the transgenic protein contents of the brain did not correlate with the levels found in the 
serum. Although the line 5.2 showed the highest sgp130-Fc protein level in serum (about 
8,800 ng/ml), only moderate amounts were quantified in brain homogenate (about 340 ng/ml). 
Similar moderate amounts in brain homogenate displayed line 15.5 (approximately  
360 ng/ml), which contained much less sgp130-Fc protein in the serum (1,100 ng/ml) than 
line 5.2. With the highest protein levels of transgenic protein in the brain (1,900 ng/ml brain 
homogenate), line 19.1 revealed only a moderate serum level (6,400 ng/ml). These results 
could be related to a different magnitude of expression outside the brain between the mouse 
lines. Interestingly, the literature pointed out that the distribution and strength of non-
astrocytic and ectopic expression respectively, may vary strongly between different lines of a 
transgenic strain, which was presumed to depend likely on both the transgene integration site 
and the expressed sequence [271]. In consequence, the transgene expression patterns in 
various organs need to be clarified for each established gfa2-sgp130-Fc line (5.2, 15.5, 19.1), 
which has yet to be performed in future.  
 
 
4.3  Future directions 
In this work two different approaches were taken to address the role of IL-6 trans-signalling 
for sleep-wake behaviour. Initially, the REM sleep-promoting effect of i.c.v. injected Hyper-
IL-6 in rats was elicited by a dose of 500 ng/rat but not by 100 ng/rat at dark onset. To further 
reinforce this recent finding it would be reasonable to conduct such a sleep recording 
experiment with additional cytokine dosages between 100 and 500 ng/animal as well as above 
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to test dose-response relations. In order to expand the relevance of Hyper-IL-6 treatment on 
sleep, the same study should be achieved at light onset. Furthermore, it would be tempting to 
establish, whether sgp130-Fc challenge could abolish the Hyper-IL-6-induced REM sleep 
increase. 
The alternative approach included the central blockade of IL-6 trans-signalling within the 
brain without affecting classic signalling. That was realised in the herein generated transgenic 
gfa2–sgp130-Fc mice. In the future, these animals will be subjected to EEG/EMG-recording 
studies of sleep-wake behaviour, in comparison to wildtype mice, IL-6 KO mice [131], 
GFAP-IL-6 mice [36] as well as pepck–sgp130-Fc mice (showing systemic expression, but 
not within brain) [220]. In this respect, it will be interesting to further explore the sleep 
architecture after sleep deprivation, LPS challenge or Hyper-IL-6 injection. Given the strong 
mutual connection between diseases and altered sleep (see 4.1.3., 1.6.3), a coupling to a 
disease/infection model could be valuable. In addition to the sleep recording, also biochemical 
measurements of sleep modulatory substances (such as GH, VIP, prolactin, IL-17, cortisol) or 
mRNA expression of sleep-related genes [46] (gene array analyses) could be examined. Since 
memory and learning is consolidated during sleep [166, 270, 284] and IL-6 is considered to be 
involved in memory formation and plasticity [5, 7, 16, 166], these issues will be investigated 
as well. For instance, a recent study demonstrated in IL-6 KO mice impaired hippocampus-
dependent and -independent memory processes, a higher susceptibility for stress, as well as 
reduced exploratory and despair behaviour. These results have been carried out by Morris 
water maze, novel object recognition memory test, open field, forced swimming test and 
elevated plus maze [5]. Such test setting will also be utilised for the gfa2–sgp130-Fc mice to 
explore behaviour and memory in comparison to wildtype animals. As aging is accompanied 
by cognitive dysfunction [95, 261], memory and behaviour in mice of different ages could be 
compared.  
The cytokine IL-6 exerts multiple and diverse functions in the CNS. It is well characterised 
for its dual role to be neuroprotective/neurotrophic in normal brain functions but also 
neuroinflammatory/deleterious (see 1.1, 1.5). Many neural cells only react to IL-6 in the 
presence of sIL-6R, thereby it was assumed that trans-signalling is of importance in neuronal 
differentiation and survival responses (see 1.3, [162]). Also the role of trans-signalling in 
pathophysiological conditions of the brain is of special interest, since IL-6 and/or sIL-6R 
increase during neuroinflammatory/degenerative disease states, such as MS, stroke and 
depression (see 1.5, [63, 325]). Consequently, the gfa2–sgp130-Fc mice with the continous 
inhibition of IL-6 trans-signalling within the brain could aid to clarify the impact of sIL-6R-
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transduced IL-6 signalling in animal models of EAE (model of human MS) (see 1.5), stroke 
(cerebral ischemia) [61, 105], traumatic brain injury [171], gliosis (tumors originated from 
astrocytes) [38], cytokine-induced depression [148] or viral/bacterial meningitis [186, 325].  
For instance, in C57BL/6 mice anti-IL-6R antibody treatment (i.p., peripheral) inhibited the 
onset of EAE and the induction of MOG-specific Th17 cells [251], whose development is 
promoted by IL-6 together with TGFβ [17, 296]. Similarly IL-6 KO mice, which are 
characterised by absence of any IL-6 signalling (peripheral and in the brain), remained 
resistant to EAE, [65]. Suppression of IL-6 trans-signalling in rats by i.v. (peripheral) 
application of sgp130-Fc could not prevent but delayed the EAE onset. In the same 
publication, Linker et al. assumed a role for trans-signalling in the early effector phase by 
regulating the expression of adhesion molecules at the BBB [146]. Although priming of 
MOG-specific autoreactive T cells, including Th17 cells, occurred in the periphal immune 
system, the blockade of trans-signalling in the brain of transgenic gfa2–sgp130-Fc mice could 
give more clues for the entry of autoreactive T cells into the brain and the development of 
EAE. 
Likewise, it is conceivable to crossbreed the gfa2–sgp130-Fc mice with GFAP–IL-6 mice 
which targeted the expression of IL-6 to astroytes by the 13-kb murine promoter GFAP2 [36]. 
GFAP–IL-6 mice developed a number of neurodegenerative changes in the brain, that might 
e.g. contribute to learning deficits of these mice. In addition, a gliosis with strong activation of 
astrocytes and microglia was found. In spite of the neuroinflammatory state in GFAP–IL-6 
animals, the neuroprotective potential of IL-6 has been emphasised by studies of acute 
traumatic brain injury [38]. How would these outcomes change in GFAP–IL-6/gfa2–sgp130-
Fc double transgenic mice; would there be a counterreaction? Resolving these questions will 
further provide valuable insight for IL-6/sIL-6R-triggered events.  
A bidirectional cytokine-mediated complex communication between the brain and the 
peripheral immune system maintains homeostasis and health. From a dysfunction within these 
processes, several disorders may evolve, including those with peripheral complications such 
as the autoimmune disease rheumatoid arthritis [63]. Available data point to an implication of 
the sIL-6R contributing to arthritic lesions [114]. Inhibition of IL-6 trans-signalling by soluble 
gp130 in mice led to an improved disease outcome in experimental arthritis [194]. In this 
respect, studying the effects of the selective blockade of IL-6 trans-signalling in the brain 
(gfa2–sgp130-Fc mice) on the course of arthritic joint inflammation may offer considerable 
clues for the IL-6 system within the interplay of CNS and peripheral immune system. 
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5  Summary 
The cytokine Interleukin 6 (IL-6) is involved in many biological functions of the immune 
system, metabolism and the central nervous system, and in the bidirectional communication 
between these systems. In the brain, IL-6 is considered to affect the modulation of sleep-wake 
behaviour and synaptic plasticity. IL-6 is further well characterised for its dual role to 
maintain homeostasis as well as to contribute to inflammatory and autoimmune processes, 
both in brain and periphery. Signal transduction of IL-6 is induced by binding of IL-6 to the 
membrane-bound IL-6 receptor (IL-6R; classic signalling) or alternatively to the soluble form 
of the IL-6R (sIL-6R; trans-signalling). The membrane-bound glycoprotein 130 (gp130) is the 
signal-transducing receptor subunit in both signalling modes. Gp130 is ubiquitously 
expressed throughout the body, whereas IL-6R expression is restricted to distinct cell 
populations. Within the brain parenchyma the IL-6R is sparsely expressed, and thus the brain 
is primarily reliant on trans-signalling in its response to IL-6.  
As a previous study revealed an upregulation of the peripheral sIL-6R in humans during sleep 
(Dimitrov et al., 2006), the influence of IL-6 trans-signalling on sleep regulation/modulation 
was scrutinised in this work initially. The effect of the IL-6 trans-signalling mimetic designer 
cytokine Hyper-IL-6 (sIL-6R coupled to IL-6) was investigated on sleep architecture of rats 
by EEG/EMG sleep recordings. Hyper-IL-6 can activate almost all cells of the brain in 
contrast to IL-6 itself. Results of this present work demonstrated that an 
intracerebroventricular injection of Hyper-IL-6 (500 ng) before the dark phase into rats led to 
increased amounts of REM sleep accompanied by a reduced EEG power density. Non-REM 
sleep was not affected. These data define a new function of IL-6 trans-signalling within the 
complex network of REM sleep modulation. That might further be of importance for altered 
sleep behaviour under pathophysiological conditions in which sIL-6R and IL-6 are elevated 
(e.g. bacterial/viral infections, major depression).  
A further approach to explore the impact of IL-6 trans-signalling on brain-regulated functions 
included the central “knock-out” of this signal transduction mode. For that purpose transgenic 
mice were generated in this work expressing the competitive antagonist of IL-6 trans-
signalling sgp130-Fc under transcriptional control of the astrocyte-specific promoter gfa2 
within the brain. The protein sgp130-Fc is a dimer of the human extracellular part of gp130 
fused to the Fc-portion of a human IgG antibody. Expression and secretion of sgp130-Fc in 
the brain of transgenic mice on the protein level could be verified. The biological activity of 
the transgenic sgp130-Fc protein was confirmed by Hyper-IL-6 precipitation tests. Likewise, 
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the protein amounts of sgp130-Fc appeared to be sufficient for the blockade of sIL-6R-
mediated cellular responses in the brain. The presence of sgp130-Fc mRNA in transgenic 
animals was detected predominantly in the brain. However, sgp130-Fc was also found in sera 
of the three different established mouse lines at varying protein levels, which did not correlate 
with the amounts observed within the brain.  
The gfa2–sgp130-Fc transgenic mice generated in this work offer an useful “in vivo tool” to 
further study the relevance of IL-6 trans-signalling for sleep-wake behaviour, memory 
consolidation, and models of peripheral and neuropathological inflammation. 
 
6  Zusammenfassung   
  82 
6  Zusammenfassung 
Das Zytokin Interleukin 6 (IL-6) ist an vielfältigen Funktionen des Immunsystems, des 
Stoffwechsels und des Zentralnervensystems beteiligt, sowie an der bidirektionalen 
Kommunikation zwischen diesen Systemen. Im Gehirn beeinflusst IL-6 die Modulation von 
Schlaf-Wach-Verhalten und die synaptische Plastizität. Charakteristisch für IL-6 ist weiterhin 
dessen duale Rolle bei der Aufrechterhaltung der Homeostasis einerseits aber auch bei der 
Förderung von entzündlichen und autoimmunen Prozessen andererseits, sowohl im Gehirn als 
auch in der Peripherie. Die Signaltransduktion von IL-6 wird durch Bindung des IL-6 an den 
membranständigen IL-6-Rezeptor (IL-6R; klassisches Signalling) oder alternativ an die 
lösliche Form des IL-6R (sIL-6R; IL-6-Trans-Signalling) induziert. Das membrangebundene 
Glykoprotein 130 (gp130) ist die signalweiterleitende Rezeptor-Untereinheit beider 
Signalling-Arten. Gp130 wird ubiquitär im Körper exprimiert, wohingegen die Expression 
des IL-6R auf bestimmte Zellpopulationen begrenzt ist. Im Gehirnparenchym ist der IL-6R 
wenig exprimiert, deshalb ist das Gehirn in seiner Reaktion auf IL-6 vornehmlich vom Trans-
Signalling abhängig.  
Eine vorherige Studie beschrieb die Erhöhung des peripheren sIL-6R im Menschen während 
des Schlafes (Dimitrov et al., 2006). Deshalb wurde in der hier vorliegenden Arbeit erstmals 
der Einfluss des IL-6-Trans-Signalling auf die Schlaf-Modulation erforscht. Die Wirkung des 
IL-6-Trans-Signalling imitierenden Designer-Zytokins Hyper-IL-6 (sIL-6R gekoppelt an  
IL-6) auf das Schlaf-Profil von Ratten wurde in EEG/EMG-Schlaf-Messungen untersucht. 
Hyper-IL-6 kann fast alle Zellen des Gehirns aktivieren, im Gegensatz zu IL-6 allein. 
Ergebnisse dieser Arbeit zeigten, dass eine intracerebroventrikuläre Injektion von Hyper-IL-6 
(500 ng) kurz vor der Dunkelphase in Ratten den Anteil an REM-Schlaf erhöhte, begleitet von 
einer reduzierten EEG-Power-Spektrum-Dichte. Dabei wurde der Non-REM-Schlaf nicht 
beeinflusst. Diese Daten definieren eine neue Funktion der IL-6-Trans-Signaltransduktion 
innerhalb des komplexen Netzwerks der REM-Schlaf-Modulation. Das könnte ebenso bei 
pathophysiologischen Zuständen, in denen der sIL-6R sowie IL-6 erhöht sind (z.B. 
bakterielle/virale Infektionen, Depression), von Bedeutung sein.  
Ein weiterer Ansatz, um die Auswirkung der IL-6-Trans-Signaltransduktion auf Gehirn-
gesteuerte Prozesse zu untersuchen, beinhaltete der zentrale „Knock-out“ dieses 
Signaltransduktionsweges. Dafür wurden im Rahmen dieser Arbeit transgene Mäuse 
generiert, die den kompetitiven Antagonisten des IL-6-Trans-Signalling sgp130-Fc im Gehirn 
unter transkriptioneller Kontrolle des astrozytenspezifischen Promotors gfa2 exprimieren. Das 
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Protein sgp130-Fc ist ein Dimer des humanen extrazellulären Teiles von gp130, das über den 
Fc-Teil eines humanen IgG-Antikörpers verbunden ist. Die Expression und Sekretion von 
sgp130-Fc konnnte im Gehirn transgener Mäusen auf Proteinebene nachgewiesen werden. 
Die biologische Aktivität des transgenen sgp130-Fc-Proteins wurde in Hyper-IL-6-
Präzipitationsversuchen bestätigt. Zudem erschienen die Proteingehalte an sgp130-Fc für die 
Hemmung sIL-6R-vermittelter zellulärer Reaktionen im Gehirn ausreichend zu sein. Das 
Vorhandensein von sgp130-Fc-mRNA transgener Tiere wurde vorwiegend im Gehirn 
detektiert. Dennoch wurde sgp130-Fc auch in Seren der drei etablierten Mauslinien mit 
unterschiedlichen Proteingehalten gefunden, die nicht mit den Mengen im Gehirn 
korrelierten.  
Die in dieser Arbeit erzeugten gfa2–sgp130-Fc-transgenen Mäuse stellen ein geeignetes „in 
vivo-Werkzeug“ dar, um die Bedeutung des IL-6-Trans-Signalling für das Schlaf-Wach-
Verhalten, die Gedächtniskonsolidierung sowie Modelle peripherer und neuropathologischer 
Entzündungen eingehend zu studieren. 
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8.1  Abbreviations 
 
°C Celsius centigrade 
µg microgram 
µl microlitre 
A adenine 
ACTH adrenocorticotropin hormone 
ADAM a destintegrin and metalloprotease 
Amp ampicillin 
APS ammoniumperoxodisulfate 
ATCC American Type Culture Collection 
ATP adenosine 5’-triphosphate 
BBB blood brain barrier 
bp base pairs 
BSA bovine serum albumine 
C cytosine 
CBM cytokine binding module 
CD cluster of differentiation 
cDNA complementary DNA 
Ci Curie 
CIAP calf intestine alkaline phosphatase 
CLC cardiotrophin-like cytokine 
cm centimetre 
CNS central nervous system 
CNTF ciliary neurotrophic factor 
CRH corticotropin releasing hormone 
CRP C-reactive protein 
CT-1 cardiotrophin 1 
C-terminus carboxy-terminus 
dATP desoxy adenosine triphosphate 
DEPC diethylpyrocarbonate 
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DMEM Dulbeccos modified eagle medium 
DNA desoxyribonucleic acid 
dNTP 2’-desoxyribonucleotide-5’-triphosphate 
E.coli Escherichia coli 
e.g. for example 
EAE experimental autoimmune encephalitis 
EDS excessive daytime sleepiness 
EDTA ethylenediaminetetraacetic acid 
EEG electroencephalogram 
EGF epidermal growth factor 
ELISA enzyme linked immunosorbent assay 
EMG electromyogram 
Epo erythropoietin 
ERK extracellular signal regulated kinase 
et al. et alteri 
FCS fetal calf serum 
FFT fast Fourier transformation 
Fig. figure 
FN III fibronectin type III 
G guanine; glycine 
g gram; gravitational constant (=9.81 m/s2) 
GABA gamma-amino butyric acid 
GDP guanosine triphosphat 
GFAP glial fibrillary acidic protein 
GFP green fluorescent protein 
GH growth hormone 
GHRH growth hormone-releasing hormone 
gp130 glycoprotein 130 
Grb2 growth factor receptor bound protein 
GTP guanosine diphosphat 
h hour 
HPA hypothalamic-pituitary-adrenal 
Hyper-IL-6 Hyper-Interleukin 6 
Hz Hertz 
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i.c.v. intracerebroventricular 
i.p. intraperitoneal 
ICAM intracellular adhesion molecule 
IFN interferon 
IGF insulin-like growth factor 
IgG immunglobulin G 
IL interleukin 
IL-1RA interleukin 1 receptor antagonist 
IL-6 interleukin 6 
IL-6R interleukin 6 receptor alpha 
IP immunoprecipitation 
JAK Janus kinase 
kb kilobase pairs  
kDa kilo-Dalton 
kg kilogram 
KO knock-out 
l litre 
L leucine 
LB Luria Bertani (medium) 
LIF leukemia inhibitory factor 
LPS lipopolysaccharide 
M molar 
MAPK mitogen activated protein kinase 
MEK MAPK/ERK kinase 
mg milligram 
min minute 
mJ millijoule 
ml millilitre 
mM millimolar 
mmol millimol 
mRNA messenger RNA 
MS multiple sclerosis 
msIL6-R murine soluble interleukin 6 receptor 
mV millivolt 
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NF-κB nuclear factor kappa B 
ng nanogram 
NGF nerve growth factor 
NK natural killer 
nm nanometre 
NO nitric oxide 
non-REM non rapid eye movement sleep 
NP neuropoietin 
N-terminus amino terminus 
OD optical density 
OSM  oncostatin M 
P phosphor; phosphate 
PAGE polyacrylgelelectrophoresis 
PBS phosphate buffered saline 
PBS-T phosphate buffered saline including Tween-20 
PCR polymerase chain reaction 
PEPCK phosphoenolpyryvate carboxygenase 
Per1 period 1 (a circadian clock gene) 
PIAS protein inhibitors of activated STAT 
POD peroxidase 
PolyA polyadenylation site 
P-STAT3 phospho-STAT3 (phosphorylated STAT3) 
PVDF polyvinylidene fluoride 
R receptor; arginine 
REM rapid eye movement 
RNA ribonucleic acid 
rpm rounds per minute 
rRNA ribosomal RNA 
RT-PCR reverse transcriptase polymerase chain reaction 
s second 
S serine 
s.c. subcutanous 
S.D. standard deviation 
S.E.M. standard error of mean 
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SCN suprachiasmatic nucleus 
SDS sodium dodecyl sulfate 
sgp130-Fc soluble glycoprotein 130-Fc 
SH2 domain src homology 2 domain 
SHP-2 src homology protein 2 tyrosine phosphatase 2 
sIL-1R soluble IL-1 receptor 
sIL-6R soluble interleukin 6 receptor 
SN supernatant 
SOCS suppressor of cytokine signalling 
SOS son of sevenless 
SRS sleep regulatory substance 
STAT (Stat) signal transducer and activator of transcription 
sTNFR soluble TNF receptor 
SWS slow wave sleep (in humans) 
T thymine 
Taq Thermophilus aquaticus 
TBS tris buffered saline 
TBS-T tris buffered saline including Tween-20 
TEMED N,N,N’,N’-tetramethylenediamine 
TF transcription factor 
tg transgenic 
TGF transformic growth factor 
TNF tumor necrosis factor 
U Unit, Uracil 
UV ultraviolet 
V volt 
VCAM vascular cell adhesion molecule 
VIP vasoactive intestinal polypeptide 
VLPO ventrolateral preoptic (hypothalamic region) 
W tryptophan 
Wake wakefulness 
X an unspecified amino acid 
Y tyrosine 
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8.2  Vector maps 
 
A  pGfa2–sgp130-Fc_optimised–mP1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-globin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGfa2–sgp130-Fc_optimised–mP1
7994 bp
Amp resistance human gfa2 
promoter
sgp130-Fc optimised
mouse protamine 1 
(intron + PolyA)
BglII
BglII
NotI
EagI
HindIII
HindIII
pCR-script–gfa2–intron_β-globin–
sgp130-Fc_optimised–polyA_β-globin
8732 bp
Amp
resistance
human gfa2
promoter
2nd intron rabbit
β-globin
sgp130-Fc 
optimised
polyA rabbit
β-globin
BglII
HindIII
EcoRV
EcoRV
EcoRI
NotI
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8.3  Sequences 
 
A  Nucleotide sequence of the gene expression cassette cutted by BglII from the vector     
     pGfa2–sgp130-Fc_optimised–mP1  
 
  cut BglII - 248 GAT 
 
  251 CTGAGCTCCC ACCTCCCTCT CTGTGCTGGG ACTCACAGAG GGAGACCTCA 
 
  301 GGAGGCAGTC TGTCCATCAC ATGTCCAAAT GCAGAGCATA CCCTGGGCTG 
 
  351 GGCGCAGTGG CGCACAACTG TAATTCCAGC ACTTTGGGAG GCTGATGTGG 
 
  401 AAGGATCACT TGAGCCCAGA AGTTCTAGAC CAGCCTGGGC AACATGGCAA 
 
  451 GACCCTATCT CTACAAAAAA AGTTAAAAAA TCAGCCACGT GTGGTGACAC 
 
  501 ACACCTGTAG TCCCAGCTAT TCAGGAGGCT GAGGTGAGGG GATCACTTAA 
 
  551 GGCTGGGAGG TTGAGGCTGC AGTGAGTCGT GGTTGCGCCA CTGCACTCCA 
 
  601 GCCTGGGCAA CAGTGAGACC CTGTCTCAAA AGACAAAAAA AAAAAAAAAA 
 
  651 AAAAAAAGAA CATATCCTGG TGTGGAGTAG GGGACGCTGC TCTGACAGAG 
 
  701 GCTCGGGGGC CTGAGCTGGC TCTGTGAGCT GGGGAGGAGG CAGACAGCCA 
 
  751 GGCCTTGTCT GCAAGCAGAC CTGGCAGCAT TGGGCTGGCC GCCCCCCAGG 
 
  801 GCCTCCTCTT CATGCCCAGT GAATGACTCA CCTTGGCACA GACACAATGT 
 
  851 TCGGGGTGGG CACAGTGCCT GCTTCCCGCC GCACCCCAGC CCCCCTCAAA 
 
  901 TGCCTTCCGA GAAGCCCATT GAGCAGGGGG CTTGCATTGC ACCCCAGCCT 
 
  951 GACAGCCTGG CATCTTGGGA TAAAAGCAGC ACAGCCCCCT AGGGGCTGCC 
 
 1001 CTTGCTGTGT GGCGCCACCG GCGGTGGAGA ACAAGGCTCT ATTCAGCCTG 
 
 1051 TGCCCAGGAA AGGGGATCAG GGGATGCCCA GGCATGGACA GTGGGTGGCA 
 
 1101 GGGGGGGAGA GGAGGGCTGT CTGCTTCCCA GAAGTCCAAG GACACAAATG 
 
 1151 GGTGAGGGGA CTGGGCAGGG TTCTGACCCT GTGGGACCAG AGTGGAGGGC 
 
 1201 GTAGATGGAC CTGAAGTCTC CAGGGACAAC AGGGCCCAGG TCTCAGGCTC 
 
 1251 CTAGTTGGGC CCAGTGGCTC CAGCGTTTCC AAACCCATCC ATCCCCAGAG 
 
 1301 GTTCTTCCCA TCTCTCCAGG CTGATGTGTG GGAACTCGAG GAAATAAATC 
 
 1351 TCCAGTGGGA GACGGAGGGG TGGCCAGGGA AACGGGGCGC TGCAGGAATA 
 
 1401 AAGACGAGCC AGCACAGCCA GCTCATGTGT AACGGCTTTG TGGAGCTGTC 
 
 1451 AAGGCCTGGT CTCTGGGAGA GAGGCACAGG GAGGCCAGAC AAGGAAGGGG 
 
 1501 TGACCTGGAG GGACAGATCC AGGGGCTAAA GTCCTGATAA GGCAAGAGAG 
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 1551 TGCCGGCCCC CTCTTGCCCT ATCAGGACCT CCACTGCCAC ATAGAGGCCA 
 
 1601 TGATTGACCC TTAGACAAAG GGCTGGTGTC CAATCCCAGC CCCCAGCCCC 
 
 1651 AGAACTCCAG GGAATGAATG GGCAGAGAGC AGGAATGTGG GACATCTGTG 
 
 1701 TTCAAGGGAA GGACTCCAGG AGTCTGCTGG GAATGAGGCC TAGTAGGAAA 
 
 1751 TGAGGTGGCC CTTGAGGGTA CAGAACAGGT TCATTCTTCG CCAAATTCCC 
 
 1801 AGCACCTTGC AGGCACTTAC AGCTGAGTGA GATAATGCCT GGGTTATGAA 
 
 1851 ATCAAAAAGT TGGAAAGCAG GTCAGAGGTC ATCTGGTACA GCCCTTCCTT 
 
 1901 CCCTTTTTTT TTTTTTTTTT TTGTGAGACA AGGTCTCTCT CTGTTGCCCA 
 
 1951 GGCTGGAGTG GCGCAAACAC AGCTCACTGC AGCCTCAACC TACTGGGCTC 
 
 2001 AAGCAATCCT CCAGCCTCAG CCTCCCAAAG TGCTGGGATT ACAAGCATGA 
 
 2051 GCCACCCCAC TCAGCCCTTT CCTTCCTTTT TAATTGATGC ATAATAATTG 
 
 2101 TAAGTATTCA TCATGGTCCA ACCAACCCTT TCTTGACCCA CCTTCCTAGA 
 
 2151 GAGAGGGTCC TCTTGCTTCA GCGGTCAGGG CCCCAGACCC ATGGTCTGGC 
 
 2201 TCCAGGTACC ACCTGCCTCA TGCAGGAGTT GGCGTGCCCA GGAAGCTCTG 
 
 2251 CCTCTGGGCA CAGTGACCTC AGTGGGGTGA GGGGAGCTCT CCCCATAGCT 
 
 2301 GGGCTGCGGC CCAACCCCAC CCCCTCAGGC TATGCCAGGG GGTGTTGCCA 
 
 2351 GGGGCACCCG GGCATCGCCA GTCTAGCCCA CTCCTTCATA AAGCCCTCGC 
 
 2401 ATCCCAGGAG CGAGCAGAGC CAGAGCAGGT TGGAGAGGAG ACGCATCACC 
 
                            HindIII 
 2451 TCCGCTGCTC GCGGGGATCT AAGCTTGCCA CCATGCTGAC ACTGCAGACA 
 
 2501 TGGCTGGTGC AGGCCCTGTT TATCTTTCTG ACCACCGAGT CTACAGGAGA 
 
 2551 GCTGCTGGAT CCTTGCGGCT ATATCTCCCC TGAGTCTCCT GTGGTGCAGC 
 
 2601 TGCATTCTAA CTTCACCGCC GTGTGTGTGC TGAAGGAAAA GTGCATGGAC 
 
 2651 TACTTCCACG TGAACGCCAA CTACATCGTG TGGAAAACCA ACCACTTCAC 
 
 2701 CATCCCCAAG GAGCAGTACA CCATCATCAA CCGGACCGCT TCTTCTGTGA 
 
 2751 CCTTCACCGA TATCGCCTCC CTGAATATCC AGCTGACCTG CAACATCCTG 
 
 2801 ACCTTTGGAC AGCTGGAGCA GAATGTGTAC GGCATCACCA TCATCTCTGG 
 
 2851 CCTGCCTCCA GAGAAGCCTA AGAACCTGTC CTGCATCGTG AATGAGGGCA 
 
 2901 AGAAGATGAG GTGTGAGTGG GATGGCGGCA GAGAGACACA TCTGGAGACC 
 
 2951 AACTTCACCC TGAAGTCTGA GTGGGCCACC CACAAGTTTG CCGACTGCAA 
 
 3001 GGCCAAGAGA GATACCCCTA CCTCTTGCAC CGTGGACTAC TCCACCGTGT 
 
 3051 ACTTCGTGAA CATCGAGGTG TGGGTGGAGG CTGAGAATGC TCTGGGCAAG 
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 3101 GTGACCTCTG ACCACATCAA CTTCGACCCC GTGTACAAGG TGAAGCCTAA 
 
 3151 CCCTCCTCAC AACCTGTCCG TGATCAACTC TGAGGAGCTG TCCTCTATCC 
 
 3201 TGAAGCTGAC CTGGACCAAC CCTTCCATCA AGTCCGTGAT CATCCTGAAG 
 
 3251 TACAACATCC AGTACAGGAC CAAGGATGCT TCTACCTGGT CTCAGATCCC 
 
 3301 TCCTGAGGAT ACCGCTTCCA CCAGATCCAG CTTCACAGTG CAGGACCTGA 
 
 3351 AGCCTTTTAC CGAGTACGTG TTCAGGATCC GGTGCATGAA GGAGGATGGC 
 
 3401 AAGGGCTATT GGTCTGACTG GTCTGAGGAG GCTTCTGGCA TCACCTACGA 
 
 3451 GGACAGACCT TCTAAGGCCC CTAGCTTCTG GTACAAGATC GACCCTTCTC 
 
 3501 ACACCCAGGG CTATAGAACA GTGCAGCTGG TGTGGAAAAC CCTGCCTCCA 
 
 3551 TTCGAGGCTA ATGGCAAGAT CCTGGACTAT GAGGTGACCC TGACCAGATG 
 
 3601 GAAGTCTCAC CTGCAGAACT ACACCGTGAA CGCTACCAAG CTGACCGTGA 
 
 3651 ACCTGACCAA CGATAGATAC CTGGCTACCC TGACCGTGAG AAATCTGGTG 
 
 3701 GGCAAGTCTG ATGCTGCTGT GCTGACCATC CCTGCCTGTG ATTTTCAGGC 
 
 3751 TACCCACCCT GTGATGGATC TGAAGGCCTT CCCCAAGGAT AACATGCTGT 
 
 3801 GGGTGGAGTG GACAACACCT AGAGAGTCCG TGAAGAAGTA CATCCTGGAG 
 
 3851 TGGTGCGTGC TGTCTGATAA GGCCCCTTGC ATCACAGATT GGCAGCAGGA 
 
 3901 GGATGGCACC GTGCATAGAA CCTACCTGAG AGGCAATCTG GCCGAGTCTA 
 
 3951 AGTGCTATCT GATCACCGTG ACCCCTGTGT ATGCTGATGG ACCTGGCTCT 
 
 4001 CCTGAGTCTA TCAAGGCCTA CCTGAAGCAG GCTCCTCCAT CTAAGGGACC 
 
 4051 TACCGTGAGG ACAAAGAAGG TGGGCAAGAA CGAGGCTGTG CTGGAGTGGG 
 
 4101 ATCAGCTGCC TGTGGATGTG CAGAACGGCT TCATCCGGAA CTACACCATC 
 
 4151 TTCTACCGGA CCATCATCGG CAATGAGACC GCCGTGAACG TGGATTCTTC 
 
 4201 CCACACCGAG TACACACTGT CCTCTCTGAC CTCTGACACC CTGTACATGG 
 
 4251 TGAGAATGGC CGCTTATACC GATGAGGGCG GCAAGGATGG ACCTGAGTTC 
 
 4301 AGATCCTGCG ACAAGACCCA CACCTGTCCT CCTTGTCCTG CTCCTGAGGC 
 
 4351 TGAGGGCGCT CCTTCTGTGT TTCTGTTCCC CCCAAAGCCT AAGGATACCC 
 
 4401 TGATGATCTC CAGAACCCCT GAGGTGACAT GTGTGGTGGT GGATGTGTCT 
 
 4451 CATGAGGACC CCGAGGTGAA GTTCAACTGG TACGTGGATG GCGTGGAGGT 
 
 4501 GCACAATGCT AAGACCAAGC CTAGGGAGGA GCAGTACAAC TCCACCTACA 
 
 4551 GAGTGGTGTC TGTGCTGACA GTGCTGCATC AGGATTGGCT GAACGGCAAG 
 
 4601 GAGTACAAGT GCAAGGTGTC CAACAAGGCT CTGCCTGCTC CTATCGAAAA 
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 4651 GACCATCTCC AAGGCTAAGG GACAGCCTAG AGAGCCTCAG GTGTACACAC 
 
 4701 TGCCTCCATC TAGGGAGGAG ATGACCAAGA ATCAGGTGTC CCTGACCTGT 
 
 4751 CTGGTGAAGG GCTTCTACCC TTCTGATATC GCTGTGGAGT GGGAGTCTAA 
 
 4801 TGGCCAGCCC GAGAACAATT ACAAGACCAC CCCTCCTGTG CTGGATTCTG 
 
 4851 ACGGCTCCTT CTTCCTGTAC TCCAAACTGA CCGTGGACAA GTCTAGATGG 
 
 4901 CAGCAGGGCA ACGTGTTCTC TTGTTCCGTG ATGCACGAGG CTCTGCACAA 
 
 4951 TCACTATACC CAGAAGTCCC TGTCTCTGTC TCCTGGCAAG TGATGAGAAT 
 
              EagI 
             NotI 
 5001 TCTCGAGGCG GCCGCTACAG ATCCGCAGAT CCCGGCCAGA TACCGATGCT 
 
 5051 GCCGCAGCAA AAGCAGGAGC AGATGCCGCC GTCGCAGGCG AAGATGTCGC 
 
 5101 AGACGGAGGA GGCGATGCTG CCGGCGGAGG AGGCGAAGTA AGTAGAGGGC 
 
 5151 TGGGCTGGGC TGTGGGGGGT GTGGGGTGCG GGACTGGGCA GTCTGGGAGT 
 
 5201 CCCTCTCACC ACTTTTCTTA CCTTTCTAGG ATGCTGCCGT CGCCGCCGCT 
 
 5251 CATACACCAT AAGGTGTAAA AAATACTAGA TGCACAGAAT AGCAAGTCCA 
 
 5301 TCAAAACTCC TGCGTGAGAA TTTTACCAGA CTTCAAGAGC ATCTCGCCAC 
 
 5351 ATCTTGAAAA ATGCCACCGT CCGATGAAAA ACAGGAGCCT GCTAAGGAAC 
 
 5401 AATGCCACCT GTCAATAAAT GTTGAAAACT CATCCCATTC CTGCCTCTTG 
 
 5451 GTCCTTGGGC TTGGGGAGGG GTGCGCGGAT GTGGTTAGGG AACATGACTG 
 
 5501 GTCAAATGGG AAGGGCTTCA AAAGAATTCC CAATATTGAC TACCAAGCCA 
                                    
 5551 CCTGTACAGA TCGAATTCA - cut BglII 
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B  Nucleotide sequence of the transgene expression cassette cutted by BglII and NotI    
     from the vector pCR-script–gfa2–intron_β-globin–sgp130-Fc_optimised–polyA_β-  
     globin used for microinjection to generate transgenic mice 
 
  cut BglII - 666 GATCT GAGCTCCCAC CTCCCTCTCT GTGCTGGGAC 
 
  701 TCACAGAGGG AGACCTCAGG AGGCAGTCTG TCCATCACAT GTCCAAATGC 
 
  751 AGAGCATACC CTGGGCTGGG CGCAGTGGCG CACAACTGTA ATTCCAGCAC 
 
  801 TTTGGGAGGC TGATGTGGAA GGATCACTTG AGCCCAGAAG TTCTAGACCA 
 
  851 GCCTGGGCAA CATGGCAAGA CCCTATCTCT ACAAAAAAAG TTAAAAAATC 
 
  901 AGCCACGTGT GGTGACACAC ACCTGTAGTC CCAGCTATTC AGGAGGCTGA 
 
  951 GGTGAGGGGA TCACTTAAGG CTGGGAGGTT GAGGCTGCAG TGAGTCGTGG 
 
 1001 TTGCGCCACT GCACTCCAGC CTGGGCAACA GTGAGACCCT GTCTCAAAAG 
 
 1051 ACAAAAAAAA AAAAAAAAAA AAAAAGAACA TATCCTGGTG TGGAGTAGGG 
 
 1101 GACGCTGCTC TGACAGAGGC TCGGGGGCCT GAGCTGGCTC TGTGAGCTGG 
 
 1151 GGAGGAGGCA GACAGCCAGG CCTTGTCTGC AAGCAGACCT GGCAGCATTG 
 
 1201 GGCTGGCCGC CCCCCAGGGC CTCCTCTTCA TGCCCAGTGA ATGACTCACC 
 
 1251 TTGGCACAGA CACAATGTTC GGGGTGGGCA CAGTGCCTGC TTCCCGCCGC 
 
 1301 ACCCCAGCCC CCCTCAAATG CCTTCCGAGA AGCCCATTGA GCAGGGGGCT 
 
 1351 TGCATTGCAC CCCAGCCTGA CAGCCTGGCA TCTTGGGATA AAAGCAGCAC 
 
 1401 AGCCCCCTAG GGGCTGCCCT TGCTGTGTGG CGCCACCGGC GGTGGAGAAC 
 
 1451 AAGGCTCTAT TCAGCCTGTG CCCAGGAAAG GGGATCAGGG GATGCCCAGG 
 
 1501 CATGGACAGT GGGTGGCAGG GGGGGAGAGG AGGGCTGTCT GCTTCCCAGA 
 
 1551 AGTCCAAGGA CACAAATGGG TGAGGGGACT GGGCAGGGTT CTGACCCTGT 
 
 1601 GGGACCAGAG TGGAGGGCGT AGATGGACCT GAAGTCTCCA GGGACAACAG 
 
 1651 GGCCCAGGTC TCAGGCTCCT AGTTGGGCCC AGTGGCTCCA GCGTTTCCAA 
 
 1701 ACCCATCCAT CCCCAGAGGT TCTTCCCATC TCTCCAGGCT GATGTGTGGG 
 
 1751 AACTCGAGGA AATAAATCTC CAGTGGGAGA CGGAGGGGTG GCCAGGGAAA 
 
 1801 CGGGGCGCTG CAGGAATAAA GACGAGCCAG CACAGCCAGC TCATGTGTAA 
 
 1851 CGGCTTTGTG GAGCTGTCAA GGCCTGGTCT CTGGGAGAGA GGCACAGGGA 
 
 1901 GGCCAGACAA GGAAGGGGTG ACCTGGAGGG ACAGATCCAG GGGCTAAAGT 
 
 1951 CCTGATAAGG CAAGAGAGTG CCGGCCCCCT CTTGCCCTAT CAGGACCTCC 
 
 2001 ACTGCCACAT AGAGGCCATG ATTGACCCTT AGACAAAGGG CTGGTGTCCA 
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 2051 ATCCCAGCCC CCAGCCCCAG AACTCCAGGG AATGAATGGG CAGAGAGCAG 
 
 2101 GAATGTGGGA CATCTGTGTT CAAGGGAAGG ACTCCAGGAG TCTGCTGGGA 
 
 2151 ATGAGGCCTA GTAGGAAATG AGGTGGCCCT TGAGGGTACA GAACAGGTTC 
 
 2201 ATTCTTCGCC AAATTCCCAG CACCTTGCAG GCACTTACAG CTGAGTGAGA 
 
 2251 TAATGCCTGG GTTATGAAAT CAAAAAGTTG GAAAGCAGGT CAGAGGTCAT 
 
 2301 CTGGTACAGC CCTTCCTTCC CTTTTTTTTT TTTTTTTTTT GTGAGACAAG 
 
 2351 GTCTCTCTCT GTTGCCCAGG CTGGAGTGGC GCAAACACAG CTCACTGCAG 
 
 2401 CCTCAACCTA CTGGGCTCAA GCAATCCTCC AGCCTCAGCC TCCCAAAGTG 
 
 2451 CTGGGATTAC AAGCATGAGC CACCCCACTC AGCCCTTTCC TTCCTTTTTA 
 
 2501 ATTGATGCAT AATAATTGTA AGTATTCATC ATGGTCCAAC CAACCCTTTC 
 
 2551 TTGACCCACC TTCCTAGAGA GAGGGTCCTC TTGCTTCAGC GGTCAGGGCC 
 
                              KpnI 
 2601 CCAGACCCAT GGTCTGGCTC CAGGTACCAC CTGCCTCATG CAGGAGTTGG 
 
 2651 CGTGCCCAGG AAGCTCTGCC TCTGGGCACA GTGACCTCAG TGGGGTGAGG 
 
 2701 GGAGCTCTCC CCATAGCTGG GCTGCGGCCC AACCCCACCC CCTCAGGCTA 
 
                                SmaI 
 2751 TGCCAGGGGG TGTTGCCAGG GGCACCCGGG CATCGCCAGT CTAGCCCACT 
 
 2801 CCTTCATAAA GCCCTCGCAT CCCAGGAGCG AGCAGAGCCA GAGCAGGTTG 
 
 2851 GAGAGGAGAC GCATCACCTC CGCTGCTCGC GGAGATCCCG ATCCTGAGAA 
 
 2901 CTTCAGGGTG AGTTTGGGGA CCCTTGATTG TTCTTTCTTT TTCGCTATTG 
 
 2951 TAAAATTCAT GTTATATGGA GGGGGCAAAG TTTTCAGGGT GTTGTTTAGA 
 
 3001 ATGGGAAGAT GTCCCTTGTA TCACCATGGA CCCTCATGAT AATTTTGTTT 
 
 3051 CTTTCACTTT CTACTCTGTT GACAACCATT GTCTCCTCTT ATTTTCTTTT 
 
 3101 CATTTTCTGT AACTTTTTCG TTAAACTTTA GCTTGCATTT GTAACGAATT 
 
 3151 TTTAAATTCA CTTTTGTTTA TTTGTCAGAT TGTAAGTACT TTCTCTAATC 
 
 3201 ACTTTTTTTT CAAGGCAATC AGGGTATATT ATATTGTACT TCAGCACAGT 
 
 3251 TTTAGAGAAC AATTGTTATA ATTAAATGAT AAGGTAGAAT ATTTCTGCAT 
 
 3301 ATAAATTCTG GCTGGCGTGG AAATATTCTT ATTGGTAGAA ACAACTACAC 
 
 3351 CCTGGTCATC ATCCTGCCTT TCTCTTTATG GTTCAATGAT ATACACTGTT 
 
 3401 TGAGATGAGG ATAAAATACT CTGAGTCCAA ACCGGGCCCC TCTGCTAACC 
 
 3451 ATGTTCATGC CTTCTTCTCT TTCCTACAGC TCCTGGGCAA CGTGCTGGTT 
 
                                       HindIII 
 3501 GTTGTGCTGT CTCATCATTT GGCAAGAATC AAGCTTGCCA CCATGCTGAC 
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 3551 ACTGCAGACA TGGCTGGTGC AGGCCCTGTT TATCTTTCTG ACCACCGAGT 
 
 3601 CTACAGGAGA GCTGCTGGAT CCTTGCGGCT ATATCTCCCC TGAGTCTCCT 
 
 3651 GTGGTGCAGC TGCATTCTAA CTTCACCGCC GTGTGTGTGC TGAAGGAAAA 
 
 3701 GTGCATGGAC TACTTCCACG TGAACGCCAA CTACATCGTG TGGAAAACCA 
 
 3751 ACCACTTCAC CATCCCCAAG GAGCAGTACA CCATCATCAA CCGGACCGCT 
 
                         EcoRV 
 3801 TCTTCTGTGA CCTTCACCGA TATCGCCTCC CTGAATATCC AGCTGACCTG 
 
 3851 CAACATCCTG ACCTTTGGAC AGCTGGAGCA GAATGTGTAC GGCATCACCA 
 
 3901 TCATCTCTGG CCTGCCTCCA GAGAAGCCTA AGAACCTGTC CTGCATCGTG 
 
 3951 AATGAGGGCA AGAAGATGAG GTGTGAGTGG GATGGCGGCA GAGAGACACA 
 
 4001 TCTGGAGACC AACTTCACCC TGAAGTCTGA GTGGGCCACC CACAAGTTTG 
 
 4051 CCGACTGCAA GGCCAAGAGA GATACCCCTA CCTCTTGCAC CGTGGACTAC 
 
 4101 TCCACCGTGT ACTTCGTGAA CATCGAGGTG TGGGTGGAGG CTGAGAATGC 
 
 4151 TCTGGGCAAG GTGACCTCTG ACCACATCAA CTTCGACCCC GTGTACAAGG 
 
 4201 TGAAGCCTAA CCCTCCTCAC AACCTGTCCG TGATCAACTC TGAGGAGCTG 
 
 4251 TCCTCTATCC TGAAGCTGAC CTGGACCAAC CCTTCCATCA AGTCCGTGAT 
 
 4301 CATCCTGAAG TACAACATCC AGTACAGGAC CAAGGATGCT TCTACCTGGT 
 
 4351 CTCAGATCCC TCCTGAGGAT ACCGCTTCCA CCAGATCCAG CTTCACAGTG 
 
 4401 CAGGACCTGA AGCCTTTTAC CGAGTACGTG TTCAGGATCC GGTGCATGAA 
 
 4451 GGAGGATGGC AAGGGCTATT GGTCTGACTG GTCTGAGGAG GCTTCTGGCA 
 
 4501 TCACCTACGA GGACAGACCT TCTAAGGCCC CTAGCTTCTG GTACAAGATC 
 
 4551 GACCCTTCTC ACACCCAGGG CTATAGAACA GTGCAGCTGG TGTGGAAAAC 
 
 4601 CCTGCCTCCA TTCGAGGCTA ATGGCAAGAT CCTGGACTAT GAGGTGACCC 
 
 4651 TGACCAGATG GAAGTCTCAC CTGCAGAACT ACACCGTGAA CGCTACCAAG 
 
 4701 CTGACCGTGA ACCTGACCAA CGATAGATAC CTGGCTACCC TGACCGTGAG 
 
 4751 AAATCTGGTG GGCAAGTCTG ATGCTGCTGT GCTGACCATC CCTGCCTGTG 
 
 4801 ATTTTCAGGC TACCCACCCT GTGATGGATC TGAAGGCCTT CCCCAAGGAT 
 
 4851 AACATGCTGT GGGTGGAGTG GACAACACCT AGAGAGTCCG TGAAGAAGTA 
 
 4901 CATCCTGGAG TGGTGCGTGC TGTCTGATAA GGCCCCTTGC ATCACAGATT 
 
 4951 GGCAGCAGGA GGATGGCACC GTGCATAGAA CCTACCTGAG AGGCAATCTG 
 
 5001 GCCGAGTCTA AGTGCTATCT GATCACCGTG ACCCCTGTGT ATGCTGATGG 
 
 5051 ACCTGGCTCT CCTGAGTCTA TCAAGGCCTA CCTGAAGCAG GCTCCTCCAT 
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 5101 CTAAGGGACC TACCGTGAGG ACAAAGAAGG TGGGCAAGAA CGAGGCTGTG 
 
 5151 CTGGAGTGGG ATCAGCTGCC TGTGGATGTG CAGAACGGCT TCATCCGGAA 
 
 5201 CTACACCATC TTCTACCGGA CCATCATCGG CAATGAGACC GCCGTGAACG 
 
 5251 TGGATTCTTC CCACACCGAG TACACACTGT CCTCTCTGAC CTCTGACACC 
 
 5301 CTGTACATGG TGAGAATGGC CGCTTATACC GATGAGGGCG GCAAGGATGG 
 
 5351 ACCTGAGTTC AGATCCTGCG ACAAGACCCA CACCTGTCCT CCTTGTCCTG 
 
 5401 CTCCTGAGGC TGAGGGCGCT CCTTCTGTGT TTCTGTTCCC CCCAAAGCCT 
 
 5451 AAGGATACCC TGATGATCTC CAGAACCCCT GAGGTGACAT GTGTGGTGGT 
 
 5501 GGATGTGTCT CATGAGGACC CCGAGGTGAA GTTCAACTGG TACGTGGATG 
 
 5551 GCGTGGAGGT GCACAATGCT AAGACCAAGC CTAGGGAGGA GCAGTACAAC 
 
 5601 TCCACCTACA GAGTGGTGTC TGTGCTGACA GTGCTGCATC AGGATTGGCT 
 
 5651 GAACGGCAAG GAGTACAAGT GCAAGGTGTC CAACAAGGCT CTGCCTGCTC 
 
 5701 CTATCGAAAA GACCATCTCC AAGGCTAAGG GACAGCCTAG AGAGCCTCAG 
 
 5751 GTGTACACAC TGCCTCCATC TAGGGAGGAG ATGACCAAGA ATCAGGTGTC 
 
                                           EcoRV 
 5801 CCTGACCTGT CTGGTGAAGG GCTTCTACCC TTCTGATATC GCTGTGGAGT 
 
 5851 GGGAGTCTAA TGGCCAGCCC GAGAACAATT ACAAGACCAC CCCTCCTGTG 
 
 5901 CTGGATTCTG ACGGCTCCTT CTTCCTGTAC TCCAAACTGA CCGTGGACAA 
 
 5951 GTCTAGATGG CAGCAGGGCA ACGTGTTCTC TTGTTCCGTG ATGCACGAGG 
 
 6001 CTCTGCACAA TCACTATACC CAGAAGTCCC TGTCTCTGTC TCCTGGCAAG 
 
            EcoRI 
 6051 TGATGAGAAT TCGATCTTTT CCCTCTGCCA AAAATTATGG GGACATCATG 
 
 6101 AAGCCCCTTG AGCATCTGAC TTCTGGCTAA TAAAGGAAAT TTATTTTCAT 
 
 6151 TGCAATAGTG TGTTGGAATT TTTTGTGTCT CTCACTCGGA AGGACATATG 
 
 6201 GGAGGGCAAA TCATTTAAAA CATCAGAATG AGTATTTGGT TTAGAGTTTG 
 
 6251 GCAACATATG CCCATATGCT GGCTGCCATG AACAAAGGTT GGCTATAAAG 
 
 6301 AGGTCATCAG TATATGAAAC AGCCCCCTGC TGTCCATTCC TTATTCCATA 
 
 6351 GAAAAGCCTT GACTTGAGGT TAGATTTTTT TTATATTTTG TTTTGTGTTA 
 
 6401 TTTTTTTCTT TAACATCCCT AAAATTTTCC TTACATGTTT TACTAGCCAG 
 
 6451 ATTTTTCCTC CTCTCCTGAC TACTCCCAGT CATAGCTGTC CCTCTTCTCT 
                         
 6501 TATGGAGATC CCTCGACGC - cut NotI 
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